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1.1 Alzheimer´s Disease (AD) – a global challenge for a society in demographic 
transition - Current situation and future trends 
 
Worldwide, approximately 35 million people suffer from a dementia disease. This chronic 
disease with a creeping deterioration of cognitive abilities leaves humans dependent on full time 
supervision by a care person. Increasing life expectancy caused by improvements in adult and 
child health along with decreasing mortality is doubtless the motor of a global demographic 
transition. In high-income countries of the northern American continent, Europe and Japan, 14 % 
of the population are aged 65 years and over. Sri Lanka, Brazil and China will reach these 14 % in 
the next 13 to 19 years [1]. A further example: In 2010, 4 % of people living in the OECD 
countries were aged 80 years and over. By 2050, 10 % of the population is expected to be older 
than 80 years [1]. Dementias, including Alzheimer´s Disease (AD) are chronic diseases, which are 
strongly age-associated. The mean age of patients with diagnosed AD is 65 years [1]. Early onset 
of AD (e.g. at the age of 50 years) is often diagnosed in case of familial dementias but is of minor 
prevalence. The demographic transition to a high percentage of people aged 65 and over and a 
chronic age-associated disease is becoming a global challenge for care systems and politicians. In 
2010, the estimated annual societal costs of dementia were US$ 604 billion worldwide. This sum 
corresponds to 1 % of the aggregated Gross Domestic Product (GDP). Due to the demographic 
transition, the estimated number of dementia sufferers worldwide will have doubled by 2030 
(70 million patients) and more than tripled by the year 2050 (115 million patients) [2]. For the 
year 2030, the cost increase is predicted to be around 85 %. This means that, instead of US$ 604 











1.2 The progress of Alzheimer´s Disease –a brief clinical review in terms of 
pathohistological abnormalities and symptoms 
 
The major changes in the brain of AD patients are cortical atrophy, neuron degeneration, 
extracellular and intracellular amyloid-β (Aβ) containing plaques and intracellular deposits of 
neurofibrillary tangles (NFT). Cellular abnormalities in the AD-affected brain are tortuous and 
dilated neurites with enlarged lysosomes, an increased number of mitochondria and paired 
helical filaments. In brains of AD patients, numerous neurons of many brain regions 
(hippocampus, parahippocampal gyrus, amygdala, frontal, temporal, parietal and occipital 
association cortices) are impaired by these Aβ-plaques and NFTs [3]. The proceeding injuries of 
neuronal tissue lead to creeping loss of cognitive abilities. This includes, apart from numerous 
psychiatric traits e.g. behavioral changes, a progressive decrease in capacity for remembering 
and orientation. The stages of the progression of AD can be divided into early, middle and final 
stage. With the deterioration of the symptoms, the reliance on nursing increases continuously 
[4]. The life expectancy of AD patients after diagnosis is approx. 8 years in a range of 4-20 years 
[5]. 
1.3 Leading hypothesis of AD-causing molecular mechanisms 
 
1.3.1 A brief historical outline of AD-related investigative milestones 
 
Since Alois Alzheimer in 1906 first described a syndrome with symptoms similar to senile 
dementia, a time span of six decades elapsed until the advance of electron microscopy revealed 
two structurally distinguishable types of depositions in the brain of AD patients [3]. Postmortem 
analyses of brain tissues of AD patients uncovered the existence of Aβ plaques and 
neurofibrillary tangles (NFT). In the 1970s, linkages between plaque and NFT depositions, 
neuronal dysfunction (e.g. decreased release of acetylcholine, acting as neurotransmitter) and 
the symptoms of senile dementia could be found. In the late 1980s, the molecular origin and the 
composition of these Aβ-plaques and NFTs was unveiled, leading to first theories about the 
mechanism causing AD-related brain pathohistology. Recent investigations demonstrated that 
on the one hand, insoluble extracellular Aβ aggregates and on the other hand, smaller and 
water-soluble intracellular Aβ-oligomers cause brain related pathohistology [6-9]. Both soluble 
and insoluble Aβ-aggregates appeared in sporadic (age-related) and inherited forms of AD. 
Today the most investigational effort in terms of the development of treatment strategies is 




1.3.2 On the molecular origin of Aβ plaques and NFTs  
 
1.3.2.1 Neurofibrillary tangles – hyperphosphorylated Tau proteins form neurotoxic fibers 
 
The microtubule-associated protein tau (MAPT) is involved in assembling and stabilizing 
neuronal microtubules. It is prevalently expressed in neurons of the central nervous system. In 
the brain of adults six isoforms of the protein Tau were found [10]. In AD, these isoforms 
become abnormally phosphorylated by phosphatases and protein kinases [11, 12] leading to the 
formation of paired helical filaments. This fibrous component is a general histopathological 
characteristic for neurofibrillary lesions [13]. 
1.3.2.2 Enzymatic cleavage of amyloid precursor protein (APP) provides fundamental 
aggregation seeds for neurotoxic plaque deposition 
 
Aβ plaques in the brain of AD patients are composed of proteolytic cleavage products of the 
amyloid precursor protein (APP). APP is ubiquitously expressed in neuronal and non-neuronal 
tissues in different splicing forms (major isoforms 695, 751 and 770 residues) [3, 14-17]. The 
gene of this transmembrane protein is located on the chromosome 21. The physiological 
function has not yet been fully investigated. It is assumed that APP and its cleavage product act 
as autocrine, neuroprotective, neuritotrophic and antimicrobial factors [18-20]. Three secretases 
(α-, β- and γ) are involved in its sequential cleavage yielding several fragments (cf. Figure 1.1). 
Depending on the type of secretases the products can be divided in non-amyloidogenic and 
amyloidogenic fragments. Both cleavage pathways release ectodomains, which differ in their 






























Figure 1.1 Different pathways of amyloid precursor protein (APP) cleavage  
The transmembrane protein APP underlies two different degradation pathways. The APP cleavage by β-
and γ-secretase liberates Aβ-fragment in the cerebrospinale fluid that exhibits a high propensity to form 
insoluble Aβ aggregates and soluble Aβ-oligomers. Extracellular accumulation of insoluble Aβ aggregates 
and enrichment of soluble Aβ oligomers in brain tissue characterizes one type of neuronal lesions in AD-
affected brain. The cleavage by α- and γ-secretase results in the release of soluble sAPPα and p3. Modified 
figure from Lichtenthaler et al. [21]  
 
The first pathway can be assigned as the non-amyloidogenic pathway. In this case α-secretase 
cleaves APP within the Aβ-domain yielding the soluble product sAPPα and the fragment C83. The 
γ-secretase cleaves the remaining membrane-bound fragment C83 into the product extracellular 
fragments p3 and APP intracellular domain (AICD). sAPPα was assumed to act as autocrine, 
neuroprotective and neuritotrophic factor [18].  
 
In the second case, β-secretase cleaves APP releasing the ectodomain product sAPPβ and a 
membrane-bound fragment C99 [22]. Subsequently, the membrane-bound C99-fragment is 
cleaved by the γ-secretase into AICD and the fragment Aβ. The heterogenous C-terminal 
cleavage by the γ-secretase leads to the formation of Aβ peptides containing 40 or 42 amino 
acids [23]. Due to the high propensity to form neurotoxic, soluble oligomers and insoluble 
aggregates, the formation of Aβ-fragments is characterized as an amyloidogenic or 
pathophysiologic pathway.  
A strong relation between APP and the occurrence of Aβ peptides is noticeable in the brain 
tissue of persons suffering from Down´s Syndrome. As mentioned above, the APP gene is located 
on chromosome 21. In Down´s Syndrome the triplication of this particular chromosome thus 
leads to overproduction of APP. The increased amount of substrate for β- and γ-secretase might 
consequently result in a significantly higher Aβ accumulation accompanied by an early (middle-
age) onset of dementia symptoms [3]. 
 
 
1.3.3 Neuron toxicity of Aβ peptides is mediated by posttranslational N-terminal and C-
terminal modification steps 
 
Nowadays it is well established that Aβ-plaques consist of distinguishable forms of Aβ peptides. 
Analysis of these components demonstrated that they consist of a spectrum of Aβ-species 
containing Aβ(1-40/42), Aβ(3-40/42), Aβ(11-40/42) [24]. The N-terminal truncated forms Aβ(3-
40/42), Aβ(11-40/42) possess a glutamate in the first position that has undergone a chemical 




Aβ(pE11-40/42), respectively [25]. As previously mentioned, sequential modifications at the C-
terminus occur by alternative γ-secretase cleavage at the C-terminus.  
Modification of the N-terminal sequence proceeds stepwise. The first step is the removal of the 
first two or ten amino acids. The Aβ(11-40/42) is most likely processed by the β-secretase [26]. 
The processing of Aβ(3-40) is not fully elucidated yet. The second step is the chemical 
modification from glutamate into glutamic acid (pyroGlu) which is performed by the enzyme 
glutaminyl cyclase (QC) [27-30] (cf. Figure 1.2). In vitro experiments have shown that these 
distinct forms of Aβ peptides exhibit significant differences with regard to solubility in aqueous 
buffers, aggregation propensity and stability [23, 31-34]. A decreased solubility in aqueous 
solutions correlates with an accelerated formation of insoluble aggregates and soluble 
oligomers. 
The most enhanced propensity to form aggregates accompanied by the lowest solubility in 
aqueous buffers was demonstrated for the N-terminally truncated and pyroGlu-modified 
Aβ(pE3-42) and Aβ(pE11-42) [23, 31, 32].  
The reasons for decreased solubility are mainly due to the loss of the N-terminal basicity, which 
is accompanied by an increased hydrophobicity after the pyroGlu-modification. The isoelectric 
points (pI) of the peptides Aβ(3-42) (pI = 5.78) and Aβ(11-42) (pI = 6.02) are shifted into the 
neutral pH range Aβ(pE3-42) (pI = 6.3) and Aβ(pE11-42) (pI = 7.32) after the pyroGlu-
modification. At the isoelectric point the surface of proteins or peptides carries no net electrical 
charge. Due to the missing electrical surface charge, interactions with solvent molecules (water) 
are minimized, leading to decreased solubility [31]. The shifted isoelectric points of pyroGlu-
modified Aβ peptides are closer to the physiologic pH range (pH 7.36 – 7.44) in humans and 
depict a lower solubility accompanied by an accelerated amyloidogeneity in vivo. Schilling et al. 
[34] could demonstrate that the initial velocity of aggregate formation of Aβ(pE3-40/42) and 
Aβ(pE11-40/42) is increased 50-fold to 250-fold compared to the full length Aβ peptide. Those 
results indicate that these fast aggregating Aβ peptides might act as nucleation seeds for Aβ 
plaque formation in vivo. Piccini and co-workers found in their studies that both brains of 
healthy elderly and AD-patients contain Aβ plaque depositions. Interestingly, the composition of 
these plaques differ. The analysis by immunohistochemical staining of brains of healthy persons 
unveil three times higher amounts of plaques containing full-length Aβ peptides than plaques 
containing truncated and pyroGlu-modified Aβ peptides. The AD-affected brain shows an 
opposite ratio of the mentioned plaques [35]. Here the pyroGlu-modified Aβ(pE3-40/42) and 




This shows that the pathohistologic characteristics of AD are obviously due to the accumulation 
of plaques consisting predominantly of pyroGlu-modified Aβ peptides. The reasons for the 
neurotoxicity of these Aβ peptides seem to be various. First, the high aggregation velocity of 
Aβ(pE3-40/42) and Aβ(pE11-40/42) accelerates the progress of neuronal lesions. These peptides 
are protected against (enzymatic) degradation [36] due to the modified N-terminus; 
consequently the plaque accumulation is almost irreversible. Further, the toxicity of plaques 
containing pyroGlu-modified Aβ species seems to be higher compared to plaques containing 
lower amounts or no modified Aβ species. The latter were also found in normal-aged individuals 
showing no dementia-related symptoms. It is suggested that the Aβ(pE3-40/42) and Aβ(pE11-
40/42) alters the membrane permeability of neurons by forming “pores” [37]. 
 
Figure 1.2 Procession of full-length Aβ peptide into toxic Aβ-species 
The full-length Aβ peptide (sequence in one-letter-code) becomes N-terminally truncated by β-
secretase and further unknown events. The resulting glutamate in the first position Aβ(3-40/42) 
and Aβ(11-40/42) is modified by the glutaminyl cyclase. The resulting Aβ peptides which possess 




1.3.3 Deciphering pathoneurophysiological mechanisms unveils strategies for the treatment of 
AD 
 
Currently no cure is available for AD or other chronic neurodegenerative disorders. Therapies 
and systemic medication for AD patients help to maintain the health-related quality of life. Due 
to numerous approaches, in this section only those strategies are described, which are related to 
the Aβ hypothesis and the recently applied therapy using an acetylcholinesterase inhibitor.  
 





















1.3.3.1 Acetylcholinesterase inhibitor 
 
As a consequence of the degeneration of basal forebrain in the course of AD, the level of some 
neurotransmitters e.g. acetylcholine is reduced. This lack of signaling molecules leads to 
impaired signal transmission accompanied by the progressive loss of cognitive abilities [38, 39].  
To improve the cholineric neurotransmission different therapeutic approaches were investigated 
in the past. The aim of these approaches was to increase the presynaptic release of acetylcholine 
and the deceleration of acetylcholine degradation by acetylchloinesterase within the synaptic 
space [38]. This approach shows only small beneficial effects on cognitive, functional and 
behavioral symptoms [40-42]. However, a minor beneficial effect was found for four 
acetylcholinesterase inhibitors: tacrine (1,2,3,4-tetrahydroacridin-9-amine), donezipil (1-Benzyl-4-
[(5,6- dimethoxyindan-1-on-2-yl) methyl]piperidin), rivastigmine ({3-[α-(Dimethylamino)ethyl]phenyl}-N-
ethyl-N-methylcarbamat) and galantamine (3-Methoxy-11- methyl-4a,5,9,10,11,12-hexahydro-6H-
 benzofurobenzazepin-6-ol). These are frequently applied in the therapy of AD patients with mild 
and moderate symptoms [43]. 
 
 
1.3.3.2 Inhibition of β- and γ-secretases can reduce Aβ peptide formation 
 
The release of full-length Aβ peptides is mediated, as mentioned above, by the secretases β and 
γ (cf. Section 1.3.2, Figure 1.1) that catalyze the sequential proteolysis of APP. The β- and γ-
secretase inhibition would lead to a reduced production of full-length Aβ peptide and 
consequently to a reduced formation of the truncated and pyroGlu-modified Aβ peptide (cf. 
Section 1.3.2).  
The current state of drug development regarding β-secretase inhibitors is still in an early phase. 
Several companies e.g. Merck (Germany) and Eisai (Japan) are evaluating potential drug 
compounds in different clinical phases. In 2012 Merck could show that an inhibitor named MK-
8931 can reduce the Aβ accumulation in the cerebral spinal fluid (CSF) of healthy (human) 
subjects by more than 90 % without dose-limiting side effects. Currently, clinical phases II and III 
are in progress to evaluate the efficacy of the mentioned drug candidate [published on Merck 
Newsroom Home (http://www.mercknewsroom.com) in March 2012]. A similar outcome of 




Aβ amount in the CSF in humans [published online in the Eisai News release 
http://www.eisai.com/news/news201247.html].  
The investigation of γ-secretase as target protein in AD treatment is, due to its complexity, less 
advanced compared to the β-secretase. The inhibition of γ-secretase activity can reduce the Aβ 
amount in brain, cerebrospinal fluid and plasma [44, 45]. The application of γ-secretase 
inhibitors in transgenic mice with AD-like neuropathology reveals an improvement of Aβ induced 
cognitive deficits [44, 45]. Among others, one physiological function of the γ-secretase is the 
processing of the Notch protein. The unspecific inhibition of γ-secretase affects also the 
maturation of Notch protein that causes a dysregulated cellular homeostasis, organ side effects 
in the gastrointestinal tract. The development of specific γ-secretase inhibitors is still in the 
preclinical phase and requires further investigations [45]. 
1.3.3.3 Enhancing α-secretase activity can reduce Aβ formation in the human brain 
 
A further therapeutic approach in the treatment of AD is the upregulation of α-secretase. As 
demonstrated in 1.3.2 (cf. Figure 1.1) this enzyme cleaves APP within the Aβ-domain. α-
secretase is the body´s own tool to diminish the Aβ production by reducing the amount of 
substrate for β-secretase. 
It could be demonstrated that α-secretase cleaves APP constitutively and can be stimulated by 
different signaling molecules [46]. The stimulation of α-secretase is not yet fully understood. It is 
likely that the non-constitutional activation is linked to the activity of protein kinase C [47]. For 
clinical applications this matter has to be investigated and remains for now a theoretical 
approach in the treatment of AD. 
 
 
1.3.3.4 Immunotherapy for AD leads to deaggreagation of Aβ plaques 
 
Extensive studies deal with the removal of already manifested Aβ depositions from neuronal 
tissue by immunoreactive mechanisms. Studies in 1999 and 2000 confirmed that the vaccination 
of mice (depicting Aβ induced AD-like pathology) with solubilized Aβ(1-42) or Aβ(1-40) lowers 
the Aβ accumulation in the brain by up to 50 – 60 % [48, 49]. Also passive immunization with 
monoclonal and polyclonal anti-Aβ antibodies leads to improvement of AD pathology in mouse 
models [50, 51].  






1.3.3.5 Inhibition of N-terminal pyroGlu-modification of truncated Aβ peptides reduces the 
accumulation of neurotoxic Aβ-species 
 
As mentioned above, the formation of pyroGlu-modified Aβ peptides (e.g. Aβ(pE3-40/42) and 
Aβ(pE11-40/42) is a crucial step in the cascade of neuropathological progress. In this step N-
terminal glutamate of previously truncated Aβ(1-40/42) into Aβ(E3-40/42) and Aβ(E11-40/42) is 
converted into pyroglutamic acid (pyroGlu or pE). The generated N-terminal lactam ring of the 
peptides Aβ(pE3-40/42) and Aβ(pE11-40/42) hallmarks Aβ peptides with high amyloidogeneity 
(propensity to form insoluble aggregates) and neurotoxicity (cf. Section 1.3.2). This chemical 
reaction is catalyzed by the enzyme glutaminyl cyclase (cf. Figure 1.3). 
 
Figure 1.3 Conversion of N-terminal glutamate into pyroglutamic acid of N-truncated Aβ 
peptides Glutaminyl cyclase (QC) catalyzes the conversion of glutamate into pyroglutamic acid 
in the N-terminal position of truncated Aβ peptides. This pathophysiological side reaction of 
the QC provides highly amyloidogenic and neurotoxic Aβ species. 
 
The interjection of this step constitutes a further strategy for the treatment of AD. The 
spontaneous cyclization reaction of glutamate into pyroglutamic acid at physiological pH exhibits 
a rate constant of 10-9 s-1 in vitro. QC mediated reaction enhances this reaction by a factor of five 
in vitro [52]. In experiments with rats it was demonstrated that an injection of Aβ(1-40) and 
Aβ(3-40) leads to a significant increase of pyroGlu-modified Aβ peptides in the cortex. Rats 
which received intracortical microinjection of QC inhibitors simultaneously with Aβ(1-40) and 
Aβ(3-40) showed significantly decreased formation of pyroGlu-modified Aβ peptides [53, 54]. 
Thus, these findings indicated that QC is involved in the initial pathoneurophysiological progress 
of the development of AD and represents a target enzyme concerning AD treatment.  
The general physiological function of QC that is described in detail in the following section is the 
maturation of peptide hormones and several chemokines e.g. thyrotropin releasing hormone 
(TRH) or chemokine(C-C motif) ligand 2 (CCL2). The down-regulation of a constitutive enzyme 





















demonstrated that QC knock-out mice suffer from mild hypothyreodism. Those mice displayed 
no distinguishable changes in fertility, cognition and ingestion behavior compared to wild-type 
mice. Even blood glucose and glucose tolerance are comparable to wild-type animals. This is a 
significant contrast to TRH knock-out mice. Also (hypothalamic) pGlu-hormones are not 
significantly changed, implying the disposability of alternative hormone maturation (pyroGlu-
modification) mechanisms. It is likely that an isoform of the QC fulfill hormone maturation 
processes (cf. Section 1.4.5) [55]. These results reveal that QC inhibition might be a promising 
strategy to reduce the formation of pyroGlu-modified Aβ peptides in the brain. Recent 
investigations have led to the development of a potent inhibitor compound (PQ912) whose 






1.4 Characterization of the QC as target protein in the treatment of AD 
 
1.4.1 QC of animals and plants/bacteria – enzymes with convergent functionality but different 
archetypes – distribution, reaction, molecular 3D structure and evolutionary aspects 
 
Glutaminyl cyclases (QC; EC 2.3.2.5) are assigned to the family of aminoacyltransferases and are 
widely distributed in vertebrates, plants, insects and bacteria.  
The reaction catalyzed by QCs is the formation of pyroglutamic acid (5-oxoproline) from L-
glutamine and L-glutamate residues at the N-terminal position of peptides or proteins. In 
contrast to plant and bacteria QCs, those from animals requires catalytically active Zn(II) ion for 
catalysis [56, 57]. 
 
 
Studies on the structural and biochemical comparison between different animal QCs revealed 
that several amino acids in the active center and in the Zn(II) binding motifs are conserved (cf. 
Figure 1.5 B). Importantly, the removal of Zn(II) from the active site by dialysis against chelators 
leads to catalytic inactivation [56].  
The most remarkable difference between animal and plant/bacterial QCs lies in the tertiary 
structure of these proteins. While animal QCs share the common globular α/β-hydrolase fold (cf. 
Figure 1.5 A) [58] plant and bacterial QC are defined by five-bladed β propeller (cf. Figure 1.5 C) 
with a central structure stabilizing Zn(II) ion [59]. The molecular weight difference between 
animal QC (38 kDa – 40 kDa) and plant and bacterial QC (approx. 31 kDa) is a further distinctive 
feature.  
 
Figure 1.4 Peptides with N-terminal glutamine and glutamate can be converted by QC 
The cyclization of N-terminal glutamine and glutamate residues into pyroglutamic acid (5-
oxoproline) leads to the loss of N-terminal basicity. It should be noted here that substrates with N-
terminal glutamine are preferred. The conversion velocity of these substrates is 10,000-fold faster 



























Figure 1.5 Tertiary structures of animal and 
plant/bacteria QC 
The hQC (A/B yellow cartoon) and the 
mitochondrial isoform of Drosophila melanogaster 
QC (A/B cyan cartoon) share the same α/β-
hydrolase fold (A) and present conserved active 
center amino acids and Zn(II) binding motifs (B). 
Exemplarily, the structure of Carica papaya QC (C) 
presents the five-bladed propeller structure of 
plants and bacteria. The Zn(II) ion in animal QC 
possesses catalytic function. The Zn(II) ion in plants 
and bacteria putatively mediates conformational 
stability.  
hQC: pdb 2AFW, Huang et al. 2005; Res.1.56 Å 
C. papaya QC: pdb 2FAW, Wintjens et al. 2006; Res 1.70 Å  
D. melanogaster QC: own (unpublished) results (c.f. 
3.5.2)  
 
Interestingly, animal QCs exhibit also two conserved Zn(II) binding motifs and one disulfide 
bridge. The strong overall structural similarity with the bacterial aminopeptidase of Aeromonas 
proteolytica (ApAP) and the sequence homology of approx. 27 % [determined using Blast® online 
protein alignment service; http://blast.ncbi.nlm.nih.gov/Blast.cgi] indicate that the bacterial 
aminopeptidase is the evolutionary ancestor of animal QC [57, 60]. At this point it should be 
mentioned that animal QC requires only one Zn(II) ion for catalysis. The second Zn(II) binding 
motif is not occupied [61, 62]. However, ApAP requires both Zn(II) ions for catalytic activity. Both 
in QC and ApAP Zn(II) the substrate binding motives are identical [63], (cf. Figure 1.6). 
 
The QC from Carica papaya and Zymomonas mobilis as representatives for plant and bacterial 













identity of approx. 41 %. Thus it can be hypothesized that bacterial QCs are evolutionary 
ancestors of plant QCs. 
 
  
Figure 1.6 Structure alignment of mono-zinc animal QC and di-zinc bacterial aminopeptidase The 
overall structure of isoDromeQC (yellow cartoon), hQC (light blue) and ApAP (pink) share the 
common α/β-hydrolase fold. The active center (B) of these enzymes depict conserved Zn(II) binding 
motifs. The bacterial aminopeptidase requires two Zn(II) ions for catalysis, Whereas in QCs only one 
Zn(II) binding site is occupied. The structural homologies imply an evolutionary relationship of ApAP 
to QCs. 
hQC: pdb 2AFW, Huang et al. 2005[62]; Res.1.56 Å; ApAP: pdb 3FH4 [65], Yong et al. 2009, Res.: 
1.95 Å; D. melanogaster QC: own (unpublished) results (c.f. 3.5.2) 
 
1.4.2 Discovering the physiological function of animal QC, posttranslational processing of 
peptide precursors by conversion of N-terminal glutamine into pyroglutamic acid 
 
For the activation of signaling molecules such as hormones, often posttranslational modification 
steps are required [66]. These steps might include glycolization, C-terminal amidation, 
hydroxylation, proteolytic cleavages and N-terminal pyroglutamyl formation [30]. Fischer and 
Spiess described in 1986 for the first time that the formation of N-terminal pyroGlu from N-
terminal glutamine in extracts from bovine pituitary is due to enzymatic activity. They observed 
the conversion of (Gln1)gonadotropin-releasing hormone (Gln1(GnRH)), (Gln1,Gly4)thyrotropin-
releasing hormone (Gln1,Gly4(TRH)), and H-Gln-Tyr-Ala-OH to the respective pyroglutamyl 
peptides GnRH, Gly4(TRH) and pyroGlu-Tyr-Ala-OH [30]. Busby and Quackenbush observed in the 
same year this reaction in rat brain, porcine pituitary and human B-lymphocytes [28]. Pohl et al. 
showed that QC is predominantly expressed in brain and peripheral endocrine and exocrine 
glands [67]. Böckers et al. accumulated evidence that the peptide hormone maturation is 








co-localized in secretory vesicles in pituitary and hypothalamus [68]. A few years later Awadé et 
al. isolated numerous regulatory peptides containing N-terminal pyroglutamic acid [69]. Schilling 
et al. proved that numerous precursors of pyroGlu-peptides and pyroGlu-proteins with distinct 
physiologic functions can be converted by QC in vitro. [57].  
The pyroGlu-modified N-terminus is crucial for receptor recognition [36, 70, 71]. The pyroGlu-
modified peptides depict a prolonged half-life time. Due to the lacking N-terminal basicity these 
peptides lost an essential recognition signal for aminopeptidases. These investigations could 
clearly demonstrate the participation of QC in hormone anabolism [57].  
A further physiological function of QC and a related isoform QC is the activation of chemokines 
e.g. CCL2 and monocyte chemoattractant protein 1 (MCP-1) [72].  
The physiological function of QC in the fruit fly Drosophila melanogaster is unknown. It is 
suggested that DromeQC and isoDromeQC also play a role in the maturation of precursors of 






1.4.3 The postulated catalytic cycle of animal QCs 
 
The catalytic cycle of the conversion of substrates with an N-terminal glutamine was postulated 
by Schilling et al. [60]. In this hypothetic catalytic cycle an acid base catalyst accepts a proton 
from the α-amino group of the glutamine substrate (cf. Figure 1.7 (2)). Structural analysis 
indicates that a glutamate residue in position 201 in hQC and 190 in isoDromeQC, respectively, 
abstracts this mentioned proton. Most likely in a concerted manner, the catalytically active Zn(II) 
ion acts as Lewis acid and accepts electrons from the γ-carbonyl oxygen accompanied by an 
increase in the electrophilicity of the γ-carbonyl carbon (cf. Figure 1.7 (2)). In this state, the α-
amino nitrogen group can attack the γ-carbonyl carbon and would form a tetrahedral 
intermediate (cf. Figure 1.7 (3)). The proposed transfer of the proton from the protonated 
glutamate residue E201/190 to the γ-amino group enables the release of ammonia from the γ-
carbonyl carbon. This proton transfer is putatively executed by the active center amino acids 
E201/190, D305/293 and D248/228. The formation of the 2-oxoproline ring is completed once 
the delocalized γ-oxygen electrons return to the oxygen carbon double bond (cf. Figure 1.7 (4)). 
This mechanistic cycle is discussed in detail in Section 4.2.2. 
 
 
Figure 1.7 Postulated reaction cycle 
of Zn(II) dependent QC in the active 
center [60] The postulated catalytic 
cycle of glutaminyl cyclase depicts 
the formation of a tetrahedral 
reaction intermediate after the 
deprotonated α-amino group has 
attacked the γ-carbonyl 
nucleophilically. This intermediate 
breaks down into ammonia and 
























































1.4.4 Structural characterization of human and Drosophila melanogaster QC 
 
As described in Section 1.4.2, hQC and isoDromeQC show a strong structural and sequence 
homology (cf. Figure 1.5 A). Both share the α/β-hydrolase fold. The center of the QC overall 
structure consists of a β-sheet, which is composed of five parallel (β1, β3-β6) and one antiparallel 
β-strand (β2). This twisted β-sheet is coated by nine α-helices. In hQC six helices (α2-α5, α8 and 
α10) encircle the convex face of the β-blade. Three further helices (α6, α7 and α9) are positioned 
on the concave face of the β-blade. One further helix (α1) is situated at the N-terminus. In 
isoDromeQC seven helices (α1 – α5, α8 and α9) encircle the convex side of the β-sheet. Hence, two 
α-helices (α6 and α7) flank the concave side. [74]. In addition to that common overall structure, 
the isoDromeQC is hallmarked by two further N-terminal, antiparallel β-strands β-1 and β0.  
In both enzymes the active center with the catalytic Zn(II) ion is located in a loop region (cf. 
Figure 1.5 B). The distance between Zn(II) ion and the surface is approx. 8 Ångström. The 
catalytically active Zn(II) ion in the resting state is tetrahedral coordinated by two conserved 
carboxylic moieties and an imidazole group (D159 (OD2), E202 (OE2) and H330 (NE2) in hQC and 
D153 (OD2) and E191 (OE2) and H318(NE2) in isoDromeQC) [75]. The fourth coordinative 
position of Zn(II) is occupied by a water molecule. This water molecule acts as placeholder in the 
resting state and will be replaced by the substrate molecule. The water molecule is in hydrogen 
bond distance to the residue E201/E190. Two further aspartate residues (D305 and D248 in hQC 
and D293 and D228 in isoDromeQC) in the second shell around the Zn(II) may play a role in 
substrate and product binding and the suggested proton transfer during the reaction trajectory. 
The human enzyme presents N-linked glycosylation at D49 which indicates no influence on the 
catalytic activity [75]. Glycosylation sites in isoDromeQC are not described [74]. 
A further characteristic is the existence of a disulfide bond in both hQC and isoDromeQC. The 
enzymes present two conserved cysteines H139 and H164 in hQC, and H136 and H158 in 
isoDromeQC, forming a disulfide bond [75].  
 
 
1.4.5 Distinct isoforms of mammalian and insect QCs are differently distributed in tissues and 
cell compartments 
 
In animals (man, mice and fruit fly), at least two isoforms of QC exist [73, 76-78]. In humans and 
mice (mQC and isomQC), QCs were found which show similarities in terms of substrate 
specificity pattern, Zn(II) dependence and inhibitor sensitivities [78]. Biochemical analysis of the 




that mediates the retention of this isoform in the Golgi complex [77]. Contrarily, hQC and mQC 
exhibit an N-terminal secretion signal sequence and are targeted to the endoplasmatic reticulum 
[67]. Investigations concerning the transcript concentration of mQC and isomQC of several 
organs of mice, as a mammalian model system, showed that secretory mQC is preferentially 
expressed in the neuronal tissue and in a minor extent in intestines [77]. The Golgi-localized 
sister enzyme (isomQC) was ubiquitously expressed in an almost equal extent in brain and 
intestine tissues. 
The sequence identity of hQC and isohQC is approx. 45 % [77]. The 3-D stucture analysis reveals 
differences in terms of overall structure and architecture of the active centers [76]. These 
differences between hQC and isohQC likely cause weaker (2–15-fold) QC activities on different 
synthetic substrates in comparison with hQC activities [77].  
Nevertheless, similarities of catalytic properties and distinct subcellular and tissue distribution of 
both isoforms unveil a new strategy in terms of QC-inhibition based AD treatment. The 
development of hQC specific inhibitors might help to down-regulate the levels of 
pathoneurological pyroGlu-Aβ-procession in the brain without an impairment of physiological 
functions. At least in the above-mentioned mouse model, the respective QC knock-out mutants 
show no severe phenotypical changes. Thus it is likely that the lack of one QC isoform can be 
compensated by its second isoform [55]. 
 
Analogously to mammals, in Drosophila melanogaster different isoforms also exist with distinct 
subcellular localization. While DromeQC possesses an N-terminal secretion signal peptide, the 
isoDromeQC contains either an N-terminal mitochondrial targeting signal or a secretion signal 
due to alternative splicing. Alongside structural aspects, kinetic and inhibition constants as well 






1.5 Aim of the work, strategy and motivation 
 
1.5.1 Aim of the work 
 
A reason for the necessity of enzyme-specific inhibition is that many inhibitors investigated so 
far interact with the catalytically active Zn(II) ion in the active center of the QC. Those inhibitors 
might interfere with other Zn(II)-dependent enzymes (e.g. dipetidyl peptidase 4) and thus might 
cause severe side effects [unpublished data of the Probiodrug Company].  
 
The long-term goal of this field of investigation is the development of enzyme-specific and 
mechanism-based hQC inhibitors. Most enzyme-specific inhibitors would adopt a molecular 
structure that occurs in the trajectory of the QC catalysis – a reaction intermediate or a 
transition state. Transient intermediate states such as the postulated tetrahedral intermediate 
(cf. Section 1.4.3) are frequently highly energetic and short-lived entities whose decomposition 
results in the formation of further intermediate states or in the release of the reaction product 
and the (regenerated) enzyme. The enzyme-specific binding of inhibitors, which mimic sterical 
and conformational features (e.g. bond length, bond angles) of the reaction intermediate or a 
transition state might interrupt the catalytic cycle and thus act as suicide substrate. Therefore, 
the structural characterization of intermediate states motivates this project.  
 
In this regard, the main goal of this work is the elucidation of the glutaminyl cyclization 
mechanism of hQC. This includes the definition of discrete mechanistic steps, e.g., substrate 
binding, formation and decomposition of postulated tetrahedral intermediate states and 
product release. In addition, microscopic reaction rates of these single steps and the definition 
of postulated proton transferring pathways is in the focus of interest. 
Furthermore, in this work it is attempted to delineate peculiarities of the glutamyl cyclization 






1.5.2 Strategy and motivation 
 
In the planning phase of this project the heterologous expression of hQC yields insufficient 
amounts of protein lacking adequate conformational stability. For this reason the mitochondrial 
isoform of the well studied model Drosophila melanogaster QC (isoDromeQC) was expressed in 
Escherichia coli. The sequence identity with hQC (cf. Section 1.4.5), conserved amino acid 
residues in the active center and nearly equal kinetic and inhibitory properties and pH behavior 
imply analogous mechanistic features.  
 
In order to investigate the role of certain amino acid residues in the active center and their 
involvement in substrate binding and further catalytic steps, e.g. deamination or proton transfer, 
the following variants were used. Zn(II)-isoDromeQC_E190Q, Zn(II)-isoDromeQC_D293N, Zn(II)-
isoDromeQC_D293A and Zn(II)-isoDromeQC_D228N. In these variants acidic (electrically 
negatively charged) γ-carboxylate moieties were substituted for polar and uncharged 
carboxamide groups with isosteric conformation. In case of Zn(II)-isoDromeQC_D293A, this 
variant possesses an uncharged non-polar methyl group with altered steric properties instead of 
acidic carboxylate.  
In the case that these amino acid residues play a role in the enzymatic reaction cycle, their 
substitution would lead to significant effects on the kinetic constants. The Michaelis Menten 
constant (KM) as a measure of affinity between substrate and enzyme would be altered in the 
event that one of these substituted reactive groups mediates the substrate binding. For the 
kinetic investigations, several synthetic N-terminal glutamine substrates were used with the 
Zn(II)-isoDromeQC wild type and the variants to determine alterations in terms of kinetic 
constants e.g. Michaelis-Menten constant (KM ), the turnover rate (kcat) and the catalytic 
efficiency (kcat /KM). 
Former investigations displayed that the deprotonation of the α-amino group of the N-terminal 
glutamine of the substrate peptide is crucial for the required proton abstraction by an acid/base-
catalyst. Further, the γ-amino group has to be protonated in order to be released as free 
ammonia. In order to determine both the mentioned acid/base catalyst as well as the proton 
transferring groups, the catalytic efficiency of Zn(II)isoDromeQC wild type and the variants was 
measured as a function of the pH. This method allows the determination of pka values of 




Substitution of pivotal amino acid residues in the variants would result in altered pH/catalytic-
efficiency profiles.  
The detection of (tetrahedral) reaction intermediates was the predominant aim of this work. For 
that purpose, two spectroscopic methods were chosen which allow the observation of the 
electronic environment of the catalytic active metal ion. UV/Vis stopped-flow analysis using the 
photodiode array and electron paramagnetic resonance spectroscopy (EPR). This analysis 
requires the substitution of diamagnetic and UV/Vis and EPR silent Zn(II) into paramagnetic 
Co(II). The metal replacement has no significant influence on the catalytic properties or the 
conformational stability of the QC. Co(II)-isoDromeQC and the variants Co(II)-
isoDromeQC_E190Q, Co(II)-isoDromeQC_D293N and Co(II)-isoDromeQC_D228N were incubated 
with different synthetic N-terminal glutamine and glutamate substrates. This enables the 
detection of changes in the electronic environment of the catalytically active Co(II) during the 
catalysis with the intention of detecting the accumulation of intermediate reaction states. 
Further, an inhibitor was incubated with the Co(II) substituted enzymes to investigate the nature 
of the inhibitor-metal interactions.  
X-ray crystallography was a further biochemical approach used to visualize intermediate states.
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Acetic acid Carl Roth GmbH & Co KG, Karlsruhe 
Acrylamid/Bisacrylamide (30 %,Mix 37.5:1) Carl Roth GmbH & Co KG, Karlsruhe 
Agar Agar AppliChem GmbH, Darmstadt 
Agarose AppliChem GmbH, Darmstadt 
Ammonium chloride Carl Roth GmbH & Co KG, Karlsruhe 
Ammonium peroxide disulfate (APS) AppliChem GmbH, Darmstadt 
Ammonium sulfate AppliChem GmbH, Darmstadt 
Ampicillin AppliChem GmbH, Darmstadt 
Baysilone paste GE Bayer Silicones GmbH & Co. KG, Leverkusen 
Bis-(2-hydroxyethyl)-imino-tris-(hydroxymethyl)-
methan (Bis/Tris) 
AppliChem GmbH, Darmstadt 
Bromophenol blue (sodium salt) AppliChem GmbH, Darmstadt 
Calcium chloride Carl Roth GmbH & Co KG, Karlsruhe 
Chelex 100 Resin 100-200 Mesh size Bio-Rad Laboratories GmbH; München 
cobalt chloride anhydrous, beads, 99.999 % trace 
metal basis 
Sigma-Aldrich Chemie GmbH, Deisenhofen 
Coomassie Brillant blue G-250 AppliChem GmbH, Darmstadt 
Dimethyldichlorsilane AppliChem GmbH, Darmstadt 
Ethanol (96 %, denatured 1 % MEK) Carl Roth GmbH & Co KG, Karlsruhe 
Ethylenediaminotetraacetic acid (EDTA) AppliChem GmbH, Darmstadt 
Glycerol (96 %) Carl Roth GmbH & Co KG, Karlsruhe 
Glycine Carl Roth GmbH & Co KG, Karlsruhe 
Guanidine Hydrochloride AppliChem GmbH, Darmstadt 
Hydrochloric acid (37%) Th. Geyer GmbH & Co. KG, Renningen 
Histidine AppliChem GmbH, Darmstadt 
Kanamycin sulfate Carl Roth GmbH & Co KG, Karlsruhe 
α-Ketoglutarate Sigma-Aldrich Chemie GmbH, Deisenhofen 
Magnesium chloride, hexahydrate Carl Roth GmbH & Co KG, Karlsruhe 
Magnesium sulfate Carl Roth GmbH & Co KG, Karlsruhe 
β-Mercaptoethanol Carl Roth GmbH & Co KG, Karlsruhe 
2-(N-morpholino)ethanesulfonic acid hydrate (Mes) AppliChem GmbH, Darmstadt 
Nickel sulfate hexahydrate AppliChem GmbH, Darmstadt 
Nicotinamide adenine dinucleotide, reduced 
(NADH) 
Sigma-Aldrich Chemie GmbH, Deisenhofen 
Parafin oil Hampton Research Coorp., USA 
1,10-phenanthroline Sigma-Aldrich Chemie GmbH, Deisenhofen 
Phenyl phosphorodiamidate Sigma-Aldrich Chemie GmbH, Deisenhofen 
Phosphoric acid (85 %) Carl Roth GmbH & Co KG, Karlsruhe 
Potassium chloride Fluka Chemie GmbH, Switzerland 
Potassium dihydrogen phosphate Carl Roth GmbH & Co KG, Karlsruhe 
Potassium hydroxide AppliChem GmbH, Darmstadt 
Polyethylene glycol (PEG) 200, 1000, 4000 6000 Fluka Chemie AG, Buchs, Switzerland 
Polypropylene glycol (PPG) 400 400 Fluka Chemie AG, Buchs, Switzerland 
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2-Propanol AppliChem GmbH, Darmstadt 
Sodium acetate, trihydrate AppliChem GmbH, Darmstadt 
Sodium chloride AppliChem GmbH, Darmstadt 
Sodium dodecylsulfate (SDS) AppliChem GmbH, Darmstadt 
Sodium hydroxide AppliChem GmbH, Darmstadt 
N,N,N´,N´-Tetramethylethylendiamin (TEMED) Carl Roth GmbH & Co KG, Karlsruhe 
Tris-(hydroxymethyl)-aminomethane (Tris) AppliChem GmbH, Darmstadt 
Tryptone AppliChem GmbH, Darmstadt 
Yeast extract AppliChem GmbH, Darmstadt 
Zinc chloride (hexahydrate) AppliChem GmbH, Darmstadt 
  
Peptides Supplier 
AFA Probiodrug AG, Halle (Saale); Bachem 
H-E-F-R-H-OH Probiodrug AG, Halle (Saale); Innovagen, Sweden 
H-E-W-OH Bachem AG, Switzerland 
H-Q-aminomethyl coumarine (Q-AMC) Bachem AG, Switzerland 
H-Q-F-R-H-OH Probiodrug AG, Halle (Saale); Innovagen, Sweden 
H-Q-G-P-OH Probiodrug AG, Halle (Saale) 
H-Q-Q-OH Bachem AG, Switzerland 
H-Q-β naphtylamine (Q-β NA) Bachem AG, Switzerland 
pyroglutamyl-F-A-OH Probiodrug AG, Halle (Saale) 
pyroglutamyl-F-R-H-OH Probiodrug AG, Halle (Saale); Innovagen, Sweden 
  
Enyzmes and Marker Supplier 
DNase AppliChem GmbH, Darmstadt 
Glutamate dehydrogenase Sigma-Aldrich Chemie GmbH, Deisenhofen 
pyroglutamyl aminopeptidase Probiodrug AG, Halle (Saale) 
Plasmid prapartion QIAprepR Spin Miniprep kit (50) Qiagen GmbH, Hilden 
Lysozyme AppliChem GmbH, Darmstadt 
Unstained protein molecular weight standard Gene 
RulerTM 1 kb DNA ladder 0,5 μg/μl 
Fermentas GmbH, St.Leon-Rot 
  
E. coli strains Supplier 
E. coli-M15 Invitrogen 
  
Plasmids Supplier 
pQE31 Probiodrug AG 
  
Devices/Materials Supplier 
AKTApurifier, AKTAprime plus GE Healthcare Europe 
Circular dichroism spectropolarimeter, Chirascan Applied Photophysics Ltd., UK 
Centrifuges,  
AvantiJ-20XPI Beckmann Coulter GmbH, Krefeld 
AvantiJ-30I Beckmann Coulter GmbH, Krefeld 
Biofuge Pico UniEquip GmbH, Martinried 
Universal 320R Hettich AG, Bach, Switzerland 
Centrifuge tubes (50, 500, 1000 ml) Beckmann Coulter GmbH, Krefeld 
Hydrophobic Interaction Chromatography 200 ml 
Butylsepharose in a XK16/20 column provided 
GE Healthcare Bio-Sciences GmbH, Munich 
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HiPrepTM 26/10 Desalting GE Healthcare Bio-Sciences GmbH, Munich 
UnoQ6- column Bio Rad Laboratories GmbH, Munich, Germany 
HisPrep FF 16/10 GE Healthcare Bio-Sciences GmbH, Munich 
HiLoad 16/600Superdex 75 pg GE Healthcare Bio-Sciences GmbH, Munich 
  
Concentrator, Vivaspin 0.5 ml, 15 ml,20 ml (10.000 
MWCO) 
Sartorius AG Göttingen 
Vivaspin Gap Sartorius AG Göttingen 
  
Cover plates, 18 mm VWR International GmbH, Darmstadt 
Crystallization plates (24 well), costar Corning, Inc., USA 
Electrophorese device, EV 231 Consort nv, Belgium 
Electroporator, MicroPulser electroporator Bio-Rad Laboratories GmbH, Munich 
EPR-spectrometer EleXsys E600 Bruker BioSpin Corporation, Billerica, USA 
Gel documentation chamber Raytest Ida Herolab, Wiesloch 
Incubation shaker Unitron Infors AG, Bottmingen, Switzerland 
ITC system, ITC200 GE Healthcare 
pH electrode Hettler Toledo, Giesen 
Precision cuvettes, suprasil Hellma GmbH & Co. KG, Muhlheim 
Sterile filters, 0.20μm VWR International GmbH, Darmstadt 
Stopped-flow system, SX.20 MV Applied Photophysics Ltd., UK 
Superloop (10 ml, 50 ml, 150 ml) GE Healthcare Europe GmbH, Freiburg 
Thermoblock, Digital Dry Bath 3721D Fisher 
Bioblock 
Scientific, UK 
UV-Vis Spectrometer, V-650 Jasco GmbH, Groß-Umstadt 
  
X-ray Supplier 
MM-007 rotating-anode generator, Micromax 007- Rikagu Corp., USA 
HF X-stream 2000, R-AXIS IV++ imaging-plate 
system 
Rikagu Corp., USA 
Software Supplier 
Blast Online alignment service 
http://blast.ncbi.nlm.nih.gov/Blast.cgi 
ClustalW2 http://www.ebi.ac.uk/Tools/msa/clustalw2/ (Larkin 
et al., 2007) 
CCP4 suite Bailey, 1994 
ExPasy, ProtParam http://web.expasy.org/protparam/ 
Kaleidagraph Synergy Software, USA 
SigmaPlot Version 11.0 Systat Software, Inc 
Origin-7 OriginLab Corporation, USA 
Phenix suite (Adams et al., 2010 a) 
PYMOL DeLano Scientific LLC 
SigmaPlot Version 11.0 Systat Software, Inc 
XDS Kabsch, W. (1993). Automatic processing of rotation 
diffraction data from crystals of initially unknown 
symmetry and cell constants. J. Appl. Cryst.26, 795-
800 




2.1 Expression of the mitochondrial isoform of glutaminyl cyclase from Drosophila 
melanogaster in Escherichia coli 
 
An untagged as well as the N-terminal His6-tagged version of wild-type QC and the variants were 
expressed heterologously in Escherichia coli under identical conditions. Plasmids bearing either 
the Drosophila-melanogaster QC isoenzyme gene (CG 5976 - PB) or the different genetically 
modified QC constructs were provided by the Probiodrug Company. After transformation in 
Escherichia coli M15 cells by electroporation, the cells were plated on lysogeny broth (LB) plates 
containing 2 % agar, 100 µg/ml ampicillin and 50 µg/ml kanamycin, and cultivated at 37°C. One 
single colony was used to inoculate 100 ml LB medium containing ampicilin and kanamycin as 
selection markers. After cultivation at 37°C for approximately 16 h, the cell culture was 
centrifuged for 10 minutes at 3320 g and re-suspended in fresh LB medium. A main culture (6 x 1 
l LB medium in 2 l chicane shaking flasks) was inoculated with these cells so that the start OD600 
was approx. at 0.1. The incubation was carried out at 37°C at 200 rpm until the OD600 had 
reached 0.8. Then 200 µM IPTG were added and the temperature was set to 20°C. After 14 –
 16 hours, the cells were harvested by centrifuging for at least 30 minutes at 5749 g.  
 
 
2.2 Cell disruption 
 
Cell lysis was performed by two freeze thaw cycles: For this purpose harvested cells were pre-
incubated with lysozyme in lysis buffer (cf. Table 2.2). The suspension was slowly frozen at –
 80°C and subsequently thawed at room temperature. A repetition of the freeze and thaw 




The original protocols for QC purification were established by the Probiodrug Company. During 
the practical phase of preparing the present doctoral thesis, various steps were optimized or 
omitted, resulting in highly modified protocols. 
The adequate conformational stability of the QCs allows that all purification steps could be 
performed at room temperature. All buffers were filtered and degassed before use. The 
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chromatography columns which were used are listed in Table 2.1, including the applied flow 
rates if these are not mentioned in the text.  
2.3.1 Purification of His6-tagged QC 
 
Immobilized metal ion affinity chromatography (IMAC) was used to obtain high amounts of 
purified QC. 
After cell disruption the supernatant obtained by centrifugation of the raw extract at 36,000 g 
for 30 minutes at 4°C was diluted to a protein concentration of approximately 10 – 15 mg/ml. 
The resulting protein solution was applied on a nickel-nitrilotriacetic acid (Ni-NTA) chelating 
column (GE Healthcare Bio-Sciences GmbH, Munich, Germany) equilibrated with Ni-NTA-buffer-
A, (cf. Table 2.2) by using an Äkta FPLC system (GE-Healthcare). Since imidazole is a potent 
inhibitor of QC [79], histidine was used for the following washing and elution steps. The column 
was washed with elution buffer containing 1 mM histidine (Ni-NTA-buffer cf. Table 2.2) until the 
absorption at 280 nm reached the baseline. A second wash step was performed by using the 
elution buffer containing 17 mM histidine. Protein elution was achieved by applying a gradient in 
which the histidine concentration was constantly increased to 100 mM histidine within 120 ml (6 
column volumes). A good peak separation was assured by using flow rates that did not exceed 
5 ml/min. In most cases SDS-PAGE with 15 % acrylamide/bisacrylamide gels showed protein 
fractions with high homogeneity. It should be noticed, however, that in some batches minor 
impurities were visible in the gel. In that case, a further run with the size-exclusion 
chromatography (SEC) column was used to eliminate the impurities and to transfer the protein 
to the storage buffer (cf. Table 2.2). If this gel filtration was not necessary, the pure protein was 
concentrated and desalted by membrane filtration (Vivaspin concentrators, 10 kDa MWCO, 
Sartorius, Göttingen, Germany). Typically QC was concentrated to 10 – 35 mg/ml before freezing 
it in liquid nitrogen.  




2.3.2 Purification of untagged QC 
 
As described above, cobalt-substituted QC was used for experiments employing UV/Vis and EPR 
spectroscopy. In order to perform successful experiments in that direction, it is a strict 
requirement to avoid any metal chelating substances in the samples. Since the affinity of a His6 
tag to metal ions might disturb these measurements in an incalculable manner, it was necessary 
to express and purify QC without an additional His6 tag.  
The purification of the untagged protein was done by the consecutive use of hydrophobic 
interaction chromatography (HIC), ion exchange chromatography and, if required, a size-
exclusion chromatography step. The HIC column was equilibrated with HIC-buffer-A (cf. Table 
2.2). The protein raw extract from cell lysis (cf. Section 2.2.) was diluted with HIC-buffer-A to a 
protein concentration of 10 – 12 mg/ml. To ensure that the QC binds to the column, it is 
important to adjust the ionic strength of the protein sample before it is loaded on the HIC-
column. The ionic strength of the protein sample has to be equal to that of the HIC buffer-A. The 
ionic strength was measured by using a conductometer. HIC-buffer-A with 1.2 M ammonium 
sulfate has a conductance of approximately 160 mS/cm. Loading was achieved with a peristaltic 
pump and a flow rate of 5 – 6 ml/min. Unbound impurities were removed by washing the 
column with HIC buffer A. The second wash step included a decrease of the ammonium sulfate 
concentration to 1.0 M (17 % HIC-buffer-B) to elute unspecific bound proteins. Subsequently the 
ammonium sulfate concentration was gradually set to zero (100 % HIC-buffer-B) and the eluate 
was collected in 10 ml fractions. The QC-containing fractions were concentrated and desalted 
three times (“Vivaspin” concentrators, 10 kDa MWCO) to change the buffer into the low-salt IEC-
buffer-A. The binding capacity of the applied ion exchange column amounts to 80 mg protein. 
Therefore, in order to get an optimal separation profile, the QC-containing protein solution was 
loaded in portions of 60 mg to the equilibrated column. The increase of the sodium chloride 
concentration from 0 mM to 300 mM (100 % IEC-buffer-B) with a flow rate of 2.5 ml/min in 
24 min led to base-line-separated elution peaks. Similar to the purification of the His6-tagged QC, 
in some cases, a size-exclusion chromatography step was required to yield QC with high 
homogeneity. This step was performed under the same conditions as described above. The 
storage conditions were identical to the His6-tagged QC. After all purifications, the enzyme 
activity was proven by the GDH-coupled assay described below [80]. 




Table 2.1 Column specifications and applied flow rates 






 His-Prep Fast Flow 16/10 20 4.0 – 5.0 
HIC
B
 Butylsepharose Fast-Flow 200 10 – 20 
IEC
C
 UnoQ 6 2.0 – 2.5 
SEC
D
 Superdex 75, 16/60,  120 1.0 – 1.3 
 A) Immobilized Metal ion Affinity Chromatography – provided by GE-Healthcare 
 
B




) Ion Exchange Chromatography – provided by-Bio Rad Laboratories GmbH, Munich, Germany 
 
D
) Size Exclusion Chromatography – provided by GE-Healthcare 
 
E
) Total volume of medium (ml) 
 
F
) Flow rate (ml/min) 
 
Table 2.2 Utilized buffers for preparation, storage and activity test 
Buffer Compounds pH 
lysis  50 mM Bis/Tris, 1 mg/ml lysozyme 6.8 – 7.0 
Ni-buffer-NTA-A 50 mM phosphate based saline (PBS), 1 mM histidine 7.2 – 7.4 
Ni-buffer-NTA- B 50 mM Na2HPO4/NaH2PO4, 100 mM histidine 6.8 
HIC-buffer-A 50 mM Na2HPO4/NaH2PO4, 1.2 M ammonia sulfate 6.8 
HIC-buffer-B 50 mM Na2HPO4/NaH2PO4 6.8 
IEC- buffer-A 25 mM Bis/Tris 6.8 
IEC- buffer-B 25 mM Bis/Tris, 300 mM NaCl 6.8 
Gel-filtration/storage buffer 25 mM Bis/Tris, 100 mM NaCl 6.8 
activity assay  50 mM Tris/HCl 8.0 
 
2.4 Determination of protein concentration 
 
The concentrations of all QC constructs were determined via UV/Vis spectroscopy at a 
wavelength of 280 nm. At this wavelength, aromatic amino acids and cysteine can be detected. 
The content of these amino acids leads to the extinction coefficient of the entire protein. A 
theoretical extinction coefficient was calculated with the online program “ProtParamTool” 
[http://web.expasy.org/protparam/]. The extinction coefficient for the native QC was calculated 
as 46,870 M-1 cm-1 ( 1 g/l = 1.237), while that of the His6-tagged is 46,995 M
-1 cm-1 (1 g/l = 1.241). 




2.5 Preparation of Cobalt (II) substituted QC 
 
A modified protocol provided by Probiodrug [56] was used to exchange the metal ions in the 
active center of the QC. Recombinant QC (≈25 mg/ml) was dialyzed against 1 l chelating buffer 
containing 50 mM sodium phospate and 100 mM sodium chloride 5 µM 1,10-phenanthroline 
and 5 µM EDTA, pH 6.8 in order to remove the Zn(II) catalytically and to generate the 
apoprotein. After 4, 8 and 14 h the chelating buffer used was exchanged for fresh buffer. Three 
additional dialyzing steps with 2,5 l 50 mM sodium phosphate buffer containing 100 mM NaCl, 
25 g/l Chelex-100, pH 6.8 were performed (buffer exchange after 4 h, 8 h, 14 h) and the 
apoenzyme was tested for QCactivity . For a typical apoprotein preparation, a residual activity of 
<1 % (compared to the holo-enzyme) was observed. The absorption of 1,10-phenanthroline at 
260 nm was used to ensure the complete removal. Chelex-100 is insoluble and can be eliminated 
by filtering the buffer. 
 
 
2.5.1 Cobalt (II) insertion 
 
In order to reconstitute QC with Co(II) ions the apoenzyme was incubated with a 
substoichiometric amount (0.95 equivalents) of CoCl2. The mixture was incubated for 15 minutes 
on ice. During that time the resulting solution changed optically from colorless to pinkish. The 
cobalt QC should show 95 % of the specific enzyme activity compared to the zinc enzyme.  
 
 




2.6 Enzyme activity assays 
 
In order to determine QC activity, two different assays were performed according to Schilling 
and co-workers [80]. The underlying principles of those experiments will be described briefly in 
the following: 
 
2.6.1 UV/Vis absorption spectroscopic assay 
 
Glutamate dehydrogenase (GDH) is used as an auxiliary enzyme in this spectrophotometric 
assay. GDH catalyzes the reductive amination reaction of ammonia generated during the QC 
reaction and exogenously added α-ketoglutarate yielding glutamate. The electrons are derived 
from the oxidation of NADH/H+ to NAD+. The NADH/H+ consumption can be monitored by UV/Vis 








NH3    +    NADH/H
+    +   α-ketoglutarate     ( GDH )             glutamate    +    NAD+    +    H2O 
 
 
Experiments were performed at 30°C for 10 min. Except for GDH, all compounds used were 
dissolved in activity assay buffer (cf. Table 2.2). 150 µl of α-ketoglutarate (50 mM) and 150 µl 
NADH/H+ (1 mM) were mixed with 30 U/ml glutamate dehydrogenase 50 µl substrate (50 mM), 
and 100 µl activity assay buffer (50 mM Tris/HCl, pH 8.0) was added and incubated for 15 
minutes. The reaction was started by adding 50 µl of the enzyme with a final enzyme 
concentration of 10 – 20 µg/ml for the Zn(II)-isoDromeQC wild-type QC. Due to their low residual 
activity, variants were used with higher concentrations in a range of about 1-6 mg/ml.  
 
The time-resolved change of extinction (ΔE) was measured with the Jasco UV- VIS spectrometer 
V-650 or in the Probiodrug labs with the microplate reader (POLARstar optima, BMG Labtech 
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GmbH, Ortenberg, Germany). When the UV/Vis spectrometer (UV/Vis spectrometer, V-650, 
Jasco GmbH Groß-Umstadt, Germany) was used, the specific activity was calculated from the 
slope of the progressive curve (ΔE/min). This slope correlates with the NADH/H+ consumption. 
While the QC reaction converts one molecule substrate, one molecule NH3 will be released. In 
the GDH reaction NH3 will be used for the oxidation of one molecule NADH/H
+. The direct 
proportional relation of QC reaction and the detection reaction allows the determination of the 
specific activity using the equation based on the Lambert-Beer Law (1). 
 






   
            
                      
                                                                                        
 
Aspecific   = specific activity (U/mg) 
∆E/min  = extinction change per minute at λ = 340 nm 
Vtotal  = total volume in the cuvette (µl) 
1000  = translation factor 
d  = path length (1 cm) 
εNADH  = extinction coefficient of NADH/H
+ at 340 nm (6220 M-1 cm-1) 
Venzyme  = applied volume of QC (µl) 
cenzyme  = QC concentration (mg/ml) 
 
This assay served as the basic activity test and was used after each purification or cobalt 
reconstitution procedure in order to test for enzymatic activity. Further, it was also used for the 
investigation of the substrate specificity. For this purpose, the microplate reader was applied. In 
this case the data were evaluated with a standard curve measured with ammonia under assay 
conditions. A limiting factor for the GDH assay is that ammonia contaminations disturb the 
activity determination [80].  
 
 
2.6.2 Fluorescence spectroscopic assay  
 
The bacterial pyroglutamyl aminopeptidase (pGAP) is the auxiliary enzyme used in the coupled 
fluorescence assay. As substrates artificial dipeptides, L-glutaminyl-2-naphtylamine (Gln-βNA) 
and L-glutaminyl-4-methylcoumarinylamide (Q-AMC) were used. These substrates are converted 
by QC to pyroglutamyl-2-naphtylamine (pGlu-βNA) or pyroglutamyl-4-methylcoumarinyl-amide 
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(pGlu-AMC) and stoichiometric amounts of NH3. In the following cleavage reaction catalyzed by 
pGAP, pyroglutamic acid (pGlu) and 2-naphylamine (βNA) and 7-amino-4-methylcoumarine 
(AMC), respectively, are formed. βNA and AMC are used as fluorophores that can be observed at 
excitation/emission wavelengths 320 nm/410 nm in the case of βNA and 380/465 nm in the case 




A) Gln-βNA           ( QC )            pGlu-NA    +    NH3 
 




A) pGlu-βNA           ( pGAP )           pGlu    +    βNA 
 
B) pGlu-AMC           ( pGAP )     pGlu    +    AMC 
 
 
For this approach, 197.5 µl substrate (2.5 mM), 2.5 µl pGAP (0.25 U) and 40 µl activity assay 
buffer were mixed (cf. Table 2.2). After 15 minutes incubation, the reaction was started by 
adding 10 µl enzyme (typically 20 µg/mL for Zn(II)-isoDromeQC wild type). Data evaluation was 
performed using a calibration curve which was measured for the fluorescence signal at different 
β-naphtylamine concentrations. 
pGAP shows robust qualities regarding its tolerance of a wide pH range and its long term 
stability [80]. For this reason, this assay was chosen for the investigation of the pH dependence 
of the Zn(II)-isoDromeQC wild type and variants. 
Since this fluorescence assay is not sensitive to ammonia formed during reaction, it could be 
used for detection of QC activity in raw extracts or other ammonia-containing solutions [80]. 
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2.7 X-ray crystallography 
 
2.7.1 Protein crystallization 
 
The crystallization protocol which was typically used in the present work was slightly modified 
from that provided by Probiodrug AG. For the hanging-drop vapor diffusion method, common 
24-well cell culture plates were used. In most cases, two droplets were set on a self silanized 
cover glass. The well was sealed with the medium viscose silicone.  
QC that was stored in the storage buffer (cf. Table 2.2) at -80°C was thawed and centrifuged for 
12 minutes at 21,000 g (Hettich AG, Bach, Switzerland) in order to remove protein precipitate. 
The resulting protein solution was adjusted to a protein concentration of 10 mg/ml, or 15 mg/ml 
if a co-crystallization attempt was planned. The reservoir buffer contained 200 mM MgCl2, 
100 mM Tris/HCl. The concentration of PEG 4000 varied from 20 % to 25 %, and the pH values 
covered a range from 8.0 to 8.7. If no ligands were added, the protein solution and the reservoir 
were mixed in a ratio of 1:1 (1 µl: 1 µl) yielding a final protein concentration of approximately 
5 mg/ml.  
In case of a co-crystallization experiment, the ligands were dissolved in reservoir buffer (100 mM 
Tris/HCl, 200 mM MgCl2, 20 % PEG 4000, pH 8.0). Ligand stock solution (cf. Table 4) and protein 
were pre-mixed in a ratio 1:2 and incubated on ice. Subsequently protein-ligand-solution and 
reservoir were mixed as described above. While the final protein concentration was set to 
5 mg/ml the ligand concentrations were variable (cf. Table 3) and were adjusted with respect to 
the Michaelis-Menten constant (KM) or the inhibition constant (KI), respectively. 
It should be emphasized that the two buffers used for crystallization had different pH values 
(enzyme storage buffer pH 6.8, reservoir buffer 8.0 – 8.7). The final pH of the droplets in each 
well led to the optimal crystal growth condition. It should also be noted that QC precipitates 
when mixing with the reservoir buffer containing 100 mM Tris/HCl. The incubation was carried 
out at 6 °C, 20 °C, and 25 °C. Depending on the QC variant, the ligand and the incubating 
temperature, the crystal grew within two days or two weeks.  
 
 
2.7.2 Crystal harvesting and cryo-protection 
 
To the droplets containing protein crystals 250 – 500 nl cryo-solution (100 mM Tris/HCl, 200 mM 
MgCl2, 10 % glucose, 7 % glycerol, 5 % PPG 400, 3 % PEG 1000, pH 8.0) and 500 nl soaking 
solution were added. The incubation time is depicted in Table 2.3. A 2 µl droplet of paraffin oil 
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was set next to the reservoir droplet. With the help of a micro-needle or a cryo-loop, the crystal 
of interest was transferred through the phase boundary into the oil droplet without contact to 
the gas phase. Finally the crystals were frozen in liquid nitrogen. 





 Soaking time 
C 
QQ  60 10 10 – 20 
QFRH  60 10 10 – 20 
QFA  60 10 10 – 20 
EW  60 10 300 – 600 
EFRH 30 5 300 – 600 
pEFRH 60 10 600 
AFA  60 10 600 
A
) Concentration (mM) of the stock solution which was used for co-crystallization or soaking attempts, 
italics: approx. for slightly oversaturated solutions 
 
B
) Final ligand concentration (mM) in the droplet in case of co-crystallization attempts 
 
C
) Incubation of the crystals in the soaking/cryo-protection solution (s) 
 
2.7.3 Data collection 
 
To test crystals for diffracting properties, an in-house facility was utilized. Structural data were 
collected in different synchrotron radiation facilities (ESRF Grenoble (beam-line ID14-1), 
Frankreich, BESSY II Berlin (beam-line BL 14-1), Germany and PETRA III (beamline B13, B14) 
Hamburg, Germany).  
 
2.7.4 Data processing, structure refinement and modelling 
 
The sets of data were processed with XDS [Kabsch 2010]. Data processing was accomplished by 
Dr. Piotr Neumann (Department for Molecular Structural Biology, University Göttingen). 
Whereas the PHENIX software [82] was used for the structure refinement, the WinCoot software 
[83] was employed for model building. Structures from the isoenzyme of Drosophila 
melanogaster had been solved previously by the Probiodrug Company. Hence, the initial 
molecular replacement for the structure data of the obtained isomorphous crystals was already 
done. A rigid body refinement fitted the model to the recorded density map using the provided 
pdb file of the pdb entry 4FAI [74]. 
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2.8 Protein stability study based on circular dichroism spectroscopy 
 
The conformational stability of protein molecules is mediated by numerous intra-molecular 
interactions such as hydrogen bonds between different amino acid residues or disulfide bridges 
between cysteins. Substitution of different amino acids by site-directed mutagenesis may 
change the scaffold of hydrogen bonds and sterical situation, and thus might affect the overall 
conformational stability. In terms of the QC variants, it was important to exclude that a possible 
decrease of the stability brings about changes of the kinetic properties.  
The stability of the variants was studied using circular dichroism spectroscopy (CD-
spectroscopy). The CD-signal arises if the absorption of the left- and the right-circular polarized 
light of an asymmetric optical center are unequal. In the far UV range (170 – 250 nm) the 
secondary structure elements of the protein composition can be determined.  
A protein which undergoes an unfolding transition loses its secondary structure elements. The 
CD signal identifying α-helices or β-sheets disappear with the ongoing denaturation [84]. In this 
study the unfolding transition was induced by a continuous temperature ramp (“thermal 
denaturation”) starting at 283 K (10 °C) to a final temperature of 367 K (94 °C). The settings of 
the CD spectrometer are listed in Table 2.4.  
 
Table 2.4 Settings of the CD spectrometer for the thermal denaturation 
Setting   
Temperature ramp start 10 °C 
Temperature ramp end 94 °C 
Data interval 0.5 °C 
Heating rate 2.0 °C/min 
Tolerance 0.2 °C 
Wavelength (λ) 196 nm 
Time per point 12 s 
Path length 1 mm 
 
QC was concentrated to 0.1 mg/ml in 10 mM potassium phosphate buffer at pH 6.8. To compare 
the native and denaturated enzyme, CD spectra were taken before and after the temperature 
ramp (settings: 190 nm – 260 nm at 10 °C and 94 °C, step 1.0 nm, time per point 1 s)(cf. 
Supplemental 8.3) 
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Thermal denaturation was monitored by spectral changes at 196 nm. At this wavelength the 
maximum change of the signal was observable. All measurements were performed in triplicates.  
 
2.8.1 Data analysis 
 
The data were normalized with respect to the slight variance in the protein concentration. The 
start point of all unfolding curves at 10°C was aligned. For a comparison in terms of 
conformational stability, the wild type and all variants, the midpoint (TM) was calculated by 
fitting the curve to equation (2) [84].  
 
        
                            
   
     
     
  
   
       
   
     
     
  
  
                                                         
 
y  =  Circular dichroism signal at 196 nm 
yf, yu  = Intercepts of pre- and post-transition baselines 
mf, mu = Slopes of pre- and post-transition baselines 
T  = Temperature in Kelvin 
Tm  = Midpoint of the thermal unfolding curve 
ΔHm  = Enthalpy change for unfolding at Tm 
R  = Gas constant 
 
The curve fitting was done with the SigmaPlot 11 software. 
This equation is valid for the determination of the midpoint for reversible unfolding transitions. 
The thermal unfolding transition of the QC is irreversible. So the unfolding transition depends on 
the heating rate and exposure time at a certain temperature. The observed midpoints may differ 
from the real transition midpoints. Nevertheless the midpoints are adequate measures for a 
comparative examination. 
 
2.9 Substrate specificity of the His6-tagged isoenzyme of the Drosophila melanogaster 
QC 
 
In order to analyze the effect of the amino acid exchange on the kinetic parameters, the variants 
were incubated with five different substrates. These measurements were executed applying the 
photospectroscopic and the fluoroscopic activity assay described above (cf. Section 2.6.1 and 
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Section 2.6.2). In the focus of interest were the KM value, the turnover number (kcat) as well as 
the catalytic efficiency (kcat/KM). The KM value or Michaelis – Menten constant of a substrate 
reflects the affinity between an enzyme and a substrate. The turnover number specifies the 
number of conversions per second per active center. A further important measure for enzyme 
reactions is the catalytic efficiency kcat/KM. The catalytic efficiency considers both values kcat and 
KM. In some cases, it was not possible to measure under substrate saturation. This means, the 
applied substrate concentration is much smaller than the KM. The kcat/KM is a suitable value for 
comparing the preference of the enzyme for a particular substrate [85]. 
 
When QQ, QGP or QFRH were used as substrates, the measurements were performed by 
employing the UV/Vis absorption spectrophotometric assay (cf. Section 2.6.1). On the other 
hand, the substrates Q-βNA and Q-AMC were studied with the fluorescence spectroscopic assay 
(cf. Section 2.6.1). In both cases the experiments were measured with the microplate reader. 
The substrate specificity was determined by measuring the reaction rates subject to substrate 
concentration. From the obtained velocity/substrate concentration characteristic the kinetic 
constants were derived by fitting these curves according to equation 3. It should be noted that 
the respective measurements for the isoDromeQC wild type enzyme have been performed by 
the Probiodrug company.  
For some variants it was important to adjust the protein concentration according to Table 2.5. 
Due to the low solubility of the substrates in aqueous solution the maximum concentration used 
in those experiments was limited to 1.5 mM for Q-βNA and Q-AMC and 3 – 4 mM for QQ, QGP 
and QFRH. 




2.9.1 Data analysis 
 
The kinetic constants KM and Vmax were calculated by fitting eight data points (measured in 
triplicates) to the Michaelis-Menten equation (3). 
 
              
   
      
                                                                                                                             
 
v  = enzyme reaction velocity (U/mg) 
Vmax  = enzyme reaction velocity under substrate saturation (U/mg) 
[S]  = substrate concentration (mM) 
KM  = Michaelis - Menten constant (substrate concentration at half of Vmax (mM) 
Vmax can be converted into kcat by applying the following equation 4. 
 
           
       
     
                                                                                                                               
 
kcat  = turnover number (s
-1) 
MW  = molecular weight of the QC (37883.3 g/mol, 38706.2 g/mol with His6 tag,) 
60000 = conversion factor  
 
Division of kcat by KM results in the catalytic efficiency kcat/KM. 
 
 Table 2.5 Applied enzyme concentrations for the determination of substrate specificity. 
Variant QQ QGP QFRH Q-βNA Q-AMC 
D228N 2.12 -- 0.50 1.05 1.05 
D293N 2.25 0.73 0.60 1.50 1.50 
D293A 1.78 1.77 0.60 -- -- 
E190Q 5.59 -- -- 3.00 3.00 
Concentrations (mg/ml) of the variants depending on the used substrate. 
 




2.10 pH Dependence of the isoenzyme of the Drosophila melanogaster QC and their 
variants 
 
In order to identify amino acids that might act as acid-base catalysts during reaction, the 
catalytic efficiency (kcat/KM) of different QC variants was determined at varying pH values using 
the substrate Q-βNA. These measurements were performed under first-order reaction 
conditions at which the applied substrate concentration is significantly (10 fold) lower than the 
respective KM value ([S] << KM). The auxiliary enzyme pGAP has been tested and found to be 
stable at pH values from pH 5.5 to  pH 8.5 by Tsuru and co-workers [81]. 
 
To ensure, that the buffer covers the whole pH range from 5.3 to 9.0 the variants were 
transferred in a three-component-buffer-system which provides a constant ionic strength [86]. 
This buffer system contains 100 mM Tris/HCl, 50 mM Mes and 50 mM sodium acetate. The 
applied microplate reader was set to a temperature of 30°C. The reaction was started by adding 
the enzyme after an incubation time of 15 minutes. 
 
 
2.10.1 Data analysis 
 
The bell-shaped curves were analyzed with the KaleidaGraph software. The rates were fitted to 
the nonlinear regression equation (5). 
  
    
    
  
              
 
                               
                                            
 
kcat/KM  =  catalytic efficiency (s
-1mM-1) 
[kcat/KM]max =  pH-independent maximum rate constant 
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2.11 Fast Kinetics applying the stopped-flow UV/Vis absorbance method 
 
For the UV/Vis spectroscopic investigation of the electronic environment of the substituted 
Co(II) ion, the stopped-flow method was used in combination with the photo diode array. The 
rapid mixing of the stopped-flow device monitors the enzymatic reaction with a dead-time of 1.5 
milliseconds. The upcoming signal can be followed via UV/Vis absorbance. The photo diode array 
enables the detection of all wavelengths of the UV/Vis-spectra simultaneously allows the 
acquirement of multiple spectra within a defined time range. For the stopped-flow experiments, 
the Co(II)-isoDromeQC wild type and variants Co(II)-isoDromeQC_E190Q, Co(II)-
isoDromeQC_D228N and Co(II)-isoDromeQC_D293N were used. The enzyme was dissolved in 
50 mM sodium phosphate buffer containing 100 mM sodium chloride at pH 6.8. Data acquisition 
was accomplished with settings shown in Table 2.7.  
Table 2.6 Compound concentrations in the 





Wild type 0.106 
E190Q, D293N 0.09 
D228N 0.076 
QQ, EW, EFRH 8.00 
AFA 7.50 
pEFRH 15.0 
A) Molar concentration of the variants or the 
compounds in mM. 
Table 2.7 Stopped-flow data acquisition with the 
photo diode array 
Setting  
Temperature 10.0 °C 
Wavelength 190 nm – 750 nm 
Split time base 
0.10 s       10 points 
150 s    200 points 
Stop syringe volume 150 µl 
Path length 1.00 cm 
 
After a baseline measurement, the spectrum of the used buffer was acquired. Subsequently the 
spectrum of the resting enzyme was recorded before the enzyme was rapidly mixed with the 
substrate or the inhibitor AFA. The stopped-flow-syringes were filled with QC and the respective 
substrate or imidazole. In the detection chamber the compounds were mixed in a ratio of one to 
one. The final concentrations are given in Table 2.6. 
 
2.11.1 Data analysis  
 
The spectra were normalized by setting the absorbance at a wavelength of 750 nm to zero 
utilizing the software “SX-Prodata Viewer”. Single spectra were assessed with SigmaPlot 11 
software.  




2.12 Electron paramagnetic resonance spectroscopy (EPR) 
 
2.12.1 Fundamental aspects of EPR spectroscopy and special details regarding the utilized 
techniques 
 
The electron paramagnetic resonance spectroscopy delivers insights into the nature of 
interactions between an unpaired electron and its environment. In biological systems unpaired 
electrons appear in bioorganic radicals and in numerous biological active metal centers. An 
electron with the spin quantum number S = ½ has the magnetic components ms = + ½ and ms = -
½. In a magnetic field the magnetic moments adopt a parallel (ms = + ½) or anti-parallel 
orientation (ms = - ½) to the magnetic field. According to the Zeeman Effect (Pieter Zeeman 
1882) the energy states of both orientations diverge equidistantly around the zero-field energy 
(E = 0) and are proportional to the effective magnetic field (Beff) (cf. Figure 2.1). The 
proportionality between the magnetic field and the energy difference is described by the factor 
g [97].  
 
                                                                                                                                                ) 
 
Figure 2.1 Proportionality 
between the outer magnetic field 
(B0) and the difference (ΔE) of the 
energy states.  
 
An unpaired electron can switch between both orientations or rather between both energy 




mS = - 1/2 
mS = + 1/2 
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In EPR spectroscopy techniques, the absorption of the magnetic component of microwave 
radiation is exploited to change the spin into the high-energy state. The resonant absorption of 
energy can be monitored as an EPR spectrum.  
 
                                                                                                                                                   
 
E   = energy difference of the spin orientations 
h  = Planck´s constant 
v  = microwave frequency 
g  = constant of proportionality  
   = Bohr magneton 
Beff = effective magnetic field 
 
The resulting EPR spectrum is rich in information about the compound of interest. The spectrum 
delivers compound specific g values. But the information cannot be read out directly for the 
following reasons: 
 
The applied magnetic field (B0) and the effective magnetic field Beff which affects the unpaired 
electron are divergent. The g value for a free electron in vacuo was determined to be ge = 
2.00232 in a resonance field of 3390 Gauss and a microwave frequency of 9500 MHz (X-band). In 
a molecule an electron is exposed to a couple of magnetic interactions. Among others, 
interactions occur between electron spins and nuclear spins (S*I) or between electron spins and 
electron spins (S*S). These additional compound-internal magnetic fields (δB) change the 
equation for the resonance condition as follows (equation 8) [97]: 
 
                                                                                                                                         
 
ge  = g value of the free electron in vacuo 
Be  = external magnetic field 
δB  = internal magnetic field 
 
The unknown quantity δB is reflected by the g value. So the condition for the resonant 
absorption is now (9): 
 
                                                                                                                                       




Finally δg is the value which holds the whole information of a molecule. This quantity contains 
the information of the electronic structure of a molecule [97]. 
2.12.2 Anisotropy 
 
Caused by randomly oriented molecules in a powder or frozen liquid EPR sample, the molecules 
have different orientations to the external field vector. If one imagines a molecule in Cartesian 
diagram with the magnetic field vector along the z axis, in the EPR spectrum a certain g-value (gz) 
appears. If the molecule rotates along the x or y axis, the molecule changes its orientation with 
respect to the field vector. In the resulting EPR spectra there are two further possible g values gy 
and gx. Depending on the molecule´s symmetry, the three g values can have three different 
relations to each other. In an isotropic molecule all g values are equal (gx=gy=gz). In the case of 
gx=gy≠gz the molecule is axial, and it is rhombic if all three g-values are unequal (gx≠gy≠gz). From 
these g values one can read out information regarding bond angles and bond length as well as 
the coordination number [97]. 
 
 
2.12.3 System parameters 
 
2.12.3.1 Temperature and Power 
 
In accordance with the Boltzmann distribution (equation 10), at a thermal equilibrium a certain 
number of molecules (n0) are in the lowest energy state and a certain number of molecules (n1) 
are in the highest energy state. 
 
                                                                                                                                         
 
ΔE  = energy difference between highest and lowest energy state 
k  = Boltzmann constant (0.695 cm-1 K-1) 
K  = absolute Temperature in Kelvin 
 
At T = 0 K all molecules are in the ground state. With increasing temperature the number of 
molecules in the highest energy state increases. At an infinite high temperature n1 and n0 
become equal. To facilitate the absorption of the magnetic component of the microwave 
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radiation, a certain difference between both populations (n1 < n0) has to be available in the EPR 
sample. The smaller the differences between n1 and n0, the smaller becomes the signal intensity. 
Further, the velocity of the energy transfer from the high-energy-state molecules to the 
environment (spin-lattice relaxation) decreases with decreasing temperature. The slower the 
spin-lattice relaxation rate the longer the life-time of a molecule in the high energy state (excited 
state). From the Heisenberg uncertainty principle it is known that the longer the life-time of the 
excited state, the higher is the accuracy of the excited state energy. This accuracy of the excited 
state energy narrows the EPR linewidth and increases the signal amplitude. On the other hand, 
higher temperature would broaden the band linewidth. 
The optimal power of the applied microwave interacts with the temperature and has to be 
determined experimentally. The aim of this optimization procedure is to obtain a sharp EPR 
spectrum with a high signal-to-noise ratio. Too low microwave power at a certain temperature 
changes the signal-to-noise ratio to the worse. If the microwave power is too high, the spin-
lattice relaxation at a certain temperature becomes the limiting factor and saturation effects 
would deform the EPR spectra. In this case, an increase in temperature could improve the shape 
of the EPR bands but also could lead to homogenous band broadening [97]. 
The microwave power and the temperature need to be adjusted carefully for each system.  
The experiments were carried out at three different temperatures. To yield a proper S =     EPR 
signal, the temperature was set to 4 K. Occurring S = ½ signals were observed at 10 K or 25 K. 
The power of the microwave was set 20 mW.  
 
 
2.12.3.2 Continuous wave X-band EPR 
 
To fulfill the resonance condition given in equation 7, there are two possibilities. The first is to 
keep the magnetic field (B) constant and change the frequency (v) of the microwave. The 
second, and for technical reasons favored, possibility is a continuous frequency and a variable 
magnetic field. The designation X-band stands for a frequency of 9500 MHz [97]. 
 
2.12.4 EPR-experiments with Co(II)-substituted enzymes 
 
The Zn(II)-dependent glutaminyl cyclase does not bear any spectroscopically detectable feature 
which allows the observation of single mechanistic steps e.g. by the accumulation of reaction 
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intermediates. The catalytically active Zn(II) is a diamagnetic transition metal and EPR and 
UV/Vis spectroscopic inactive.  
With Co(II) as a virtually equivalent substitute for Zn(II), a spectroscopically detectable probe can 
be inserted into the active center of the QC molecule. Zn(II) and Co(II) exhibit comparable atomic 
properties. The ionic radii for octahedral Zn(II) and Co(II) ions are nearly the same (Zn(II) 0.88 Å 
and Co(II) 0.89 Å). Further the electro-negativities according to the Allred-Rochow scale are 
similar (Zn(II) 1.66 and Co(II) 1.70). Both transition metals can adopt a four- or five-fold 
coordination [87]. In some proteins the five- or six-coordinated Co(II) replaces tetrahedral 
coordinate Zn(II). In these cases, often the resulting EPR spectra lead to an incorrect 
interpretation [87] [63] [88, 89]. Co(II) substituted enzymes exhibit a high-spin EPR signal of 
S =    . To obtain reliable signals these measurements have to be accomplished at very low 
temperatures and high microwave power. This is due to the very fast relaxation of the excited 
state [87]. A further challenge is the high protein concentration which is required in the high-
spin cobalt EPR experiments, especially for the Rapid-freeze-quench-EPR experiments. A 
characteristic of the S =    EPR signals is that they are broad and small in intensity. For proper 
signals and an adequate signal-to-noise ratio, concentrations of at least 0.2 mM are necessary.  
 
2.12.5 Experimental procedures and methods  
 
All EPR experiments were accomplished under the supervision of Prof. Dr. Brian Bennett in the 
Department of Biophysics of the Medical College of Wisconsin (USA).  
The goal of these experiments was to investigate the coordination sphere of the substituted and 
the catalytic active Co(II) ion in the active center of the Co(II)-isoDromeQC wild type and the 
variants Co(II)-isoDromeQC_E190Q, Co(II)-isoDromeQC_D228N plus Co(II)-isoDromeQC_D293N. 
The proteins were analyzed in their resting state and with the addition of glutaminyl substrates, 
glutamyl substrates as well as an inhibitor and a puyroglutamyl compound. Along with the 
coordination number of the coordination sphere, the changes in the geometry of the Co(II) ion 
was a matter of interest in this examination.  
 
2.12.5.1 Sample preparation 
 
The different freeze-quench techniques described below require different protein 
concentrations to obtain adequate signal-to-noise ratios. Further it was necessary to perform 
these experiments with multiple protein preparation batches. The applied concentrations as well 
2 Materials and Methods 
62 
 
as the incubation times of the protein and the reaction partners are presented in the Results 
section. For the measurements the EleXsys E600 (Bruker BioSpin Corporation, Billerica, USA) 
spectrometer was applied. The cooling to the very low temperature was achieved utilizing liquid 
helium.  




2.12.5.2 Samples which require a long reaction time 
 
To observe the Co(II) coordination when the formation of intermediates or product was 
suggested to be very slow, the equilibration time was prolonged to minutes or hours. 
Samples that should be scanned after such a long reaction time (substrates) or incubation time 
(inhibitors and product) were pipetted in an EPR quartz tube. After the desired incubation time 
the tube was transferred in liquid nitrogen to stop the reaction.  
 
2.12.5.3 Manual freeze-quench EPR 
 
For a reaction time in the seconds range, the first component (enzyme) was poured into an EPR 
tube. The rapid mixing of the two components was achieved by emptying a syringe filled with 
the second component (e.g. substrate) in the EPR tube. The mixture was freeze-quenched in 
cryogenic isopentane (153 K).  
 
2.12.5.4 Rapid freeze-quench EPR 
 
To examine the cobalt coordination in the pre-steady-state phase, the reaction has to be 
stopped as early as possible. A pre-experiment showed that an incubation time of 20 
milliseconds led to reliable signals. For these rapid freeze-quench trials a self-made device was 
available. Here the enzyme and the substrate were filled in separate syringes. The automated 
drain of the syringes into a mixing chamber and the liberation of the mixture into isopentane 
guaranteed the observance of the desired reaction time. The samples were stored in liquid 
nitrogen. 
 
2.12.5.5 Sample concentration 
 
The concentrations of protein stock solutions were in a range of 600 µM in some cases higher. 
The accurate concentrations were specified in the results section. The ligand stock solutions 
were concentrated as follows: for the slow freezing and manual freezing technique the substrate 
QQ, QFRH, EFRH, EW and the product pEFA were concentrated to 30 mM. The inhibitors were 
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used in a concentration of 15 mM for AFA. For the RFQ technique QFRH was concentrated to 
10 mM and QQ to 30 mM.  
For the measurements the proteins and the ligands were mixed in a ratio of 1:1. For the RFQ 
technique a higher protein concentration was required. In these cases the mixing ratio was 
2 (protein):1 (ligand). 
 
 
2.12.6 Data analysis 
 
For data analysis the software XSophe was utilized for computer simulations. The g values were 




3 Results  
 
 
3.1 Thermal stability study of His6-tagged Zn(II)-isoDromeQC wild type and the variants 
employing CD-spectroscopy 
 
3.1.1 Substitution of active center residues as a tool for structure-function analysis 
 
Crystal structures of former investigators [74, 75] and structural comparison of QCs with the 
putatively evolutionary ancestor - a bacterial aminopeptidase [60] - implicates that particular 
amino acid residues are involved in discrete mechanistic steps of catalysis. 
To explore the role of active center amino acid residues in the native enzyme (Zn(II)-isoDromeQC 
wild type) in detail, they were substituted by utilizing site-directed mutagenesis. The plasmid 
DNA of the variants Zn(II)-isoDromeQC_D228N, Zn(II)-isoDromeQC_E190Q, Zn(II)-
isoDromeQC_D293A and Zn(II)-isoDromeQC_D293N was provided by the Probiodrug Company. 
The recombinant expression and purification of these variants was accomplished according to 
the previously described protocols (cf. Section 2.1 – 2.3).  
Electronically negatively charged, amino acid residues were exchanged for uncharged but 
isosteric residues (Zn(II)-isoDromeQC_E190Q, Zn(II)-isoDromeQC_D228N and Zn(II)-




3.1.2 Amino acid substitution may influence the structural stability 
 
The examination of the conformational stability is in most cases the initial work on an enzyme 
after the preparation. In particular, when working with different enzyme variants which are 
created by site directed-mutagenesis, it is important to assure that substitution of a single amino 
acid residue does not impair the conformational stability of the enzyme. Along with the chemical 
unfolding achieved by adding guanidinium hydrochloride or urea, the unfolding transitions can 
be induced by the pH and ionic strength. In this work, the choice fell on heat-induced unfolding. 
The thermal denaturation is in case of Zn(II)-isoDromeQC an irreversible process as has been 




straightforwardness of this approach. The reversibility is not essential if one only wants to 
compare the midpoints (melting point (TM)) of the unfolding transition curves. The melting point 
correlates with the inflection point of the unfolding transition curve and can be calculated by a 
curve fit based on equation 2 (cf. Section 2.8.1).  
The thermal denaturation (unfolding) experiment was done by measuring changes in the 
composition of secondary structure elements (e.g. α-helices, β-sheets, etc.) with circular 
dichroism spectroscopy in the far UV range. In this wavelength range, absorption occurs due to 
the peptide bond with its n  π* transitions in the region around 220 nm and around 190 nm. In 
this experiment the maximum change of absorption was determined at 196 nm. While observing 
the CD signal at this wavelength, the protein sample (0.1 mg/ml in 10 mM potassium phosphate 
buffer at pH 6.8) was heated gradually from 283 K to 360 K (cf. 2.8) 
Figure 3.1 and Table 3.1 present the results of these experiments. The curves show three distinct 
phases. The first linear phase in the low temperature region from 283 K to approximately 310 K. 
The second phase describes a sigmoid shaped decay from 310 K to 340 K. The third phase is 
again linear and comprises the temperature range between 340 K and the 360 K. 
This study shows that the decay of the curves of the Zn(II)-isoDromeQC wild type and the 
variants Zn(II)-isoDromeQC_E190Q and Zn(II)-isoDromeQC_D228N starts at higher temperatures 
compared to those of the variants Zn(II)-isoDromeQC_D293A and Zn(II)-isoDromeQC_D293N (cf. 
Figure 3.1). Hence, the determined midpoints of the transition curves of Zn(II)-isoDromeQC wild 
type and Zn(II)-isoDromeQC_E190Q and Zn(II)-isoDromeQC_D228N can be found at higher 
temperatures compared to those of Zn(II)-isoDromeQC_D293A and Zn(II)-isoDromeQC_D293N 







Figure 3.1 Thermal denaturation curves of Zn(II)-isoDromeQC wild type and variants 
monitored by measuring the ellipticity employing CD spectroscopy at 196 nm The 
temperature ramping from 283 K to 360 K of the protein samples (approx. 0.1 mg/ml) leads to 
different transition (denaturating) curves. The decay of the curves of Zn(II)-isoDromeQC wild 
type (red dots), Zn(II)-isoDromeQC_E190Q (yellow dots) and Zn(II)-isoDromeQC_D228N (cyan 
dots) starts at higher temperatures than for the variants Zn(II)-isoDromeQC_D293A and Zn(II)-
isoDromeQC_D293N. The regression curve (continuous line) is based on equation 2 (cf. 2.8.1) 
and allows the calculation of the theoretical midpoints of the thermal transition (cf. Table 3.1). 




Table 3.1 Midpoints (TM) of the thermal unfolding transition curves  The ellipticity was measured by 
using CD-spectroscopy at 196 nm in 10 mM phosphate buffer at pH 6.8 in a temperature range 
between 283 K (10° C)and 360 K (87° C). The calculated midpoints of transition (cf. equation 2 and 








































variant TM [°C] 
wild type (His6) 55 (± 2.00) 
E190Q (native) 59 (± 0.00) 
D293N (His6) 46 (± 1.73) 
D293A (His6) 48 (± 1.00) 





3.2 Kinetic investigation of His6-tagged Zn(II)-isoDromeQC wild type and variants using 
photospectroscopic methods indicate a distinct substrate specificity pattern 
 
The preference of a subtrate can be investigated by determination of the kinetic constants KM 
(Michaelis-Menten constant), the turnover number kcat and the catalytic effieciency kcat/KM. 
From the structure, steric properties and partial charges of a highly preferred substrate, 
conclusions can be drawn about the architecture of an enzyme binding pocket, or the active 
center. 
 
The kinetic constants KM and kcat were determined under steady state conditions (substrate 
concentrations beyond KM, [S]>KM). For that purpose, the reaction velocity was measured 
subject to substrate concentration [S]. The KM and kcat were obtained by fitting the resulting 
velocity/substrate concentration dependence curve (v/[S]-characteristic) to equation 3 (cf. 
Section 2.9.1). Applying equation 4 (cf. Section 2.9.1) kcat can be calculated. The catalytic 
efficiency was calculated by division of kcat by KM. Due to the low solubility of the peptide 
substrates, in many cases the applied substrate concentration was equal or slightly below the 
KM. In case of Zn(II)-isoDromeQC_D293N/A with the substrate QGP and Zn(II)-
isoDromeQC_D293A with QQ, the kcat/KM was assessed under first order rate conditions with 
substrate concentrations of one tenth of the KM.  
This substrate specificity study was carried out by utilizing UV/Vis absorption spectroscopy (cf. 
Section 2.6.1) and fluorescence spectroscopy (cf. Section 2.6.2). All measurements were done 
using the microplate reader (POLARstar optima, BMG Labtech GmbH, Ortenberg, Germany) at 
30° C in 50 mM Tris/HCl, pH 8.0.  
 
The substrate specificity pattern of the Zn(II)-isoDromeQC wild type was investigated in the past 
by the Probiodrug Company [73]. It has been shown that for Zn(II)-isoDromeQC wild type, the 
efficiency of substrate conversion increases with the peptide length. Further, the catalytic 
efficiency increases if the substrate contains a positively charged residue. In contrast, a negative 
charge leads to higher KM values and a reduction of the catalytic efficiency. Along with these 
observations it could be demonstrated that the turnover number increases and KM value 
decreases if the second N-terminal position of the substrate is occupied by an aromatic amino 
acid [73]. 
According to these findings, the following peptides and peptide surrogates were chosen to carry 
out analogous investigation of the corresponding variants of the active center amino acid 




QQ and QGP represent uncharged di- and tripeptides, respectively. QFRH as a tetrapeptide 
consists of a hydrophobic and aromatic system in the second position and a positively charged 
arginine at position three. The dipeptide surrogates Q-βNA and Q-AMC also represent substrates 
with an aromatic system in the second position.  
 
Figure 3.2 and Table 3.2 depict the kinetic constants of the Zn(II)-isoDromeQC wild type and the 
variants. The substrate specificity study points out a dramatically impaired catalysis if one of the 
amino acid residues as outlined above has been exchanged. The variants exhibit catalytic 
efficiencies below one per mill in comparison to the wild type. Nevertheless, the variants exhibit 
a wild type-like substrate specificity pattern. The ranking of the substrates with reference to rate 
constant and the KM value is similar to that of the Zn(II)-isoDromeQC wild type enzyme. 
Measurements with shorter peptides QQ and QGP show the highest KM values except for the 
E190Q variant. Significantly declined Michaelis-Menten constants are observed in the case of the 
substrates QFRH and both peptide surrogates Q-AMC and Q-βNA.  
  
 
Figure 3.2 Kinetic constants of the Zn(II)-
isoDrome wild type and the variants determined 
with several non-physiological peptide and 
peptide surrogate substrates employing UV/Vis 
absorption and fluorescence spectroscopy The 
catalytic efficiency (A) was calculated after the 
determination of kcat (B) and KM (C) at pH 8.0 
(50 mM Tris/HCl, 100 mM NaCl) and 30°C under 
steady state (substrate saturation [S]>KM) 
conditions. The turnover number kcat of all variants 
is significantly diminished in comparison to the 
Zn(II)-isoDromeQC wild type. 
 
However, when QQ, QGP and QFRH were used as substrate, higher turnover numbers with a 



















































































































































































































































surrogates show better KM values than QQ and QGP. Conversely, measurements with peptide 
surrogates Q-AMC and Q-βNA yield worse rate constants. 
In general, the longest peptide with the aromatic system and the electronically positively 
charged residue QFRH shows the highest catalytic efficiency in reaction with the wild type as 
well as the variant. The high catalytic efficiency is also a result of the very low KM value of this 
substrate. 
Side chain substitution of D293 leads to higher Michaelis-Menten constants. In case of D293A, 
the KM value is too high for a reliable determination with low-solubility substrates. A more 
moderate but also low substrate affinity was observed if D293 was replaced by an isosteric 
asparagine (Zn(II)-isoDromeQC wild type_D293N).  
The D228N variant yielded similar results. For all tested substrates KM values were determined 
that were at least five-fold higher than that of Zn(II)-isoDromeQC wild type. Along with the Zn(II)-
isoDromeQC_D228N, Zn(II)-isoDromeQC_E190Q shows kcat and kcat/KM values that are reduced 
by the factor of 10,000 compared to the values determined for the Zn(II)-isoDromeQC wild type. 
Conversely, the measurements with the Zn(II)-isoDromeQC_E190Q variant yield lower KM values 



























Table 3.2. Kinetic constants of the Zn(II)-isoDromeQC wild type and the variants measured with 
diverse substrates The kinetic constants KM and kcat were determined using UV/Vis absorption (cf. 
2.6.1) and fluorescence (cf. 2.6.2) spectroscopy at pH 8.0 and 30 °C under steady state conditions 
([S]>KM). 
 KM (mM) kcat (s
-1) kcat/KM (mM
-1 s-1) 
wild type       
QQ 0.94 ± 0.05 7.4 ± 0.5 7.9 ± 0.2A 
QGP 1.17 ± 0. 6 14.0 ± 2 23.4 ± 0.4A 
QFRH 0.048  13.9  150.0  
Q-AMC 0.205 ± 0.008 2.09 ± 0.03 10.2 ± 0.3A 
Q-ßNA 0.15 ± 0.01 1.1 ± 0.1 7.4 ± 0.3A 
D293A       
QQ n.d.  n.d.  3.8 *10-3 ± 0.1*10-3 B 
QGP n.d.  n.d.  2.3 *10-3 ± 0.3*10-3 B 
QFRH 0.51 ± 0.09 22.2*10-3 ± 2.3*10-3 43.5 *10-3  
D293N       
QQ 7.9 ± 1.1 8.7*10-3 ± 1.9*10-3 1.1*10-3  
QGP n.d.  n.d.  4.8*10-3 ± 0.6*10-3 B 
QFRH 0.45 ± 0.04 11.0*10-3 ± 0.4*10-3 24.2*10-3  
Q-AMC 2.61 ± 0.26 2.9*10-3 ± 0.2*10-3 1.1*10-3 C 
Q-ßNA 0.97 ± 0.05 3.0*10-3 ± 0.1*10-3 3.1 *10-3 C 
E190Q       
QQ 0.04 ± 0.01 0.43*10-3 ± 0,03*10-3 10.75*10-3 C 
Q-AMC 0.14 ± 0.008 0.97*10-3 ± 0.02*10-3 6.9*10-3 C 
Q-ßNA 0.085 ± 0.008 0.27*10-3  ±0.03*10-3 3.0*10-3 C 
D228N       
QQ 7.1 ± 1.3 2.80*10-3 ± 0.29*10-3 0.40*10-3 C 
QFRH 1.78 ± 0.14 34.6*10-3 ± 1.6*10-3 19.4*10-3 C 
Q-AMC 1.15 ± 0.065 0.92*10-3 ± 0.03*10-3 0.80*10-3 C 
Q-ßNA 0.83 ± 0.02 0.333*10-3 ± 0.003*10-3 0.40*10-3 C 
A
) Results from the Probiodrug Company [73]
 
B




) kcat/KM determined under first-order rate conditions ([S] <<KM). 







3.3 Catalytic efficiency measurements as a function of the pH 
 
Concerted acid-base catalysis is a common enzymatic mechanism. Many amino acid side chains 
are enabled to donate (acidic) or to receive (alkaline) protons from a functional group of the 
substrate or a proximate amino acid side chain. These proton transferring steps are able to 
reduce the free enthalpy of a transition state of an enzymatic reaction. Subsequently these steps 
become accelerated compared to the uncatalyzed reaction. To find out whether acid-base 
catalyzing amino acids are involved in the QC reactions, pH titration is a tool used to determine 
the pka values of such amino acid residues. To identify a putative acid-base catalyst, the amino 
acid residue of interest can be substituted by site-directed mutagenesis. In the event that the 
substituted amino acid is involved in proton transferring steps, we would expect a change in the 
pka values.  
For this purpose, the catalytic efficiencies (kcat/KM) of the Zn(II)-isoDromeQC wild type and all 
variants were determined as a function of the pH using the fluorescence spectroscopy method 
(cf. Section 2.6.2). The catalytic efficiency was determined in equidistant steps from the mild 
acid to moderate alkaline pH range at 30° C utilizing the microplate reader (POLARstar optima, 
BMG Labtech GmbH, Ortenberg, Germany). From the resulting curve of the pH dependence, it is 
possible to obtain parameters like pka1 (inflection point of the ascending branch), pka2 (inflection 
point of the descending branch) as well as the maximum catalytic efficiency (kcat/KM max) by fitting 
this curve to equation 5 (cf. Section 2.10.1).  
 
In a second experiment it was investigated whether different protonation states of functional 
groups of the substrate have effects on the catalysis. Therefore, KM values as a measure for the 
substrate affinity were determined at three different pH values. 
For this purpose, the reaction velocity under steady state (substrate saturation [S]>KM) 
conditions was measured as a function of the concentration of Q-βNA as a dipeptide surrogate 
at 30°C using the fluorescence spectroscopic assay (cf. Section 2.6.2). Finally, the KM was 
obtained by fitting the obtained velocity/substrate concentration dependence curve (v/[S]-







The pH dependence of the catalytic efficiency of the Zn(II)-isoDromeQC wild type (cf. Figure 3.3 
A) exhibits a relatively narrow and symmetric bell-shaped curve with a maximum of catalytic 
efficiency (kcat/KM max) between 7.5 and 8. The determined pKa values around pH 6.56 and pH 
9.10 (cf. Table 3.2) are reproducible. This result tallies well with a former study carried out by 
the Probiodrug Company [73]. The pH profiles of the variants (cf. Figure 3.3 B – E) do not reveal 
any outstanding changes. The observed maximum of kcat/KM varies in small ranges around pH 
7.9. The pka values of the acid-base catalysts remain almost equal. 
 
Table 3.3-1 Catalytic efficiency subject to the pH 
Calculated parameters of Zn(II)-isoDromeQC wild type and variants. The pH optimum corresponds to 
the maximum catalytic efficiency (kcat/KM max). kcat/KM max and the pkaa values were determined by fitting 
the obtained pH dependence curves (cf. Figure 3.3) to equation 5 (cf. 2.10.1). 



























 6.82 ± 0.04 9.45 ± 0.14 
 
Table 3.3-2 KM values determined under steady state conditions at different pH values The KM values 
were determined by fitting the obtained v/[S]-characteristic (cf. text) to equation 3 (cf. 2.9.1). The KM 
values are given in mM of the used substrate Q-βNA employing the fluoroscence spectroscopic assay 
(cf. 2.6.2) at 30° C in 100 mM Tris/HCl, 50 mM Mes and 50 mM sodium acetate. 
 Zn(II)-isoDromeQC … 
pH 











5.24 2.6 ± 0.4 5.80 n.d. 2.02 ± 0.66 n.d. 1.20 ± 0.2 
7.00 0.73 ± 0.03 7.00 0.43 ± 0.011 1.83 ± 1.25 4.35 ± 0.70 0.34 ± 0.02 
8.39 0.60 ± 0.05 8.39 0.31± 0.025 1.60 ± 0.18 3.42 ± 0.30 0.56 ± 0.09 
n.d. not determinable  
 
The results of the second part of the experiment show that the KM values determined from v/[S]-
characteristic at different pH conditions decrease with rising pH (cf. Table 3.3). 
 
Notwithstanding the extremely decreased catalytic deficiency, the pH profiles of the variants are 








Figure 3.3 Catalytic efficiencies (kcat/KM) of Zn(II)-isoDromeQC wild type and variants as a function of 
the pH The catalytic efficiency of Zn(II)isoDromeQC wild type (A) and the variants (B-E) was measured 
under first-order law conditions ([S]<<KM ), i.e. that the Q-βNA concentration was around one tenth of 
the pre-experimentally determined KM (Zn(II)-isoDromeQC wild type: 11.85 µM, (Zn(II)-
isoDromeQC_D228N: 43.50 µM, (Zn(II)-isoDromeQC_E190Q: 19,75 µM, (Zn(II)-isoDromeQC_D293N: 
99.5 µM and (Zn(II)-isoDromeQC_D293A: 320 µM). The error bars reflect the standard deviation, 
conveyed from multiple determinations. Measurements were executed in 100 mM Tris/HCl, 50 mM 
Mes and 50 mM sodium acetate at varying pH values at 30 °C. The calculated pka values (cf. Table 3.2) 
and the obtained pH optimum (pH at maximum kcat/KM) of the variants do not vary significantly from 
that of the Zn(II)-isoDromeQC wild type. The kcat/KM of the variants is significantly diminished.  
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3.4 Stopped-flow UV/Vis absorption analysis of Co(II)-isoDromeQC wild type and 
variants 
 
In order to detect direct interactions between the catalytically active metal ion and several 
components including substrates, reaction intermediates, reaction products and inhibitors, the 
stopped-flow technique was utilized. The stopped-flow device mixes the enzyme and the 
component of interest together within milliseconds. That allows the observation of the reaction 
after a very short dead time of 1.5 milliseconds. As the detecting device, the photo diode array 
was utilized in order to observe all wavelengths spontaneously in a range of 185 nm – 723 nm by 
UV/Vis absorption spectroscopy. 
In this experiment the Co(II)-substituted isoDromeQC has to be used because the native Zn(II)-
isoDromeQC shows no band transitions in the UV/Vis absorption spectra. d-d Band transition of 
Co(II) in the active center of the QC allows photospectroscopic detection in a wavelength range 
of approx. 400 nm to 650 nm. The way to detect metal interaction in this experiment with the 
ligands described above is to observe changes in the UV/Vis absorption spectra due to 
distortions in the electronic environment of the enzyme bond Co(II). If the component is a 
substrate, it is possible to detect short-lived transition states during the catalysis.  
The Co(II)-isoDromeQC wild type and the variants Co(II)-isoDromeQC_E190Q, Co(II)-
isoDromeQC_D228N, Co(II)-isoDromeQC_D293N and all used ligand components were dissolved 
in 50 mM Tris/HCl, 100 mM NaCl, pH 6.8. All experiments were carried out at 10° C to slow down 
chemical reactions according to the correlation between reaction velocity and temperature. For 
the detailed experimental setup, see Section 2.11, Tables 2.6 and 2.7. For this purpose, the 
enzymes were shot together in two-fold concentration with buffer (50 mM Tris/HCl, 100 mM 
NaCl, pH 6.8). Due to mixing in a ratio of 1:1, the enzyme concentration (see below) is divided by 
a factor of two. 
 
 
3.4.1 Stopped-flow UV/Vis absorption analysis of the resting state  
 
The first step of all measurements was to monitor the enzyme in the resting state. The UV/Vis 
absorbance spectra of the Co(II)-isoDromeQC wild type (0.106 mM) and the variants Co(II)-
isoDromeQC_E190Q (0.090 mM), Co(II)-isoDromeQC_D228N (0.076 mM), Co(II)-
isoDromeQC_D293N (0.090 mM) indicate differences in the coordination sphere of the Co(II) 




517 nm, 550 nm and 570 nm. Further, two small peaks can be observed in the range between 
410 nm and 450 nm.  
The E190Q (B) variant shows two distinct absorption bands at 513 nm and 571 nm. The 
absorption band at 550 nm, which was observed in the Co(II)-isoDromeQC wild type spectrum, is 
not clearly pronounced. In the range of 400 nm to 500 nm, different absorption bands become 
more prominent (e.g. 435 nm and 471 nm). In general, this range reveals higher absorbance as 
the wild type. 
The major absorption bands in the spectrum of variant Co(II)-isoDromeQC_D293N (C) appear at 
517 nm and 560 nm. In contrast to the Co(II)-isoDromeQC wild type and the Co(II)-
isoDromeQC_E190Q and Co(II)-isoDromeQC_D228N, the peak at 517 nm is the dominant one. 




Figure 3.4 UV/Vis absorption spectra of Co(II)-isoDromeQC wild type and variants in the resting 
state The monitored resting state of the Co(II-isoDromeQC wild type (A) and the variants (Co(II)-
isoDromeQC_E190Q (B) Co(II)-isoDromeQC_D293N (C) and Co(II)-isoDromeQC_D228N (D)) reveal distinct 
absorption spectra. The measurements were carried out in 50 mM Tris/HCl, 100 mM NaCl, pH 6.8 at 10 °C 
using the stopped-flow device combined with the photo diode array. The molar concentration after 
mixing the proteins amounts to (Co(II)-isoDromeQC wild type) 0.106 mM, (Co(II)-isoDromeQC_E190Q, 
Co(II)-isoDromeQC_D293N) 0.09 mM and (Co(II)-isoDromeQC_D228N) 0.076 mM. 
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The absorption spectrum of the Co(II)-isoDromeQC_D228N variant (D) is comparable to the 
variants Co(II)-isoDromeQC_E190Q, Co(II)-isoDromeQC_D293N. Absorption bands can be 
observed at 431 nm, 471 nm, 517 nm and 567 nm. In general, all variants demonstrate a higher 
absorption in the region between 400 nm and 500 nm compared to the wild type. 
 
3.4.2 Stopped-flow analysis of Co(II)-isoDromeQC wild type and the variants incubated with 
the substrate QQ 
 
In this experiment, the focus of interest is on the detection of (short-lived) intermediates states 
during the enzyme reaction. According to the expectations that the substrate would interact 
with the catalytically active Co(II) ion, this interaction would lead to changes in the UV/Vis 
absorption spectra. 
 
Therefore, the dipeptide substrate QQ was mixed with the Co(II)-isoDromeQC wild type and the 
variants. The enzyme concentrations are described above (cf. Section 3.4.1). The concentration 
of QQ was 8.0 mM after mixing. This substrate concentration assures steady state conditions (KM 
approx. 1.00 mM QQ, cf. Table 3.2). 
The spectrum which was monitored first (cf. Figure 3.5-1 A spectrum 2, after approx. 0.01 s 
reaction time) depicts increased absorption signals at 515 nm and 555 nm. These absorption 
signals reach a maximum within approx. 0.1 s (cf. Figure 3.5 A spectrum 3). After approx. 25 s the 
absorption signals begin to decrease (cf. Figure 3.5 A spectrum 4). The signals at both 
wavelengths have almost completely disappeared after approx. 55 s (cf. Figure 3.5 A spectrum 
5). Spectra monitored after 55 s remain constant and they are similar to that of the resting state 
(cf. Figure 3.5 A spectrum 1), which was recorded as described in Section 3.4.1. The spectrum 
contains two isosbestic points at the wavelengths 525 nm and 571 nm.  
 
Analog experiments with the different variants mentioned above revealed that only minor 
spectral changes can be observed (cf. Figure 3.5-1 B – D). Thus, only small time-dependent 







Figure 3.5-1 UV/Vis absorption spectra of the Co(II)-isoDromeQC wild type and the variants during the 
the reaction with the substrate QQ The diagrams depict the UV/Vis absorption spectra of the Co(II)-
isoDromeQC wild type (A) and the variants Co(II)-isoDromeQC_E190Q (B), Co(II)-isoDromeQC_D293N (C) 
and Co(II)-isoDromeQC_D228N (D) measured after rapid mixing in the stopped-flow device and 
monitored with the photo diode array in the wavelength range from 350 nm to 700 nm. Only in the case 
of Co(II)-isoDromeQC wild type are clear changes in the absorbance spectra observable during the 
reaction with the substrate.. The variants do not exhibit prominent photospectroscopic changes in the 
course of the reaction. The measurements were carried out in 50 mM Tris/HCl, 100 mM NaCl at 10 °C.  
 
 
Observing the band wavelengths of Co(II)-isoDromeQC wild type in a time-resolved diagram (cf. 
Figure 3.5-2 A), one can observe a significant increase of the mentioned signals at the 
wavelengths 525 nm and 555 nm within the 1.5 ms (dead-time of the stopped-flow device). This 
increase can be assigned to the pre-steady state. The absorption at this wavelength remains 
nearly constant for approx. 25 s. This phase correlates to the steady state of the reaction and is 
followed by the substrate consumption phase lasting approx. 20 s in which the absorption 
signals decrease. 
The time-resolved diagrams of the analog experiments with the variants depict only a slight 
increase of absorbance. In case of Co(II)-isoDromeQC_E190Q (cf. Figure 3.5-2, B) the absorbance 
maxima at the wavelengths at 435 nm, 471 nm, 513 nm and 571 nm was detected after approx. 
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four s. In the experiment with Co(II)-isoDromeQC_D293N, the maximum absorbance at the 
wavelengths 420 nm, 470 nm, 517 nm and 560 nm was reached after 40 s (cf. Figure 3.5-2, C). In 
the case of Co(II)-isoDromeQC_D228N, the reaction has to be detected for about 400 s (cf. 
Figure 3.5-2, D) to observe also marginal changes in the absorbance at the wavelengths of 
431 nm 471 nm and 517 nm. 
  
  
Figure 3.5-2 Time-resolved diagrams of the reaction of Co(II)-isoDromeQC wild type and variants with 
the substrate QQ The time-resolved diagramms reflect the reaction under steady state conditions. Only 
the Co(II)-isoDromeQC wild type show distinct phases of the reaction. These phases can be divided into 
pre-steady state, which shows an increase of absorbance signals within the dead time of the stopped-
flow device (not detectable) and the steady state lasting approx. 20 s showing constant absorbance at 
the specified wavelengths. The following phase depicts an decrease of absorbance signals that 
corellates to the substrate consumption. In contrast, the variants yielded only marginal increases in 
absorbance during the incubation. Measured in 50 mM Tris/HCl, 100 mM NaCl at 10°C using the 
stopped-flow device in combination with the photo diode array. 
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3.4.3 Stopped-flow analysis of Co(II)-isoDromeQC wild type incubated with the substrate QFRH 
 
The measured KM value with QFRH and Zn(II)-isoDromeQC wild type is 0.048 mM. This measure 
for the affinity between substrate and active center is 20-fold lower than the KM of QQ.  
Interestingly, when Co(II)-isoDromeQC wild type was incubated with the tetrapeptide QFRH 
stronger changes in the absorption band, especially at 525 nm and 555 nm, could be observed 
compared to the resting state (cf. Figure 3.5-3). According to the experiment with QQ, several 
absorbance spectra were recorded in the different phases of the reaction progress (cf. Section 
3.4.2). Two isosbestic points are observable at wavelengths around 515 nm and 575 nm. The 
time-resolved diagram points out progression curves, which are similar to the conversion of QQ.  
 
  
Figure 3.5-3 UV/Vis absorbance spectra recorded during the reaction of Co(II)-isoDromeQC wild type 
with the tetrapeptide QFRH Analogously to the experiment with Co(II)-isoDromeQC wild type and QQ 
UV/Vis, absorbance spectra were recorded as a function of wavelength (A) and time (B) using the 
stopped-flow device under the same conditions (cf. Section 3.5.1)The resting state (figure A, spectrum 
1) was recorded with buffer. Approximately 0.01 s after mixing with QFRH, a spectrum during the pre-
steady state (figure A, spectrum 2) could be recorded. After approx. 0.1 s the spectra show the 
maximum absorbance at the mentioned wavelength (figure A, spectrum 3). After approx. 30 s the 
spectra show decreased absorption bands (cf. Figure A, spectrum 4). In this phase the substrate 
concentration decreases continuously. One minute after the reaction starts, the intensities of the 
absorption bands remain constant (cf Figure A, spectrum 5). 
 
3.4.4 Stopped-flow analysis of Co(II)-isoDromeQC wild type incubated with substrates 
possessing an N-terminal glutamate 
 
As mentioned earlier, truncated Aβ peptides consisting of an N-terminal glutamate are 
converted by QCs [54]. Evidence could be mounted that the resulting highly amyloidogenic 
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products are involved in neurodegenerative processes leading to dementia diseases such as 
Alzheimer´s. [25]. 
In the following experiments, the analysis of the QC catalyzed pathophysiological conversion of 
N-terminal possessing glutamate substrates is in the focus of investigation. 
In order to detect changes in the coordination sphere of the catalytically active Co(II) when 
Co(II)isoDromeQC was incubated with substrate harboring an N-terminal glutamate, stopped-
flow experiments were executed in the same manner as described in Section 3.4.1. EFRH and EW 
possess an aromatic system in the second position. According to the results of the substrate 
specificity (cf. Section 3.2), such substrates show higher catalytic efficiencies compared to 
substrates lacking aromatic amino acids in the second positions. For Zn(II)-isoDromeQC there are 
hitherto no kinetic data collected with substrates bearing N-terminal glutamate. 
Interestingly, the monitored stopped-flow UV/Vis absorbance spectra of Co(II)-isoDromeQC wild 
type incubated with the substrate EW or EFRH showed no significant spectral changes compared 
to the spectra of the resting state (cf. Figure 3.6 A/B). The slight spectral changes derive most 
likely from a general increase of absorbance at shorter wavelengths.  
It should be noted that the EW substrate exhibits an intrinsic absorption in the range around 
490 nm (cf. Figure 3.6 B).  
 
  
Figure 3.6 Stopped-flow UV/Vis absorbance spectra of Co(II)-isoDromeQC wild type incubated with 
EFRH and EW The absorbance spectra display the Co(II)isoDromeQC wild type in resting state and 
incubated with EFRH (A) and EW (B). Significant spectral changes are not detectable. The diagram (B) 
additionally displays the UV/Vis spectrum of pure EW (dashed line). The measurements were carried out 
in 50 mM Tris/HCl, 100 mM NaCl at 10 °C. The reactions were detected employing the stopped-flow 
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3.4.5 Stopped-flow analysis of Co(II)-isoDromeQC wild type incubated with competitive 
inhibitors 
 
Enzyme-specific inhibition of QC plays a role in treatment of AD. Inhibition of QC reaction leads 
successfully to a reduction of Aβ-plaque deposition in mouse models [54]. The interference of 
many inhibitors investigated so far with other Zn(II)-dependent enzymes requires further 
investigations regarding inhibitor-metal interaction (unpublished data, Probiodrug). 
In order to analyze the effect of different inhibitors on the spectral properties of Co(II)-
isoDromeQC, analogous experiments were performed using the following compounds. These 
peptides show competitive inhibition effects on the reaction of hQC and isoDromeQC (kinetic 
measurements were accomplished by Dr. Franziska Seifert using Zn(II)-isoDromeQC wild type, 
unpublished data, cf. Supplemental 8.9 and 8.10).  
As inhibitors the following substances were used: The tripeptide alanine-phenylalanine-alanine 
(AFA), and the reaction product pyroglutamamic acid-phenylalanine-arginine-histidine (pEFRH).  
The tripeptide AFA exhibits an inhibition constant (KI) of 0.6 mM. This peptide possesses neither 
glutamine nor glutamate in the first N-terminal position. However, this compound inhibits the 
QC activity. This experiment should show whether the inhibitor binding is mediated by 
interaction with the catalytically active metal. The UV/Vis spectrum of Co(II)-isoDromeQC wild 
type incubated with AFA showed an increased absorption in the range from 350 nm and 570 nm. 
In particular around 555 nm the signal seems to indicate a slightly increased absorption band. 
However, from 570 nm to 700 nm the absorption was similar to that of Co(II)-isoDromeQC 
incubated with buffer as control. In general, the spectrum demonstrates a rise of absorbance at 
lower wavelengths.  
 
It was also kinetically determined that peptides bearing pyroglutamic acid in the first position 
exhibit an inhibition constant of KI=1.8 mM (pEFRH). These peptides are products of the QC 
reaction. In general, product inhibition indicates that the product release is likely the rate 
limiting catalytic step in the catalytic cycle. Under this aspect, it could be possible to 
demonstrate the interaction of the product and the Co(II) ion in this experiment. When Co(II)-
isoDromeDQC wild type is incubated with synthesized pEFRH, a slightly increased absorption at 






Figure 3.7 Stopped-flow UV/Vis absorption spectra of Co(II)-isoDromeQC wild type and inhibitors Here 
the UV/Vis spectra of Co(II)-isoDromeQC wild type incubated with AFA (A) and pEFRH (B) are shown. 
The UV/Vis spectra of the respective inhibitors (dotted lines) and enzyme (black line) are shown as 
controls. Co(II)-isoDromeQC wild type shows slight changes of the absorbance spectra at 555 nm. 
Significant differences in the shape of the spectra are observable with the product pEFRH. The 
measurements were executed in 50 mM Tris/HCl, 100 mM NaCl at 10 °C. The reactions were detected 
employing the stopped-flow device in combination with the photo array detector. 
 
 
3.5 Protein crystallization – X-Ray structure of Zn(II)- and Co(II)-isoDromeQC wild type 
and the variants Zn(II)-isoDromeQC_E190Q and Zn(II)-isoDromeQC_D228N 
 
A high-resolution crystal structure of an enzyme is rich in information about the nature of its 
biological and mechanistic functionality. The overall structure of a single molecule provides 
information about the composition of secondary structure elements (e.g. α-helices, β-sheets or 
loops). Furthermore, the exploration of an enzyme's crystal structures can reveal binding sites 
for substrates or regulatory biomolecules (e.g. inhibitors) as well as binding sites for cofactors. 
Especially the architecture of the active center plays a central role if the issue of interest lies in 
mechanistic considerations. Mechanistic insights can be obtained by the resolution of structures 
of crystallized substrates, reaction intermediates, products or inhibitors in complexes with the 
active center.  
 
To accumulate information about the structural and mechanistic features of the QC, overall 
crystal structures of Zn(II)-isoDromeQC wild type, Zn(II)-isoDromeQC_E190Q and Zn(II)-
isoDromeQC_D228N were resolved. Interestingly, Co(II)-isoDromeQC wild type could be 
crystallized in complex with the substrates QFRH and EFRH and their product pEFRH. Further, a 
crystal structure could be obtained by crystallization of Co(II)-isoDromeQC wild type in complex 
with the competitive inhibitor AFA. 
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3.5.1 Overall crystal structure of Zn(II)-isoDromeQC and variants 
 
Crystallizing attempts of Zn(II)-isoDromeQC wild type, Zn(II)-isoDromeQC_E190Q and Zn(II)-
isoDromeQC_D228N leads to crystals with the space group P1. Those crystals diffract between 
resolutions of 1.12 and 2.23 Å if the data collection was accomplished at a synchrotron facility 
(ESRF, Grenoble, France; BESSYII, Berlin/Adlershof or PETRAIII, Hamburg, Germany). The 
asymmetric unit comprises two autonomic molecules (cf. Figure 3.9 A). In most cases, both 
molecules are different with respect to the isotropic displacement parameter (B-factor). 
Currently, no crystallization conditions were found to yield crystals of Zn(II)-isoDromeQC_D293A 
and Zn(II)-isoDromeQC_D293N with a resolution better than 4 Å.  
The center of the QC overall structure consists of a β-sheet, which is composed of five parallel 
(β1, β3-β6) and one antiparallel β-strand (β2). This twisted β-sheet is coated by nine α-helices (cf. 
Figure 3.9). Seven helices (α1 – α5, α8 and α9) encircle the convex side of the β-sheet. Hence, two 
α-helices (α6 and α7) flank the concave side. This tertiary structure of the isoDromeQC is 
characteristic for the globular α/β-hydrolase fold superfamily [58, 74]. In addition to this 
common overall structure, the isoDromeQC is hallmarked by two further N-terminal, antiparallel 
β-strands β-1 and β0. The active center with a Zn(II) ion is located in a loop region. The distance 




Figure 3.9 The Overall structure of the Zn(II)-isoDromeQC wild type in the unit cell and the single 
molecule Figure A illustrates two molecules in one asymmetric unit. Both molecules exhibit variant B-
factors (blue-colored segments correspond to very rigid structure elements, red-colored segments 
reflect highly flexible regions). The overall structure of the monomer resembles the α/β hydrolase fold 
with nine α-helices (red), eight β-sheets (yellow) and several loops (green). The catalytically active zinc 
ion is embedded in a loop region near the protein surface. Resolutions: wt 1.12 Å, R-work = 0.155, R-





3.5.2 The crystal structure of the active center in the resting state of the Zn(II)-isoDromeQC 
wild type and the variants Zn(II)-isoDromeQC_E190Q and Zn(II)-isoDromeQC_D228N 
 
The catalytically active Zn(II) ion in the resting state is tetrahedrally coordinated by two 
carboxylate moieties (D153 and E191) and an imidazole group (H318) (cf. Figure 3.10). The 
fourth position is occupied by a water molecule. This water molecule acts as placeholder in the 
resting state and will be replaced by the substrate molecule. The water molecule is in hydrogen 
bond distance to the residue E190. Two further acidic aspartate residues (D293 and D228) in the 
second shell around the Zn(II) may play a role in substrate and product binding and the 
suggested proton transfer that is part of the reaction trajectory. 
 
The variants Zn(II)-isoDromeQC_E190Q and Zn(II)-isoDromeQC_D228N were crystallized in order 
to investigate the influence of the amino acid substitution on the structural feature of the active 
center. 
  
Figure 3.10 Crystal structure of the active center of Zn(II)-isoDromeQC wild type aligned with the 
active center of the variants Zn(II)-isoDromeQC_E190Q and Zn(II)-isoDromeQC_D228N These structure 
images demonstrate the aligned active centers of the Zn(II) isoDromeQC wild type (grey) and Zn(II) 
isoDromeQC_E190Q (A, lemon) as well as Zn(II) isoDromeQC_D228N (B, deep cyan). The active center is 
characterized by three zinc-coordinating residues (D153, H317 and E191) and at least three catalytic 
obligate acidic residues (D228, D293 and E190). The hydrogen bond lengths (red dashes) between the 
residues are in a range between 2.6 -3.6 Å. The substitution of the acidic side chain against uncharged 
side chains results in a distorted tetrahedral coordination of the zinc ion along with changed bond 
angles in particular with respect to the coordinated water molecule. Resolutions: wt 1.12 Å, R-
work = 0.155, R-free = 0.179, D228N 2.23 Å, R-work = 0.183, R-free = 0.243, E190Q 1.70 Å, R-
work = 0.146 R-free = 0.204 
 
The substitutions of the amino acid E190 to glutamine in the active center (cf. Figure 3.10 A) lead 
to slight distortions of the residues H317, and E191 compared to the Zn(II)-isoDromeQC wild 


















are also marginally distorted. In this structure the catalytically active Zn(II) ion is shifted 
approximately 0.2 Å.  
Remarkable is the clear change of the bond angles of the tetrahedron in Zn(II)-
isoDromeQC_E190Q and Zn(II)-isoDromeQC_D228N. This significant distortion of the bond 
angles (cf. Table 3.4) in comparison to the Zn(II)-isoDromeQC wild type is mainly due to the 
dislocated water molecule that occupies the fourth ligand binding position.  
 
Table 3.4 Bond angles between Zn(II) coordinating residues, the Zn(II) ion and the water molecule 
The bond angles were determined using the Pymol program version 1.3 based on the structures shown 
in Figure 3.10. 
bond angles D153/OD2-Zn(II)-H2O E191/OE1-Zn(II)-H2O H318/NE2-Zn(II)-H2O 
Zn(II)-isoDromeQC 
wild type 
108.0 ° 115.1 ° 112.5 ° 
Zn(II)-isoDromeQC 
_E190Q 
124.8 ° 98.4 ° 112.7 ° 
Zn(II)-isoDromeQC 
_D228N 
129.5 ° 113.6 ° 110.8 ° 
 
 
3.5.3 The crystal structure of Co(II)-isoDromeQC wild type soaked with the substrate QFRH 
 
In this experiment the aim was to obtain a structure of the QC in complex with a substrate or an 
intermediate state of the glutaminyl cyclization reaction. As mentioned in the introduction, the 
glutaminyl cyclization correlates to the physiological function of QCs. No other substrate 
possessing an N-terminal glutamine leads to analyzable structure data. This substrate shows high 
affinity to the Zn(II)-isoDromeQC wild type and reveals a high catalytic efficiency (cf. Section 3.2). 
The crystallization attempts with QFRH and Zn(II)-isoDromeQC were without success. 
Interestingly, the Co(II)-substituted isoDromeQC provides analyzable crystal structures of the 
enzyme substrate complex. 
The analysis of Co(II)-isoDromeQC wild type crystals soaked with substrate QFRH showed that 
varying ligand orientations in both the molecules of the unit cell are possible. In one of the 
molecules the γ-amido oxygen of the first-position glutamine acts as the fourth coordination 
partner of the Co(II) ion (cf. Figure 3.11 A, B and C). Different structure refinements show 




In this orientation (cf. Figure 3.11 B), the γ-carbonyl oxygen of E190 is in hydrogen bond contact 
with the α- and γ-amino nitrogen of the N-terminal glutamine. The γ-carboxylate oxygen atoms 
of D228 may form a hydrogen bond to the γ-amino nitrogen of the N-terminal substrate 
glutamine. The backbone of D292 (not shown) acts as a further binding motif. The main chain 
nitrogen of D292 interacts with the main chain oxygen of the second amino acid in the substrate 
sequence and the main chain oxygen from D292 interacts with the main chain nitrogen from the 
phenylalanine via hydrogen bond. This binding motif occurs also when an N-terminal glutamate 
(cf. Figure 3.12 B) or pyroglutamic acid (cf. Figure 3.13 B) is bound to the active center. Even if 
the inhibitor AFA is bound (cf. 3.14 B), both hydrogen bond interactions occur. 
An alternative orientation of the substrate is shown in Figure 3.11 (D: view from above, and E: 
side view). In this position, the hydrogen bond mediated contact between the substrate and the 
enzyme is bridged by six water molecules. The distance between the γ-amido moiety of the N-
terminal glutamine and the metal ion is too large for chemical bonding.  
Nevertheless, the N-terminal glutamine residue of the substrate is directed into the acidic 
binding pocket of the QC molecule. The measured electron density for residues in the second 






Figure 3.11 Crystal structure of Co(II)-isoDromeQC 
wild type in complex with the substrate QFRH The 
soaked synthetic substrate QFRH (surrounded by a 
2Fo-Fc electron density map (sigma contour 
level = 1.0 (yellow) was found in two different 
localizations. The first exhibits the γ-amido oxygen 
of the N-terminal glutamine in a cobalt-bound state 
along with potential hydrogen bond interactions 
(dashed line) (A, B and C). The monodentate ligand 
coordinates a tetrahedral Co(II) ion. The second 
position of the substrate shows an outlying ligand 
(D and E). The contact between substrate and QC is 
mediated by water molecules. The resolution of 
this structure is 1.31 (R-work = 0.143, R-













3.5.4 Co-crystallization of Co(II)-isoDromeQC wild type with the substrate EFRH 
 
The following crystallization attempt was performed to analyze the structure of the complex 
between the Co(II)-isoDromeQC wild type and a substrate containing an N-terminal glutamate. 
Substrates with N-terminal glutamate are involved in the pathophysiological side reaction 
leading to neurodegenerative process in the brain of humans [23]. 
In this experiment again, the use of Co(II)-substituted isoDromeQC wild type leads to analyzable 
structure data. 
The analysis of the XDS-processed and Phenix-refined structure data showed an observed 
electron density, which indicates that the active center might be occupied by EFRH as well as by 
the reaction product pEFRH (cf. Figure 3.12 A). The appearance of the product in this structure is 
obviously due to the substrate conversion during the co-crystallization-procedure. Despite the 
minimal rate constant for this substrate (kcat = 1/10000 s
-1, measured with hQC), apparently the 
high concentration of EFRH (approx. 7.5 mM) and the typical high QC concentration in the 
crystal lattice has led to sufficient product conversion. The most reliable statistic values, such as 
the R-work and R-free factors, were obtained when the PHENIX refinement definitions were 
assessed to an occupancy nEFRH = npEFRH = 0.5. This indicates that the ratio of the protein-bound 
substrate and product molecules, respectively, is one to one.  
The Co(II)-isoDromeQC in complex with the product pEFRH is described in a separate Section 
below (cf. Section 3.5.5). In this section, only the binding mode of EFRH will be described.  
The flexibility of the side chain of phenylalanine (the second residue of EFRH) is apparently too 
high. This leads to a lack of electron density (B). The corresponding averaged B-factor of the 
phenylalanine side chain is approx. 45 Å2 and is hence increased by a factor of two compared to 
the N-terminal glutamate residue (Bfaveraged = 25 Å
2).If a substrate with an N-terminal glutamine is 
bound to the active center (cf. Section 3.5.3), the Co(II) ion is four-coordinated. In stark contrast 
thereto, in this structure the Co(II) ion is five-coordinated (cf. Figure 3.12. B). This is the result of 
the bidentate coordination of the γ-carboxylate moiety belonging to the N-terminal glutamate 
side chain. The coordinative bond lengths between the Co(II) ion and both oxygen atoms is 2.2 Å. 
Further substrate protein interactions are displayed in Figure 3.12 B. Next to possible polar 
contacts between the γ-carboxylate moiety and H318 and W317 respectively, and the α-amino 
moiety and the carboxylate moiety of E190, the backbone of E292 and one water molecule 
provide hydrogen bond donators as well acceptors.  
As mentioned above, clear differences in the binding mode of the glutamate substrate is the 
five-coordinated Co(II) ion and the missing polar contact between the N-terminal glutamate side 






Figure 3.12 Crystal structure of Co(II)-isoDromeQC wild type co-crystallized with the N-terminal 
glutamate substrate EFRH The resolved structure of a crystal co-crystallized with EFRH (orange rods) 
resolution: 1.42, R-work = 0.154, R-free = 0.1940) provides an observed electron density of the substrate 
and accumulated reaction product pEFRH (green rods) (A). The γ-carboxylate oxygens of the N-terminal 
substrate glutamate indicate bidentate coordination of Co(II)(dark salmon sphere) (B) Both ligands are 
surrounded by a 2Fo-Fc electron density map with a sigma contour level of 1.0 σ. 
 
 
3.5.5 X-ray structure of the enzyme product complex 
 
The observed electron density of the product pEFRH in the enzyme demonstrates the 
conformation of the N-terminal glutamate residue (figure 3.13 A). Besides the three Co(II) ion 
coordinating residues (D153, E191 and H318), the keto-oxygen of the N-terminal pyroglutamic 
acid is the fourth ligand of the Co(II) ion. The product-enzyme complex possesses a tetrahedral 
coordinated Co(II). The coordinative bond length between the keto-oxygen of the pyroglutamate 
residue and the Co(II) ion is with 2.1 Å and thus 0.1 Å shorter compared to the bond length 
between both the γ-carboxylate oxygen atoms of the substrate and the Co(II) ion (cf. Figure 3.12 
B). Additional polar contacts are comparable to the glutamate substrate EFRH, as described in 
Section 3.5.4 (cf. Figure 3.12 C) with the exception that the hydrogen bond interaction between 







Figure 3.13 Crystal structure of Co(II) isoDromeQC wild type in complex with the reaction product of 
pEFRH after the conversion of EFRH The structure of the enzyme-product complex (resolution: 1.42, R-
work = 0.154, R-free = 0.1940) reveals the first two N-terminal positions of the product pEFRH (green). 
The monodentate keto-oxygen of the N-terminal pyroglutamic acid represents the fourth coordination 
partner of the tetrahedral Co(II) ion. In addition, polar contacts between the product residues and the 
active center side chains function as potential binding motifs. The product is surrounded by a 2Fo-Fc 
electron density map with a sigma contour level of 1.0 σ. 
 
 
3.5.6 Crystal structure of Co(II)-isoDromeQC wild type co-crystallized with the tripeptide AFA 
reveals an enzyme inhibitor complex  
 
Kinetic analysis of incubations of the tripepitde AFA with Zn(II)-isoDromeQC (perfomed by Dr. 
Franziska Seifert), indicated that this compound functions as a competitive inhibitor. AFA was 
thus used for co-crystallization experiments to obtain structural explanations for the inhibiting 
effect. When these crystals were analyzed, electron density for the first two amino acids could 
be observed. 
The AFA tripeptide bound in the active center of Co(II)-isoDromeQC wild type exists in two 
distinct conformations. In the first conformation (cf. Figure 3.14 A), the distance between the α-
amino nitrogen of the N-terminal alanine and the Co(II) ion is 2.3 Å and displays a stretched 
tetrahedral coordinative bond. Besides polar contacts to unbound water, this structure does not 
show any further direct interactions between AFA and the enzyme.  
The second conformation of AFA bound to Co(II)-isoDromeQC is shown in Figure 3.14 B. Here, 
the α-nitrogen (peptide bond) of the phenylalanine in the second position of AFA interacts with 
the oxygen of the main chain of E292. A second interaction between AFA and the enzyme exists 
between the α-nitrogen (peptide bond) of the main chain of E292 and the carbonyl oxygen of 
phenylalanine. Further, in this conformation, polar contact exists between three free water 








Figure 3.14 Crystal structure of two distinct conformations of the inhibitor AFA in complex with 
active center of Co(II)-isoDromeQC wild type This structure (resolution: 1.31 Å, R-work = 0.162, R-free 
=0.196) represents the first two N-terminal residues from the competitive inhibiting tripeptide AFA 
surrounded by a 2Fo-Fc difference electron density map (1.0 σ)(orange rods) in two distinct 
conformations. The α-amino nitrogen of the N-terminal alanine coordinates the Co(II) ion in the fourth 
position (A) as the only direct interaction with active center (grey rods). Alternatively, the peptide is 
























3.6 Electron paramagnetic resonance spectroscopy (EPR) 
 
The investigation of the electronic environment of a catalytically active metal ion in the active 
center of an enzyme during the catalysis can provide information about the reaction trajectory. 
In order to observe changes in the coordination number or coordination geometry of the metal 
ion, the EPR technique was employed. Due to the fact that the Zn(II) ion in the native 
isoDromeQC raises no EPR signals, the insertion of a catalytically active Co(II) ion into the active 
center is a necessary pre-requisite. Here the observation of the EPR-active transition metal ion is 
the central issue of interest. In order to gather insights about binding states of substrates, 
transient intermediate reaction states or the liberation of the product, the following EPR 
experiments were performed.  
Further, to explore the functions of the active center amino acids E190, D228 and D293, variants 
of Co(II)-isoDromeQC were analyzed in which one of these amino acids was substituted. 
 
The EPR experiments were carried out under the supervision of Prof. Dr. Brian Bennett at the 
Department of Biophysics at the Medical College of Wisconsin in Milwaukee (Wisconsin, USA). 
The enzyme and used compounds (e.g. substrates, product and inhibitors) were dissolved in 
buffer containing 50 mM sodium phosphate, 100 mM sodium chloride at pH 6.8. The frozen 
protein samples (cf. Section 2.12.5 sample preparation/freeze techniques) were measured with 
the EleXsys E600 (Bruker BioSpin Corporation, Billerica, USA). The spectrometer was applied at 
4 K, 10 K and 25 K to examine the high spin S =     EPR signal as well as the S = ½ signal. In the 
following sections only the EPR spectra of the high spin S =    EPR signals measured at 4 K are in 
the focus of interest. 
 
For the experiments in the recent work three characteristics of the EPR signals are of particular 
importance. The number of appearing signals, the signal position (resonance position or signal 
maximum) and the band width. The signal position and the number of appearing signals provide 
information regarding the Co(II) coordination number. A four-coordinate Co(II) in the active 
center presents one prominent resonance position in the range of 1000 Gauss– 1100 Gauss. 
Whereas, a five-coordinate Co(II) ion presents one signal in a range of 1100 and 1200 Gauss and 
at least one second signal at over 1200 Gauss. EPR spectra of samples containing both four- and 
five-coordinated Co(II) species present a signal between 1000 G and 1100 G (four-coordinated 
Co(II)) and a mostly less pronounced second signal between 1100 G and 1200 G, indicating five-
coordinated Co(II) species. The second signal that is typical for five-coordinated Co(II) is in these 




Changes in the resonance position are indicative for distorted (stretched or compressed) 
coordination geometry. Such changes are observable when ligands effectuate a delocalization of 
electron(s) along the Z-axis.  
The band width can be altered depending on the flexibility of the coordination geometry. A 
narrow band width correlates to a rigid Co(II) coordination sphere. In contrast, broad signals 
imply that the coordination sphere is flexible due to a weakly bound or small ligand e.g. water. 
 
 
3.6.1 EPR-analysis of Co(II)-isoDromeQC wild type and variants in the resting state 
 
The EPR measurement of the Co(II)-isoDromeQC wild type and the variants Co(II)-
isoDromeQC_E190Q, Co(II)-isoDromeQ_D228N and Co(II)-isoDromeQC_D293N in the resting 
state is the basis for the following experiments with substrates and inhibitors.  
For this purpose the protein samples with a molar concentration of approx. 680 µM were frozen 
in liquid nitrogen and measured as described above.  
The obtained EPR spectrum of Co(II) ion in the resting Co(II)-isoDromeQC wild type (cf. Figure 
3.15 A/B) shows a maximum at 1038 G (g = 6.443). 
This type of EPR spectrum is characteristic for a predominantly four-coordinate Co(II) ion. A 
small percentage of about ten percent of the cobalt bears a five-coordinate signal (internal 
discussion with Prof. Dr. Brian Bennett). This is also true for the EPR spectrum of Co(II)-
isoDromeQC_E190Q that shows a shifted maximum of the resonance signal 1056 G, (g = 6.333) 
into the high field. The signal of this variant in the resting state is broadened compared to the 
resting state of Co(II)isoDromeQC wild type.  
The variant Co(II)-isoDromeQC_D228N gives a signal, that corresponds to a spectrum of 
tetrahedrally bound Co(II) and does not show any clear difference to that of Co(II)-isoDromeQC 
wild type. The maximum of this resonance signal is encountered at 1036 G with resonance 
condition at (g = 6.455). The substitution of this side chain obviously does not bring about any 
significant change in the coordination sphere of the Co(II) ion.  
The maximum of the resonance position of the signal of Co(II)-isoDromeQC_D293N is found at 
1058 G (g = 6.321) and presents a similar shift as the Co(II)-isoDromeQC_E190Q of 16 G 
compared to the Co(II)-isoDromeQC wild type. The measured spectrum corresponds to a 
tetrahedrally coordinated Co(II) ion. 
The crystal structure of Co(II)-isoDromeQC wild type, Co(II)-isoDromeQC_E190Q and Co(II)-




the fourth coordination partner of the metal ion. Such a solvent molecule frequently represents 
a flexible ligand that often leads to broadened band width of a signal. The distortions of the 
bond angles of Co(II) and its coordinating ligands (cf. Table 3.4), are shown in the crystal 
structure of Co(II)-isoDromeQC_E190Q (cf. Figure 3.10 A). These alterations in the active center 
may cause measurable changes in the resonance condition. 
 
  
Figure 3.15 Co(II) EPR spectra of the Co(II)isoDromeQC wild type and variants in the resting state 
Figure A depicts the entire EPR-spectra of Co(II)-isoDromeQC wild type and variants in the resting state. 
Figure B presents a zoomed diagram to ilustrate the details of the spectra in the magnetic field of 
interest. The shown spectra are characteristic for predominantly tetrahedrally coordinated Co(II) 
ions.The perpendicular black line defines the resonance position of Co(II)-isoDromeQC wild type. 
Measured at 4.0 K, 20 mW at X-band wavelength (9.36 GHz) in 50 mM sodium phosphate buffer, 
100 mM sodium chloride, pH 6.8 with a molar enzyme concentration wt/variants 0.68 mM. 
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3.6.2 Freeze quench EPR analysis of Co(II)-isoDromeQC wild type and variants after defined 
incubation times with the substrate QQ 
 
Potential intermediates of the reaction might lead to differences in the coordination geometry 
of the catalytically active Co(II). In order to investigate these discrete steps of the catalysis, 
incubations of Co(II)-isoDromeQC wild type and mentioned variants with QQ as substrate were 
quenched at defined points in time. The quench of the reaction after 20 ms was executed by 
rapid freeze quenching in cryogenic isopentane. The incubation was quenched after 2 s by 
manual freeze quenching in cryogenic isopentane. After 2 min, 30 min and 6 h, the incubations 
were stopped by freezing in liquid nitrogen. By this means, the reaction should be halted at 
different states of the catalysis. The used concentration of the substrate QQ was 10 mM or 
15 mM for rapid freeze quench and for manual freeze quench EPR spectroscopy, respectively. 
The enzyme concentration was set to 0.40 mM for rapid freeze quench EPR and 0.3 mM for 
manual freeze quench EPR experiments. The incubations were carried out at 20°C. 
The experiments with Co(II)-isoDromeQC wild type incubated with QQ were performed by Dr. 
Franziska Seifert. As shown in Figure 3.17 A, a significant shift of the signal maximum from 
1077 G (g = 6.209) (resting state with defined experimental setup of 4.8 K, 9.36 GHz and 
200 mW) to 1046 G (g = 6.393) to the lower magnetic field was observed after 10 ms reaction 
time. The maximum shift of the band position can be observed after 160 ms. Here, the signal 
maximum appears at 1030 G (g = 6.493). After 160 ms the resonance signal appears with its 
narrowest width.  
After 2 s incubation time with the substrate, the resonance signal becomes broader and the 
signal maximum at 1056 G (g = 6.333) returns to the higher magnetic field. The spectra after 
2 min and 16 h are comparable, revealing signal maxima at 1060 G (g = 6.309) and the band 
width becomes narrower. Even after 16 hours, the signal does not return completely to the 
resting state situation. The coordination of the enzyme bound Co(II) ion can be assigned as 
predominantly four-coordinate. A small population (~ 10 %) of the cobalt is five-coordinate 






   
  
Figure 3.17 EPR spectra of Co(II)isoDromeQC wild type and variants freeze quenched after defined incubation 
times with the substrate QQ Entire (left) and zoomed EPR spectra (right) from the Co(II)-isoDromeQC wild type 
(A) and the variants (Co(II)-isoDromeQC _E190Q –B, Co(II)-isoDromeQC_D293N –C, Co(II)-isoDromeQC _D228N 
–D). The reaction was (rapid) freeze quenched after different reaction times to monitor the coordination sphere 
of the catalytically Co(II) ion at varying steps of catalysis. The perpendicular black line defines the resonance 
position of Co(II)-isoDromeQC wild type in the resting state. Measured at 4.0 K, 20 mW at X-band wavelength 
(9.36 GHz) in 50 mM sodium phosphate buffer, 100 mM sodium chloride, pH 6.8 with a molar enzyme 
concentration wild type/variants 0.30 mM (manual freeze quenche) and 0.40 mM RFQ) and QQ 15 mM or 
10 mM (RFQ) after mixing. 
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Analogous experiments were performed with the different Co(II)-isoDromeQC variants. The 
results from these analyses showed a certain EPR-profile for each variant (cf. Figure 3.17 B).  
In case of Co(II)-isoDromeQC_E190Q the maximum of the signal in its resting state was observed 
at 1056 G (g = 6.333). The signal for resonance conditions shifts to lower magnetic field after 
20 ms to 1033 G (g = 6.474) and its shape becomes narrower. The signal maximum and the band 
width stays constant at all times at which the reaction was freeze quenched. The signal, 
corresponding to the Co(II) coordination is indicative for four-coordinated Co(II) but a distinct 
signal of Co(II) with a higher coordination number appears after 20 ms at approx. 1150 G 
(g = 5.815). After 2 s this signal arises with a maximum distinction after 30 min. After 6 h this 
signal decreases slightly. This signal can be assigned to five or six-coordinated Co(II). 
 
The signal maxima of the Co(II) ion in the Co(II)-isoDromeQC_D293N variant (cf. Figure 3.17 C) 
remains constant at 1058 G (g = 3.321) after the reaction was quenched at specific incubation 
times. After 30 min a new signal at 1390 G (g = 4.811) appears. These spectra indicate four and 
five-coordinated Co(II) ions. 
 
The EPR spectra of the variant Co(II)-isoDromeQC_D228N exhibit only marginal changes 
compared to the resting state (cf. Figure 3.17 D). After 2 s the signal maximum is shifted from 
1036 G (g = 6.455) to 1044 G (g = 6.406) to the higher magnetic field. When the incubation with 
QQ was stopped after 2 min, the maximum signal returned to 1036 G (g = 6.455). After 6 h 
incubation time the signal maximum shifted slightly to the lower magnetic field to 1024 G 
(g = 6.531). These spectra indicate a tetrahedrally coordinated Co(II) ion with a residual 
probability that the Co(II) ion is five-coordinated (internal discussion with Prof. Dr. Brian 




3.6.3 EPR spectroscopic analysis of the coordination sphere of the catalytically active Co(II) ion 
in Co(II)-isoDromeQC wild type and variants after incubation with N-terminal 
glutamine and N-terminal glutamate substrates  
 
These substrates mimic pathophysiological QC substrates. In this context, the EFRH hold a prior 
position because this substrate has the same initial amino acid sequence as the truncated Aβ 




neurotoxic oligomers these peptides play a key role in the development of toxic plaque 
deposition in the brain of AD patients [7, 23]. 
In order to analyze differences in the Co(II) coordination sphere induced by glutamate-substrates 
(e.g. EFRH, EW), the following experiment was performed. The N-terminal glutamate substrates 
were incubated at 20° C with the Co(II)-isoDromeQC wild type, Co(II)-isoDromeQC_E190Q, Co(II)-
isoDromeQC_D228N and Co(II)-isoDromeQC_D293N for 5 min before the reaction was stopped 
by freezing in liquid nitrogen. In contrast to the attempts with N-terminal glutamine substrates, 
the incubation time was increased due to the low rate constant of N-terminal glutamate 
substrates as determined for hQC (Dr. Franziska Seifert, internal discussion).  
The reaction of Co(II)-isoDromeQC wild type with the N-terminal glutamine substrate QFRH was 
stopped after 20 ms using the RFQ technique (cf. Section 2.12). The determined rate constants 
of the Zn(II) containing variants (cf.section 3.2) are 10,000-fold slower compared to the Zn(II)-
isoDromeQC wild type. For this reason the incubation time for these measurements was 
increased to 5 s. The used concentrations of the substrate QFRH were 15 mM or 10 mM for 
rapid freeze quench and for manual freeze quench technique, respectively. The enzyme 
concentrations were set to 0.40 mM for rapid freeze quench EPR (only Co(II)-isoDromeQC wild 
type plus QFRH) and 0.34 mM Co(II)-isoDromeQC_E190Q, 0.32 mM Co(II)-isoDromeQC_D228N 
and 0.30 mM Co(II)-isoDromeQC D293N (for manual freeze quench EPR experiments). 
After 20 ms of QFRH incubation time, the measured EPR spectra of Co(II)-isoDromeQC wild type 
exhibits a shift to the lower magnetic field from 1038 G (g = 6.443) (resting state) to 1024 G 
(g = 6.531) (cf. Figure 3.18 A). The band width of the resonance signal is narrowed. This type of 
EPR spectrum indicates a four-coordinated Co(II) ion. 
A more significant shift into the lower magnetic field could be observed with the 
Co(II)isoDromeQC_E190Q (cf. Figure 3.18 A). The signal maximum was displaced from 1056 G 
(g = 6.333) (resting state) to 1026 G (g = 6.518). The band width of this signal is also narrowed 
significantly. The EPR spectra mirrors a predominantly four-coordinated Co(II) ion with 
indications that also five-coordinated Co(II) ions exist in the sample. 
The signal maximum of the variant Co(II)-isoDromeQC_D228N after 5 s incubation time shows 
also deviation into the lower magnetic field from 1036 G (g = 6.455) (resting state) to 1022 G 
(g = 6.544). This resonance signal shows a narrower band width compared to the resting state. 
Interestingly, this EPR spectrum contains a second signal at 1140 G (g = 5.866), implying that 
besides the predominantly four-coordinate Co(II) ions also five and six-coordinated Co(II) ions 
are present in the sample (cf. Figure 3.18 A). The variant Co(II)-isoDromeQC_D293N shows a 




(g = 6.418) into the lower magnetic field combined with a narrower band width. This EPR 







Figure 3.18 EPR spectra of Co(II)-isoDromeQC wild type and variants after incubation with N-
terminal glutamine substrate and two N-terminal glutamate substrates The EPR spectra of Co(II)-
isoDromeQC wild type and QFRH were measured after 20 ms. The variants and QFRH were incubated 
for 5 s (A). The incubation time for the reaction between Co(II)isoDromeQC wild type and the variants 
with the substrates EW (B) and EFRH (C) were set to 5 min. The EPR spectra illustrate different binding 
modes between substrate with N-terminal glutamine (A) displaying a tetrahedrally coordinated Co(II) 
and N-terminal glutamate (B, C) which evokes a five-coordinate Co(II) ion. The dotted line marks the 
resting state spectrum and the perpendicular black line defines the signal maximum of Co(II)-
isoDromeQC wild type. Measured at 4.0 K, 20 mW at X-band wavelength (9.36 GHz) in 50 mM sodium 
phosphate buffer, 10 mM sodium chloride, pH 6.8 with a molar enzyme concentration wt/variants 
0.23 µM B, C and 0.34 µM A rapid freeze quenche), QFRH 5 mM, EW, EFRH 15 mM after mixing. 
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The EPR spectra of Co(II)-isoDromeQC wild type incubated with the dipeptide EW (15 mM) 
points out a significantly broadened EPR signal. The maximum of the signals is shifted compared 
to the resting state from 1038 G (g = 6.443) to 1142 G (g = 5.856) (cf. Figure 3.18 B). Besides this 
signal a further less pronounced signal appears at approx. 1560 G (g = 4.29). This spectrum 
indicates a five-coordinated Co(II) ion. 
The EPR measurement of Co(II)-isoDromeQC_E190Q yields a spectrum that is not significantly 
changed from that of the resting state of this variant. The maximum of the resonance signal is 
shifted into the higher magnetic field from 1056 G (g = 6.333)(resting state) to 1069 G 
(g = 6.256). The bandwidth of this signal is comparable to the resting state and indicates a four-
coordinate Co(II) ion. 
In contrast to Co(II)-isoDromeQC_E190Q, the EPR spectrum Co(II)-isoDromeQC_D228N 
incubated with EW presents a significant deviation of the signal maximum from 1036 G 
(g = 6.455) (resting state) to 1142 G (g = 5.856) into the higher magnetic field combined with a 
broadened band width. A second, smaller signal occurs at aprox. 1800 (G) (g = 3.75). This signal 
can be assigned to a five-coordinated Co(II) ion (cf. Figure 3.18 B). 
The spectrum of Co(II)-isoDromeQC_D293N measured after the incubation with EW depicts that 
the maximum of the EPR signal is marginally shifted from 1058 G (g = 6.321) to 1052 G 
(g = 6.357) (cf. Figure 3.18 B). The difference of this spectrum to the resting state is that the 
descending branch of the signal is transferred into the higher magnetic field. This spectrum 
correlates to a predominantly four-coordinated Co(II) ion with indications that also five-
coordinated Co(II) exists in the sample. 
Nearly the same results were obtained when Co(II)-isoDromeQC wild type and the mentioned 
variants were measured after incubation with the substrate EFRH (15 mM). 
The measurement of Co(II)-isoDromeQC_D293N after incubation with EFRH reveals an EPR signal 
that shows a significant shift of the signal maximum from 1058 G (g = 6.321) to 1144 G 
(g = 5.846) (cf. Figure 3.18 C). Additionally, a second signal appears in the range of 1800 to 
1900 G. The bandwidth is extended significantly. In contrast to the attempt with EW, this 







3.6.4 EPR spectroscopic analysis of the coordination sphere of the catalytically active Co(II) ion 
in Co(II)-isoDromeQC wild type and variants after incubation with competitive 
inhibitors 
 
The recent strategy in AD treatment is the inhibition of QC in order to avoid harmful 
accumulation of highly amyloidogenic species in the brain. The issue of interest in this regard is 
to analyze the type of influence of the inhibitor on the electronic environment of the 
catalytically active Co(II) ion.  
Former investigations by Dr. Franziska Seifert reveal that also the reaction product acts as a 
competitive inhibitor (cf. Supplemental 8.10). Thus, a product analog compound pEFA 
(pyroglutamic acid-phenylalanine-alanine) was analyzed to investigate the effect of the reaction 
product on the Co(II) ion. 
 
In these experiments the inhibitors were incubated at 20° C with Co(II)-isoDromeQC wild type, 
Co(II)-isoDromeQC_E190Q, Co(II)-isoDromeQC_D228N and Co(II)-isoDromeQC_D293N for two 
minutes. To freeze the samples, liquid nitrogen was used. Analogously to the former EPR 




3.6.4.1 EPR analysis of Co(II)-isoDromeQC wild type and variants incubated with the tripeptide 
AFA 
 
The EPR data of Co(II)-isoDromeQC wild type incubated with AFA and pEFA (described in the 
following section) were measured by Dr. Franziska Seifert. Here a qualitative comparison of the 
Co(II)-isoDromeQC wild type in resting state and incubated with these inhibitors is presented. 
The used concentration of AFA was 7.5 mM (KI = 0.62 mM). The concentration of Co(II)-
isoDromeQC_D228N and Co(II)-isoDromeQC_D293N was 0.30 mM. The concentration of Co(II)-
isoDromeQC_E190Q was 0.34 mM. 
The EPR spectrum of Co(II)-isoDromeQC wild type incubated with AFA shows two signals. The 
first signal displays a maximum around 1050 G (g ~ 6.37) and the second around 1250 G 





Figure 3.19-1 Manual freeze quench EPR experiments with the inhibiting tripeptide AFA The EPR 
spectra of Co(II)-isoDromeQC wild type (resting state), Co(II)-isoDromeQC_E190Q and Co(II)-
isoDromeQC_D228N reveal a signal that indicates a Co(II)-hyperfine pattern in the magnetic field range 
between 620 G and 940 G. The left diagram shows entire spectra and the right depicts the zoomed 
spectra. While the bandwidth of Co(II)-isoDromeQC_D228N and Co(II)-isoDromeQC_D293N is narrowed 
with a shift of the signal maximum to lower magnetic field, the variant Co(II)-isoDromeQC_E190Q depicts 
a broadened resonance signal without any noticeable shift of the signal maximum. The dotted lines 
hallmark the EPR spectra of the resting state. Measured at 4.0 K, 20 mW at X-band wavelength (9.36 GHz) 
in 50 mM sodium phosphate buffer, 100 mM sodium chloride, pH6.8 with a molar enzyme concentration 
variants 0.30 mM (0.34 mM Co(II)-isoDromeQC_E190Q) and AFA concentration 7.5 mM. 
 
The EPR spectrum of the variant Co(II)isoDromeQC_E190Q (cf. 3.19-1) displays a marginal shift of 
the maximum resonance signal from 1056 G (g = 6.333) to 1054 G (g = 6.345), in connection with 
a broadened band width. The spectrum shows a second signal at approx. 1250 G (g = 5.350) and 
a small but broad third signal occurs around 1560 G (g = 4.287). This spectrum implies that the 
Co(II) is predominantly four-coordinate but includes indications for five-coordinated Co(II). 
Interestingly, this spectrum indicates a Co(II)-hyperfine pattern in the low magnetic field from 
approx. 620 G to 940 G (cf. Figure 3.19-2)).  
A clearly pronounced shift of the signal maximum into the lower magnetic field can be observed 
in the case of Co(II)isoDromeQC_D228N from 1036 G (g = 6.455) to 1005 G (g = 6.654) and 
exhibits a significantly smaller band width. This spectrum correlates to a four-coordinated Co(II) 
geometry. This EPR spectrum reveals an Co(II)-hyperfine signal occurring in the same magnetic 
field range as described for Co(II)-isoDromeQC_E190Q but with decreased amplitudes (cf. Figure 
3.19-2) . 
In the case of Co(II)isoDromeQC_D293N incubated with AFA, the signal maximum is transferred 
from 1058 G (g = 6.321) to 1017 G (g = 6.576) to the lower magnetic field. This EPR spectrum 
indicates four-coordinate Co(II). An additional five-coordinate signal, as observed in the resting 
state, has completely disappeared. 
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Figure 3.20 Co(II) hyperfine structure measured in Co(II)-isoDromeQC E190Q and Co(II)-
isoDromeQC_D228N incubate with AFA The zoomed EPR spectra of Co(II)-isoDromeQC_E190Q and 
Co(II)-isoDromeQC_D228N reveal a signal that indicates a Co(II)-hyperfine pattern in the magnetic field 
range between 620 G and 940 G. The dotted lines hallmark the EPR spectra of the resting state.  
 
3.6.4.2 EPR analysis of Co(II)-isoDromeQC wild type and variants incubated with the reaction 
product pEFA 
 
The tripeptide pEFA possessing an N-terminal pyroglutamic acid corresponds to the reaction 
product of the QC reaction. As described above, QC reaction products act as competitive 
inhibitors. This experiment was performed to reveal potential interactions between the reaction 
product and the catalytically active Co(II) ion. For the EPR analysis, 10 mM pEFA (KI = 3.12 mM) 
and 0.4 mM QC were used.  
 
The EPR spectrum of Co(II)-substituted wild type enzyme incubated with pEFA presents a signal 
that indicates a four-coordinated Co(II) ion. Further, the signal maximum is slightly shifted into 
the lower magnetic field corresponding to a changed electronic Co(II) sphere along the Z-axes. 
This in turn corresponds to binding interaction between the product and the metal ion.  
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Figure 3.21 Manual freeze quench EPR experiments of Co(II)(II)-isoDromeQC wild type and variants 
after incubation with the product analog pEFA The influence of pEFA to the catalytically active Co(II) 
ion is reflected clearly in the EPR spectra of the variants which exhibit significant deviations of the signal 
maximum into the lower magnetic field. A second hallmark of the spectra is the narrowed bandwidth of 
the resonance signals compared to their resting states. The left diagram shows entire spectra and the 
right depicts the zoomed spectra. The dotted line represents the EPR spectra of Co(II)-isoDromeQC wild 
type and variants in the resting state while the solid line represents the EPR spectrum of Co(II)-
isoDromeQC incubated with pEFA. The spectrum with wild type is described in the Supplemental due to 
missing ASCI files. The analysis was performed at 4.0 K, 20 mW at X-band frequency (9.36 GHz) in 
50 mM sodium phosphate buffer, 100 mM sodium chloride, pH 6.8 with a molar enzyme concentration 
of 0.40 mM and a pEFA concentration of 15 mM. 
 
The EPR spectrum of the variant Co(II)isoDromeQC_E190Q (cf. Figure 3.23) exhibits a significant 
low-field shift of the maximum resonance signal from 1056 G (g = 6.333) to 1007 G (g = 6.641), in 
conjunction with a clearly narrowed band width. In addition, the spectrum shows a second but 
not very pronounced signal at approx. 1100 G (g = 6.08). This spectrum implies that the Co(II) is 
predominantly four-coordinate but includes indications for higher coordination numbers (5 and 
6). 
A shift of the maximum of the EPR resonance signal into the lower magnetic field was observed 
in the case of Co(II)isoDromeQC_D228N. The signal maximum moves from 1036 G (g = 6.455) to 
1017 G (g = 6.576) and displays a significantly smaller band width. This spectrum correlates to 
Co(II) which is four-coordinated. 
In the case of Co(II)isoDromeQC_D293N, the signal maximum is displaced from 1058 G 
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4 Discussion 
4.1 Characterization of the active center and the binding mode of N-terminal 
glutamine substrate binding  
 
4.1.1 The lock-and-key principle – Basic correlations between active center and the substrate  
 
The architecture of an enzyme, in particular of the binding pocket and the active center, plays 
the key role in substrate recognition and selectivity. The exploration of a binding pocket´s 
structural design often explains the acceptance and preferences for substrates. Along with the 
identification of distinct amino acids constituting the substrate binding motif, information about 
the lock (enzyme) -and-key (substrate) principle can be gathered. Thus the knowledge about the 
structure-function relationship of specific amino acids in the binding pocket contributes to 
understanding different details about the catalytic mechanism. Furthermore, these findings 
might help to design potential inhibitors, which can be useful for drug development in the 
treatment of dementia.  
The following section discusses the meaning of the results described above with regard to the 
interplay between the structure of the substrate and that of the binding pocket. In this context, 
the function of different amino acids in the active center is discussed.  
 
 
4.1.1.1 The electronic surface charge around and in the binding pocket is crucial for substrate 
selectivity 
 
Figure 4.1 demonstrates the electrostatic surface potential of Zn(II)-isoDromeQC wild type. As 
indicated, the surface in and around the active center is highly negatively charged. This can be 
explained by the presence of several carboxylic amino acid side chains that are localized within 
the substrate channel (e.g. E292, D293, D228, E190). Consequently, QC substrates possessing 
positively charged residues (e.g. arginine in QFRH) can be considered as preferred substrate due 
to electrostatic attractant forces between enzyme and substrate (cf. Section 3.2, Table 3.2). In 
line with this idea are former investigations indicating that substrates containing a negatively 






Figure 4.1 Electrostatic surface potential Displayed is the electrostatic potential level of the 
isoDromeQC surface from -7 (red surface is negatively charged) to 7 (blue surface is 




4.1.1.2 The length of the substrate sequence is decisive for substrate affinity and catalytic 
efficiency 
 
The length of the substrates improves the kinetic constants as described in Section 3.2. The 
Zn(II)-isoDromeQC wild type measured with QFRH depicts a strong decrease of the KM value that 
indicates a higher affinity between substrate and enzyme. Further the catalytic efficiency 
(kcat/KM) is increased by the factor of 6 to 19 compared to QQ or QGP representing a di- and 
tripeptide, respectively. Interestingly, the turnover number (kcat) of QFRH is comparable to that 
observed with QGP and only two-fold higher than that found with QQ. This shows that the 
strongly increased kcat/KM is only due to the very low KM value. Thus it can be concluded that 
compared to shorter substrates the equilibrium between substrate association and dissociation 
is extensively shifted to the enzyme substrate complex. The variants Zn(II)-isoDromeQC_D293A, 
Zn(II)-isoDromeQC_D293N and Zn(II)-isoDromeQC_D228N show in general higher KM values and 
approx. 10,000-fold decreased kcat/KM. Nevertheless incubated with QFRH, these variants 
present the lowest KM value and the highest kcat/KM. In line with these results are the data 
acquired by the Probiodrug Company revealing that longer physiological oligopetides as for 
example the decapeptide Gonadotropin releasing hormone (Q1-GnRH) or Q1-Gastrin (consisting 
of 17 residues) are highly preferred by hQC [57]. With hQC this tendency can also be observed 
with truncated Aβ peptides containing an N-terminal glutamine residue [90].  
The crystal structure of the Co(II)-isoDromeQC in complex with the substrate QFRH (cf. Figure 




are directly bound to the binding pocket. It can be assumed that an increasing peptide length 
provokes a rising number of hydrogen bonds on the surface of the QC supporting the substrate 
binding for QFRH.  
 
 
4.1.1.3 Hydrophobic effects between aromatic amino acids in the second N-terminal position of 
the substrate and the active center may improve kinetic constants 
 
As described in Section 3.2, substrates containing voluminous and aromatic amino acid side 
chains in the second N-terminal position (e.g. phenylalanine) are preferably converted by Zn(II)-
isoDromeQC. This was indicated by low KM values. It was speculated that this effect is due to π-
stacking interactions between the enzyme and this particular amino acid. Interestingly, no 
interaction partner could be found in the structure of the substrate binding pocket. Since no -
stacking interaction partner is available, another reason for the preference could be the 
hydrophobicity of these amino acids. Possibly due to the high flexibility of the amino acid in the 
second position, the crystal structures reveal no specific hydrophobic interactions. The presence 
of several non-polar amino acids in and around the substrate binding pocket e.g. I291, F313, 




4.1.1.4 Active-center residues correlate with thermal stability 
 
An additional aspect regarding the structure of the active center of isoDromeQC is the 
conformational stability. As described in Section 3.1, the conformational stability was studied by 
thermal unfolding utilizing the circular dichroism spectroscopy. The determined midpoints (or 
melting points) of the thermal unfolding transition curves can be used as measures for thermal 
stability. Enzymes with high thermal stability present the midpoint at higher temperatures.  
 
The midpoint of the transition curve of the wild type is approx. 55°C (cf. Table 3.1). The side 
chain substitution of D293 either by alanine or asparagine yields midpoints at lower 
temperatures corresponding to less conformational stability. The crystal structure of 
Zn(II)-isoDromeQC wild type (cf. Figure 3.10 A and B) shows a network of possible hydrogen 




amino acid in this network by alanine or asparagine would interrupt these connections. These 
interrupted hydrogen bond interactions may be causal for the loss of stability. This finding might 
thus indicate that amino acid side chains of the active center have a strong influence on the 
overall structural stability of isoDromeQC. 
 
 
4.1.2 The function of the native Zn(II) ion in the catalysis of animal QCs  
 
4.1.2.1 The metal in the active center 
 
A multitude of metalloenzymes requires Zn(II) ions for enzymatic activity. Zn(II) can easily switch 
the coordination geometry between four-, five- or six-fold coordination numbers. In enzymes 
Zn(II) is often coordinated by four or five ligands [91]. Therefore, in the coordination geometry at 
least one binding site is free that can be occupied by different ligands. For example substrates 
can bind to the free binding site by raising the coordination number [91]. Ligand binding or 
dissociation events provoke changes in the electronic environment of the bioactive metal. 
Furthermore, the chemical reaction that the ligand undergoes during the catalysis is mostly 
combined with delocalization of electronic charges. Delocalized electronic charges influence the 
coordination sphere for example by stretching or compressing bond lengths or by distorting 
bond angles. Thus the investigation of the metal coordination geometry during the catalysis can 
help to understand discrete mechanistic steps of the catalysis. 
The divalent and diamagnetic Zn(II) ion with the electron configuration [Ar] 3d10 4s2 ion exhibits 
neither optical electronic absorption signals nor paramagnetic resonances. For this reason the 
Zn(II) ion was exchanged for a divalent and paramagnetic Co(II) ion. Co(II) has the electron 
configuration [Ar] 3d7 4s2 and possesses three orbitals with one unpaired electron and is suitable 
for probing  the coordination sphere by photospectroscopic methods as well as by the EPR 
method.  
 
Despite the propensity to adopt higher coordination geometries [92], in isoDromeQC the Co(II) 
ion adopts the original tetrahedral coordination of the Zn(II) ion and thus helps to mimic the 
catalytically active form of the Zn(II) enzyme. Compared to native Zn(II)-QC, the Co(II)-
substituted isoDromeQC exhibited a catalytic activity of approx. 85 % – 95 % (in rare cases 
higher) measured by Dr. Franziska Seifert (Supplemental 8.7). The loss of approximately 5 % - 




formation of catalytically inactive five-coordinated Co(II) besides the four-coordinated Co(II). 
This hypothesis was strengthened by the finding that EPR signals of the wild type in its resting 
state displays four and five-coordinate Co(II) in a ratio of 90 % to 10 % (internal discussion with 
Prof. Dr. Brian Bennett)(cf. Section 3.6.1, Figure 3.15 A and B). Nevertheless, the reasons for 
good commutability of the metals are especially the almost equal ionic radii and the Alfred-
Rochow electronegativities. Octahedral Zn(II) has an ionic radius of 0.88 Å and high-spin 
octahedral Co(II) 0.89 Å. Electronegativities (Zn, 1.66 and Co, 1.70) are also comparable. [87]. 
 
 
4.1.2.2 The characterization of the metal site in Zn(II)-isoDromeQC  
 
That isoDromeQC requires the zinc ion was proven by adding the chelating agent 1,10-
phenanthroline. The molecules of that compound are small and fit into the binding channel, 
where it coordinates the Zn(II) ion in a very tight manner. It leaves the apo-enzyme, which does 
not exhibit any catalytic activity [56]. The question of how many Zn(II) ions are required was 
unresolved for a long time. The bacterial aminopeptidase of Aeromonas proteolytica (ApAP), 
which is the potential evolutionary ancestor of animal QCs [56, 60] (cf. Section 1.4.1) requires 
two Zn(II) ions. Structural alignment of the active centers of isoDromeQC, hQC and ApAP (cf. 
Figure 1.6) demonstrated that both Zn(II) binding motifs are conserved isoDromeQC as well as 
hQC. However, the crystal structure of hQC and isoDromeQC showed an unoccupied second 
Zn(II) binding motif, which is in close proximity (3.5 Å) to the occupied Zn(II) binding motif on the 
bottom surface of the active center. Furthermore, increasing concentration of Zn(II) in vitro 
leads to a loss of catalytic activity [56]. For these reasons it is established that for catalysis only 
one Zn(II) ion is required.  
The binding site of the catalytically active Zn(II) ion is located at the bottom of the substrate 
channel. Inorganic Zn(II) ions have a high affinity towards nitrogen and oxygen donor atoms [91]. 
Hence, it is not very remarkable that in QC the metal binding site is characterized by two 
carboxylic amino acid site chains (D153, E191) and one imidazole moiety (H318). As described 
above, the fourth coordination ligand is a water molecule in the resting state. The Zn(II) and the 
Co(II) ion, respectively, hold a slightly distorted tetrahedral coordination sphere. For an ideal 
tetrahedral geometry all bond angles between the substituents would be cos-1(-1/3) ≈ 109.5°. 
Table 4.1 depicts selected angles including one amino acid, the metal ion and the water 




obtained EPR data. A perfect four-coordinate central atom would be EPR silent (internal 
discussion with Prof. Dr. Brian Bennett). 
 
Table 4.1 Bond angles between Zn(II) coordinating residues, Zn(II) and water molecule in the active 
center of Zn(II) isoDromeQC. The bond angles were determined by analyzing x-ray crystal structure in 
the “pymol” program version 1.3.  
Bond angles D153/OD2-Zn(II)-H2O E191/OE1-Zn(II)-H2O H318/NE2-Zn(II)-H2O 
Wild type 108.0° 115.1° 112.5° 
E190Q 124.8° 98.4° 112.7° 
D228N 129.5° 113.6° 110.8° 
 
The bond angles in the active center of the variants are partially significantly distorted. Data 
from EPR (cf. Section 3.6.1 and Figure 3.15) and stopped flow UV/Vis spectroscopy (section 3.4.1 
and Figure 3.4) visualize clear distinctions in the coordination geometry Co(II) between Co(II)-
isoDromeQC wild type and variants. Changes in the bond angles due to side chain substitution in 
the variants affect the geometry of the metal ion.  
 
 
4.1.2.3 The Zn(II) as Lewis acid activates the γ-carbonyl moiety of the N-terminal glutamine  
 
The role of the Zn(II) ion for catalysis of QCs is currently becoming clearer. The crystal structure 
of isoDromeQC in complex with QFRH (cf. 3.11 A and B) showed that the γ-amido oxygen atom 
of the substrates’ N-terminal glutamine residue binds to the fourth position of the Co(II) ion. This 
finding might indicate that the Co(II) ion is used to activate the substrate carbonyl for 
nucleophilic attack. The formation of a coordinative bond between Co(II) and the γ-amido 
oxygen induce a delocalization of electronically negative charge from the γ-amido carbon atom 
towards the γ-amido oxygen-Co(II) bond. Subsequently the positively polarized γ-amido carbon 








4.2 The catalytic cycle of the cyclization reaction of substrates with N-terminal 
glutamine 
 
4.2.1 Substrate binding  
 
The formation of the enzyme substrate complex is the initial event in the trajectory of a catalytic 
cycle. Enzyme kinetic studies, EPR experiments and x-ray crystallography were employed to 
analyze this catalytic step in terms of binding velocity, involved binding motifs and structural 
features. 
 
UV/Vis and EPR spectroscopic trials visualize the binding between substrate and Co(II)-
substituted enzyme when the electronic environment of the Co(II) is affected. In the UV/Vis 
experiments the absorbance spectra change due to altered extinction coefficients of the Co(II) 
ion when a substrate ligand is bound. The EPR spectra of the Co(II)-enzyme substrate complex 
tended to show shifted band positions due to stretched or compressed bond length along the Z-
axes. 
The stopped-flow UV/Vis absorption spectra of Co(II)-isoDromeQC wild type after rapid mixing 
with the substrates QQ (cf. Figure 3.5-1 A; 3.5-2 A) and QFRH (cf. Figure 3.5-3 A and B) present 
an increase in the absorption at several wavelengths within the dead time of the stopped-flow 
detector device. Considering the EPR results, the binding of QQ (cf. Figure 3.17 A) and QFRH (cf. 
Figure 3.18 A) affect the coordination sphere of Co(II) after 10 ms in case of QQ and 20 ms in 
case of QFRH. Thus we can conclude that the replacement of the water molecule by the 
substrate in the fourth coordination position occurs immediately after the mixing. Hence the 
substrate binding can be assigned as a very rapid step in that reaction trajectory.  
The EPR spectra of Co(II)-isoDromeQC wild type incubated with both QQ and QFRH also indicate 
a tetrahedrally coordinated Co(II) ion. The N-terminal glutamine of the substrate thus binds  in a 
monodentate manner. This result tallies with the crystal structure (cf. Figure 3.11 A and B) 
showing a coordinating interaction between the γ-amido oxygen of the N-terminal glutamine 
and the Co(II) ion with a bond length of approx. 2.0 Å. The crystal structure further discloses 
polar contacts between the substrate and side chains of active-center amino acids D228 and 
E190 (cf. Section 3.5.3) as well as the main chain of D292. As described in the introduction, also 
the active-center amino acids D293 may act as substrate binding motifs. Further evidence for the 
hypothesis that these side chains are involved in substrate binding were accumulated by side-
chain substitution of E190, D228 and D293. The kinetic constants of the variants were 




the variants Zn(II)-isoDromeQC_D293N, _D393A and Zn(II)-isoDromeQC_D228N showed six to 
eight-fold higher KM values reflecting an impaired substrate binding. EPR and stopped-flow 
experiments performed analogously to those of the Co(II)-isoDromeQC wild type yield results 
implying a tremendously reduced substrate metal interaction (cf. stopped flow: Section 3.4.2 
Figure 3.5-1,2; Section 3.4.3 Figure 3.5-3; EPR: Section 3.6.2 Figure 3.17). This means that the 
substrate binding is strongly impaired in these variants.  
Contrarily, the KM value determined with the variant Zn(II)-isoDromeQC_E190Q is decreased (cf. 
Section 3.2, Table 3.2). EPR (cf. Section 3.6.2 Figure 3.17) and stopped-flow (cf. Section 3.4.2 
Figure 3.5-1,2) analysis of the Co(II)-substituted variant showed a rapid change (after 20 ms) in 
the Co(II) coordination sphere after the mixing. At least the postulated interaction between the 
γ-carbonyl oxygen of the N-terminal substrate glutamine and the Co(II) ion may occur (cf. 
Section 1.4.3). The EPR spectra obtained after longer incubation times are nearly identical to 
those obtained after 20 ms. This indicates that after the substrate binding no further changes in 
the Co(II) sphere occur. This is in line with the low KM value and the strongly decreased kcat and 
kcat/KM. Due to a missing crystal structure, the reason for substrate binding cannot be clarified. It 
is likely that the formation of a hydrogen bond between γ-amido oxygen in position 190 and α-
amino nitrogen of the N-terminal substrate glutamine mediates the substrate affinity as 
depicted in Figure 4.2.  
 
 
Figure 4.2 Postulated substrate enzyme 
interaction in Zn(II)-isoDromeQC_E190Q Kinetic 
studies and EPR data indicate a fast substrate 
binding. Hypothetically this could be mediated by 
the non-covalent interactions between the Zn(II) 
and the γ-carbonyl oxygen and in particular 
between substituted asparagine and the α-amino 






















4.2.1.1 Mild alkaline pH supports the substrate affinity by deprotonation of the α-amino group of 
the substrate's N-terminal glutamine 
 
A further aspect relevant to the formation of a substrate enzyme complex is the protonation 
degree of the α-amino group of the N-terminal glutamine. The pH dependence measurement 
allows the calculation of pka values (inflection points in pH-catalytic efficiency curve) of amino 
acids which act as acid/base catalysts. The pKa2 values calculated from the measurements with 
Zn(II)-isoDromeQC wild type as well as all variants indicate a value of approx. 9.13 (cf. 3.3, Table 
3.3-2). This is in accordance with the literature pka value for α-amino groups of glutamine [93]. 
This identifies this α-amino group as the acid/base catalyst in the QC reaction. In this and former 
work, a pH optimum [57] for activity of (isoDrome) QC at the alkaline pH range around pH 7.9 
has been reported. At this pH the α-amino group is predominantly deprotonated. Additionally, 
the conclusion that a deprotonated α-amino group is required for substrate binding (and 
catalysis) is strengthened by the fact that the KM values decrease at alkaline pH and increase at 
acidic pH (cf. 3.3, Table 3.3-1). This means that the substrate affinity increases with the rising 
concentration of deprotonated α-amino groups.  
 
 
4.2.2 Characterization of discrete mechanistic steps in the trajectory of QCs 
 
The chemical reaction from glutamine to pyroglutamic acid is assigned to the addition-
elimination mechanism SN2t [60]. This bimolecular reaction is characterized by the concerted 
addition of a nucleophile to a polarized molecule and the release of a leaving group 
(elimination). During the reaction a short-lived tetrahedral transition state occurs. Considering 
the cyclization reaction of glutamine, the nucleophile and the polarized group belong to the 
same molecule. The QC enhances this intra-molecular ring closure reaction by the activation of 








4.2.2.1 Chemical activation of substrate moieties support the nucleophilic attack 
 
 
Figure 4.3 Postulated reaction cycle of Zn(II)-dependent QC The postulated catalytic cycle of glutaminyl 
cyclase depicts the formation of a tetrahedral reaction intermediate after the α-amino group has attacked 
the γ-carbonyl nucleophilically. This intermediate breaks down into ammonia and pyroglutamic acid.  
 
Once the substrate is bound to the enzyme, it is suggested that it becomes activated from two 
sides (cf. Figure 4.3). As shown in Section 3.6.2 and Figure 3.17, the EPR data obtained with the 
Co(II)-isoDromeQC wild type after several incubation periods depict a strong shift of the signal 
maximum after 10 ms. This shift is at its maximum after 160 ms. As described above, the 
substrate binding can already be observed after 10 ms. Almost simultaneously with the detected 
deformation of the coordination geometry of Co(II) induced by substrate binding, a further 
increase of the deformation occurs. This indicates that electron(s) from Co(II) become strongly 
delocalized along the Z-axes of the Co(II) coordination sphere. According to the postulated 
mechanism, this electron delocalization would occur along the axis of the γ-carbonyl carbon - γ-
carbonyl oxygen and the Co(II) ion. This non-covalent metal-oxanion interaction effectuates a 
polarization of the γ-carbonyl carbon and increases its electrophilic force. Simultaneously, as 
indicated in the crystal structure (cf. Figure 3.11), it is most likely that the γ-carboxylic group of 
E190 abstracts a proton from the -amino group of the N-terminal glutamine. This 
deprotonation step enhances the already high nucleophilicity of the -amino nitrogen. [73, 90]. 













































highly excited and short-lived tetrahedral intermediate. In this state the bond formation 
between the nucleophile and the polarized carbon atom is still incomplete. The bond between 
the leaving group and the carbon atom is prolonged but still existent. The tetrahedral 
intermediate is possibly stabilized by the catalytically active metal ion. Currently the existence of 
this intermediate state is likely but remains for now hypothetical.  
The question of whether the formation or decomposition of the tetrahedral intermediate is rate-
limiting was investigated by Dr. Franziska Seifert employing beta-secondary isotope effect 
experiments (results see Supplemental Section 8.8). For this trial the deuterated Q-AMC (cf. 
Figure 4.4 A) was used as substrate for the fluorescence spectroscopic assay (cf. Section 2.6.2). 
Characteristic for -secondary isotope effects is that the moiety harboring the isotope, in this 
case deuterated methylen groups, are in the proximity of these moieties which are involved in 
bond formation. This experiment can unveil differences in the activation energies that are 
required for the formation or stabilization of the tetrahedral intermediate when this step is rate 
limiting. The stabilization of this tetrahedral intermediate is most likely due to hyperconjugation. 
In this case an electron from the orbital of the σ-bond between the -carbon atom and the 
hydrogen or deuterium stabilizes the polarized γ-carbon by mesomeric effect (cf. Figure 4.4. B). 
Hyperconjugation and the related stabilizing effects to transition states are a source of -
secondary isotope effects [98]. In case of a deuterated δ-methylen group the stabilization of the 
transition state requires higher activation energy. This in turn leads to lower reaction velocity. 
The quotient of the determined kinetic constants of the reaction with deuterated and 
undeuterated substrate corresponds to the equilibrium isotopic effect (KM) and the kinetic 
isotopic effect (kcat). The isotopic effects become significant in a range between 1.5 and 7. The 
determined isotopic effects were below 1.5 and consequently not significant. Hence, we can 
conclude that the formation or the decomposition of the suggested tetrahedral intermediate is 







Figure 4.4 Deuterated fluorogenic substrate Q-AMC and the postulated tetrahedral intermediate (A) 
The fluorogenic substrate was utilized to examine a beta-secondary isotope effect employing 
fluorescence spectroscopy. (B) The postulated tetrahedral intermediate is possibly stabilized by 
hyperconjugation. In case of deuterated methylene groups, the hyperconjugation requires higher 
activation energy compared to hydrogen-containing groups. When the formation of this intermediate 
is rate-limiting, this effect causes lower rate constants. 
 
 
4.2.2.2 The release of ammonia (deamination) is accompanied by the decomposition of the 
reaction intermediate 
 
The EPR data of Co(II)-isoDromeQC wild type incubated with QQ after several incubation times 
show that the shift of the signal maximum after 2 s becomes smaller compared to the signal 
after 160 ms. This indicates that the strong distortion in the coordination sphere of Co(II) is 
reconstituted. This relaxation can be induced by the decomposition of the putative tetrahedral 
intermediate. This step includes the cleavage of the γ-amino moiety and the removal of the 
delocalized electron (cf. Figure 4.3). Crystal structures of Co(II)-isoDromeQC wild type (cf. Figure 
3.11 B and C) depict that the γ-carboxylic moiety of D228 and γ-amino nitrogen are in hydrogen 
bond distance. It is suggested that this amino acid provides a proton to the leaving γ-amino 
group. This proton transfer possibly enhances the elimination of ammonia. The release of 
ammonia makes the cyclization reaction quasi-irreversible. Schilling et al. al showed that 
ammonia concentration up to 50 mM does not inhibit the reaction [80]. The missing product 





























































































4.2.2.3 Proton transfer pathways are crucial for the release of ammonia 
 
As described above, in this reaction mechanism at least two different proton transferring steps 
are included. First, E190 abstracts a proton from the -amino group of the substrate. Second 
D228 transfers a proton to the leaving group. Furthermore, for a complete regeneration of the 
enzyme, E190 has to be deprotonated. 
Crystal structures of this work and of other investigators imply that the transport of protons in 
isoDromeQC as well in hQC [94] is presumably organized by at least three conserved carboxylate 
moieties in the active center residues (cf. Figure 4.5). In isoDromeQC the supposed residues are 
E190 (proton abstraction from α-amino group of the N-terminal glutamine), D293 (proton 
transfer) and D228 (protonation of the leaving γ-amino group). Kinetic studies with variants 
Zn(II)-isoDromeQC_E190Q, Zn(II)-isoDromeQC_D293N and Zn(II)-isoDromeQC_D228N (cf. 
Section 3.2) present vastly diminished rate constants. Along with the crystal structure and the 
results from the kinetic investigations, it seems that these three amino acids are involved in this 
postulated proton transfer.  
 
Figure 4.5 Suggested proton transfer pathways in 
isoDromeQC during the catalysis The crystal 
structure image of Co(II)-isoDromeQC wild type 
depicts the supposed proton transfer pathways 
(red arrows) and possible (in hydrogen bond range) 
alternatives (dashed arrows). This supposed 
pathway explains the proton abstraction from the 
α-amino moiety of the N-terminal glutamine 
(yellow rods) and the protonation of the leaving γ-
ammonia group. 
 
Experiments investigating solvent isotope effects (performed by Dr. Franziska Seifert, results see 
Supplemental 8.6) were carried out to investigate whether the proton transfer is the rate-
limiting step of catalysis. In these experiments, deuterated water was used for buffer 
preparation to replace protons in the relevant acid/base catalysts e.g. the a-amino group of the 
N-terminal glutamine by deuterons. Due to the doubled mass of this ion, the transfer requires 
higher activation energy. This effect can be reflected in lower rate constants of the enzymatic 
reaction when this transfer is rate-limiting for the catalysis. Kinetic constants of Zn(II)-
isoDromeQC were determined in water and deuterium oxide-based buffers, respectively. The 
quotient of the kinetic constants (kcat) of both measurements corresponds to the solvent isotope 




are involved in rate-limiting mechanistic events. The measurements showed no significant 
solvent isotopic effect. Thus we can conclude that the proton transfer can be excluded as rate-
limiting step in the QC reaction. 
 
 
4.2.2.4 Release of pyroglutamic acid as final step of the catalytic cycle 
 
Product release is the final step of catalysis. The substrate-derived compounds used here i.e. 
pEFA and pEFRH, were determined to be competitive inhibitors with inhibition constants in the 
low millimolar range. The structure of the product possesses the same binding motif as the 
substrate (cf. Figure 3.13 and 3.12). The aromatic amino acid phenylalanine mediates the 
moderate affinity (cf. 4.1.1; 3.2) to the active center. Furthermore, the keto-oxygen still interacts 
with the catalytic metal ion. The EPR-measurements with the compound pEFA (cf. Figure 3.20) 
and QQ (cf.figure 3.17) presumes that the product enzyme complex is stable even 16 hours after 
the reaction. The band position of the EPR signal after two min (and even after six hours) 
reaction time is not completely identical with the EPR signal obtained from the enzyme in the 
resting state (cf. Figure 3.17 A) The interactions between product and enzyme (cf. Figure 3.13) 
mediate a certain stability of the enzyme product complex which is a condition for a successful 
co-crystallization attempt. The stability of this complex is most likely the reason for the product 
inhibition. This indicates that the product release is rate-limiting in the QC reaction. Further, the 
former catalytic steps can be excluded as rate-limiting factors. Nevertheless, the product release 
cannot be determined with reliability as the rate-limiting step in the catalytic cycle. In all 
experiments the concentration of the product was in the millimolar range (7.5 mM – 15 mM) 
and thus higher than in vivo. Hence, the equilibrium between product association and 






4.3 QCs provide unfavorable conditions for conversion N-terminal glutamate 
substrates  
 
A multitude of investigations concerning toxic depositions in the brain revealed that truncated 
Aβ peptides e.g. Aβ(E3-40/42) and Aβ(E11-40/42) possessing an N-terminal glutamate residue 
play a major role in development of neurodegenerative disorders [23, 31, 95, 96]. For this 
reason, the examination of discrete catalytic steps during N-terminal glutamate cyclization 
reaction is very important but poorly investigated so far with animal QC. The first 
crystallographic, UV/Vis- and EPR spectroscopic experiments concerning N-terminal glutamate 
cyclization led to new insights, which are discussed in the following section. 
 
 
4.3.1 N-terminal glutamate conversion lacks efficiency due to protonation conflict between 
crucial functional groups 
 
In this work, EPR and UV/Vis spectroscopic approaches were performed with Co(II)-isoDromeQC 
wild type and variants using two N-terminal glutamate substrate derivatives. These substrates 
were EFRH or Aβ(3-6) a shortened form of Aβ(3-40/42) and EW. The UV/Vis stoppedflow 
analysis (cf. Section 3.4.3) measured at pH 8.0 depicts no significant change of the Co(II) 
absorbance spectra after incubation with both EFRH and EW. The change of the Co(II)´s 
coordination number from four to five accompanied by spectral changes was unfortunately not 
detectable via UV/Vis spectroscopy. Interestingly the crystal structure obtained from co-
crystallization attempts of Co(II)-isoDromeQC wild type with EFRH (cf. Section 3.5.4) reveals a 
bidentate coordination between both γ-carboxylate oxygen atoms from the substrate and the 
catalytically active Co(II) ion. However, EPR spectroscopic analysis of Co(II)-isoDromeQC wild 
type and the variants Co(II)-isoDromeQC_D228N and Co(II)-isoDromeQC _D293N at pH 6.8 (cf. 
3.6.3) points to a clear change of the absorption spectra. The obtained spectra indicate a five-
coordinated Co(II) ion, which is in line with crystallographic results. The EPR spectra of the 
variant Co(II)-isoDromeQC_E190Q is nearly superimposable with the resting state spectrum, 
indicating hampered substrate binding. Those results solely demonstrate that N-terminal 
glutamate substrates bind to the active center of the Co(II)-isoDromeQC. Using these 
approaches, a catalytic conversion could not be determined in a quantitative manner. One 
unique indication of substrate conversion is given by the co-crystallization experiment with EFRH 




Co(II)isoDromeQC after an incubation time of approx. one week at 20° C. The fact that electron 
density for EFRH was still detectable in the same crystal indicates that the turnover velocity is 
very slow. In former studies with hQC, the conversion velocity of N-terminal glutamate was 
found to be approx. 10,000-fold slower than the glutamine conversion [52]. The animal QCs 
show an explicit preference for N-terminal glutamine substrates. Seifert et al. demonstrated that 
spontaneous cyclization of N-terminal glutamine residues occur with a rate constant of approx. 
10-6 s-1 and can be accelerated by a factor of 107 by hQC. On the other hand, the rate constant of 
spontaneous N-terminal glutamate cyclization is approx. 10-9 s-1 and can be enzymatically 
enhanced by a factor of 105 [52]. There are two cogent reasons for the low efficiency of the 
glutamate conversion. The first reason is that the N-terminal glutamate is bivalently charged 
around neutral pH. The determined pKa values for N-terminal glutamate were 4.2 for γ-
carboxylic group and 7.5 for the α-amino group in papaya QC which most likely converts the N-
terminal glutamate in a similar mechanistic manner[90]. Around neutral pH the N-terminal 
glutamate bears a protonated positively charged α-amino group and an unprotonated, 
negatively charged γ-carboxylic group. In this state neither the electrophilicity of the γ-carbonyl 
nor the nucleophilicity of the α-amino nitrogen is adequate for an intra-molecular nucleophilic 
attack (cf. Figure 4.3.). Glutamate conversion by animal QCs in dependence of pH has not been 
reported so far. Schilling et al. reported that Zn(II)-independent papaya QC showed maximum 
activity at pH 6.0 in terms of glutamate conversion [90]. Considering the pKa values of the N-
terminal glutamate, these findings are coherent. At pH 6 the population of protonated γ-
carboxylic moieties increases. The generated γ-hydroxyl group leads to an increasing 
electrophilicity of the γ-carbonyl group. Further, the concentration of unprotonated nucleophilic 
α-amino nitrogen is still sufficient. In accordance with the glutaminyl cyclization reaction, these 
circumstances are required for the nucleophilic attack of the α-amino nitrogen. To summarize, 
the mildly acidic milieu reflects a “compromise“ pH at which low concentrations of both 
activated groups are still present [90].  
 
A further reason for slow glutamate conversion is possibly due to the bidentatic coordination of 
the catalytically active metal ion of the γ-carboxilic group. 
As mentioned above, EPR studies and x-ray crystallography experiments of Co(II)-substituted 
isoDromeQC wild type indicate a different binding mode of the N–terminal γ moiety. In contrast 
to four-fold coordinated Co(II) during glutaminyl cyclization, substrates with an N-terminal 
glutamate residue generate EPR signals which are indicative of five-coordinate Co(II). The 




manner. In this context it is important to note that the EPR as well the x-ray crystallography 
experiments were carried out at pH 6.8 and pH 8.0, respectively. At this pH-range the γ-
carboxylate group is most likely partially (pH 6.8) or nearly completely deprotonated (pH 8.0). 
Considering the bidentate coordination of Co(II) in the Co(II)-isoDromeQC structure (cf. Figure 
3.12 B), it can be assumed that Co(II) functions as a Lewis acid and receives electrons from both 
γ-carbonyl oxygen atoms of the substrate. This makes a ring closure reaction unlikely since no 
hydroxyl leaving group is available. Thus one can speculate that the five-coordinate Co(II) 
mirrors an almost catalytically inactive state of isoDromeQC (wild type). 
 
 
4.3.2 N-terminal glutamine substrates assist the delineation of postulated amino acids as 
substrate binding motifs 
 
In order to further analyze the substrate binding mode of Co(II)-isoDromeQC, additional EPR 
measurements with different enzyme variants were performed. In particular, EPR analysis of 
incubations of Co(II)-isoDromeQC_D228N with substrates harboring an N-terminal glutamate 
residue (i.e. EW and EFRH) should demonstrate if this D228 residue is an important substrate 
binding motif as described for N-terminal glutamine substrates depicted in Figure 3.11 B and C. 
This experiment was also used to investigate the role of D228 in the postulated proton transfer 
pathway (cf. Section 4.2.2.3, and Figure 4.5). The EPR spectrum of isoDromeQC_D228N 
incubated with QQ (cf. Figure 3.17 D) showed that signal maxima after several incubation times 
do not show significant shifts. This implies that the substrate has no influence on the electronic 
environment of the Co(II) ion. This leads to the conclusion that (hardly) any substrate binding 
occurs with this substrate. However, when incubated with EW as substrate, this variant shows a 
prominent EPR signal that is indicative for five-coordinated Co(II). This suggests that an 
interaction between substrate and metal occurs (cf. Figure 3.18 B). Thus, this observation 
underlines the function of D228 as a glutamine substrate binding mediator.  
As shown in Figure 4.6 A, N-terminal glutamine substrates may interact via hydrogen bond 
between γ-amino nitrogen of the N-terminal substrate glutamine and the the γ-carboxylic 
oxygen of D228 in the wild type. Conversely, in isoDromeQC_D228N (cf. Figure 4.6. C) the γ-
amino nitrogen of asparagine in position 228 can mediate hydrogen-bond contact with the γ-
carboxylic oxygen of the N-terminal glutamate substrate.  
Considering the results of the substrate specificity study (cf. Section 3.2 and Figure 3.2) Zn(II)-




suggests that D293 is also involved in substrate binding. In line with this result, the EPR spectra 
of the variant Co(II)-isoDromeQC_D293N incubated with QQ or QFRH (cf. Section 3.6.2, Figure 
3.17 and Section 3.6.2, Figure 3.18) show also no significant change in the coordinative geometry 
of Co(II). This finding is indicative for a frustrated substrate binding. EFRH induces strongly 
altered EPR signal when incubated with Co(II)-isoDromeQC_D293N; this implies a substrate-
induced distortion of the Co(II) geometry. Hypothetically, this could be the result of an inverse 
hydrogen bond donor/acceptor situation as previously described for Co(II)-isoDromeQC_D228N 
incubated with EW or EFRH. The nitrogen of the substituted γ-amido residue in position 293 may 
form a hydrogen bond to the γ-carboxylic oxygens of the N-terminal glutamate in EFRH and 
possibly enables an early substrate binding step.  
  
  
Figure 4.6 Suggested interactions between substrates and isoDromeQC wild type, 
isoDromeQC_D228N and isoDromeQC_E190Q in the active center The scheme illustrates the active 
center in Zn(II)-isoDromeQC wild type with N-terminal glutamine substrates and tetrahedrally 
coordinated Zn(II) (A). In contrast, the N-terminal glutamate substrates are bidentately bound to the 
catalytically active metal ion (B). In isoDromeQC_D228N (C) the N-terminal glutamate is also 
bidentately bound to Zn(II). A hypothetically inverse hydrogen bond donor/acceptor situation between 
the γ-carboxylic group of the N-terminal glutamate and γ-amido group of the substituted residue 228 
may occur. Around pH 7 in isoDromeQC_E190Q (D) it is likely that the substrate α-amino group and the 
γ-amino group are protonated (according to their pKa values). This postulated situation would lead to 
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4.3.3 The glutamyl cyclization requires protonation of the leaving group - a proposed proton 
transferring pathway 
 
Analogously to the postulated reaction cycle of substrates with N-terminal glutamine, the 
glutamate cyclization depends on proton transfer as depicted in Figure 4.7 for two reasons. First, 
the α-amino group has to be deprotonated to enhance the nucleophilicity of the nitrogen (cf. 
Figure 4.7). Second, the leaving group (hydroxyl ion) has to be protonated. The crystal structure 
of N-terminal glutamate substrate in complex with the wild type (cf. 4.8 A) shows many possible 
polar contacts, which can be employed as proton transfer pathway. In Figure 4.8 B, possible 
pathways for proton transfers are depicted. The proposed network uses the same active center 
residues as described in the cyclization reaction of N-terminal glutamine (cf. Section 4.2.2, Figure 
4.5). It is most likely that E190 acts as proton abstracting group which transfers the proton to 
D293. D228 receives this proton and protonates the leaving hydroxyl ion with the result that 
water will be released. In case that the γ-carboxilic group is deprotonated e.g. at pH 8, one 
proton has to be received from the solvent. 
 
Figure 4.7 Postulated reaction cycle of N-terminal glutamate substrates Under mild acidic conditions 
the major part of N-terminal glutamates are bivalently charged and the γ-carboxylic group of N-
terminal glutamate is bidentately bound to Zn(II). A minor population of glutamates bears an 
unprotonated α-amino group and a protonated γ-carboxylate moiety. In those molecules, the α-amino 























































Figure 4.8 N-terminal glutamyl substrate in complex with Co(II) isoDromeQC wild type The γ-carboxylic 
group (A) of the N-terminal glutamate substrate EFRH (orange rods) coordinates the catalytically active 
Co(II) (firebrick-red sphere) in a bidentate manner. All distances (red arrows in B) between the Co(II) 
isoDromeQC wild type residues (grey rods) and the substrate are in hydrogen bond ranges and describe 


























4.4 Investigation of the binding mode of enzyme inhibiting tripeptide AFA 
 
Considering the fact that hQCs support the release of toxic Aβ peptides in a pathophysiological 
side reaction as described in the introduction, this enzyme represents a suitable target enzyme 
in the treatment of dementia diseases like AD. The inhibitors which were investigated so far 
interact with the catalytically active Zn(II) ion. To avoid severe or toxic side effects by the 
interference of these inhibitors with other Zn(II)-dependent enzymes, it is the long-term goal to 
explore enzyme-specific and mechanism-based inhibitors. 
As a prerequisite the Zn(II)-isoDromeQC and Co(II)-isoDromeQC were used to study two 
inhibiting components with respect to their binding mode and their interaction with the 
catalytically active metal ion. Furthermore, the investigation of inhibitor binding can provide 
information about putative substrate binding motifs.  
For that purpose, Co(II)-isoDromeQC wild type and the variants Co(II)-isoDromeQC_D228N, 
Co(II)-isoDromeQC_E190Q and Co(II)-isoDromeQC_D293N were incubated with the peptide-
based competitive inhibitor AFA. Crystallographic attempts, EPR experiments and UV/Vis 
spectroscopic trials were used to investigate this enzyme inhibitor complex.  
 
The results of the crystallographic experiments with Co(II)-isoDromeQC and AFA (cf. Figure 3.14) 
showed that the α-nitrogen of the N-terminal alanine residue acts as coordination partner of the 
Co(II) ion. This is in contrast to the result from the EPR experiments. The obtained EPR signal of 
Co(II)-isoDromeQC wild type and AFA at pH 6.8 indicates a five-coordinated Co(II) ion (cf. Section 
3.6.4, Supplemental 8.13). This indicates that the AFA influence the electronic sphere of Co(II). 
One reason for this conflicting result could be that the electron density of a water molecule is 
not observable due to high flexibility. This water molecule may act as a fifth coordination 
partner. Nevertheless, considering all results we can conclude that the α-amino nitrogen 
interacts with the Co(II) ion. In contrast to the substrate or product compounds, in this case the 
Co(II) ion interacts with a nitrogen atom instead of an oxygen atom. The precise delineation of 
the binding mode in terms of the coordination partner currently remains hypothetical.  
 
In case of the variant Co(II)-isoDromeQC_E190Q, the EPR data indicate four- and five coordinate 
Co(II) ions and Co(II) hyperfine structure. The latter fact is typical for Co(II) ions when their 
coordination geometry is very rigid resulting from a tightly bound ligand. It is most likely that the 
insertion of a glutamine provides an additional binding motif for AFA. It was previously discussed 




in position 190 and α-amino nitrogen of the N-terminal glutamine that enhances the substrate 
affinity. The tight AFA binding might be mediated by an analog hydrogen bond. 
 
Interestingly, EPR spectra of the variants Co(II)-isoDromeQC_D228N and D293N incubated with 
AFA are indicative for four-coordinated Co(II) ions. Significantly shifted band positions and 
altered band width revealed evidence for a ligand-metal interaction. The Co(II) hyperfine pattern 
in case of Co(II)-isoDromeQC_D228N as described above is indicative for a tight ligand binding. 
The substitution of active center amino acids, which were discussed as putative binding motives 
for N-terminal glutamine substrates (cf. Sections 4.2.1 and 4.3.2) does not impair the binding of 
AFA. The above-mentioned crystal structure (cf. Figure 3.14 A and B) shows two distinct 
conformations of the AFA in the active center. Figure 3.14 A depicts the Co(II)–bound 
conformation with additional hydrogen bonds to several water molecules. The alternative 
conformation in Figure 3.14 B shows no Co(II) interaction but a direct hydrogen bond contact 
between the main chain of amino acid E292 and the phenylalanine in the second position of the 
substrate. A further hydrogen bond can be established between α-amino nitrogen of the 
substrate and the γ-carbonyl oxygen of amino acid E190. These binding motifs are similar to the 
substrate binding motifs and most likely mediate the inhibitor binding. The γ-carboxylate group 
of residue 228 would interact with the γ-amino nitrogen of the N-terminal glutamine of the 
substrate (cf. Section 4.2.1 and Figure 3.11 B and C). The substitution of the γ-carboxylate group 
in Co(II)-isoDromeQC_D228N leads to impaired substrate binding (cf. Section 3.2; 3.4.2, 3.6.2 
and 4.2.1). In case of AFA binding this γ-amino nitrogen is missing. Thus the substitution of this 
moiety in Co(II)-isoDromeQC_D228N has no influence on AFA binding. This observation 






Zn(II)-dependent QC converts N-terminal glutamine or glutamate residues of peptides and 
proteins [25, 30, 90]. The reaction product is in both cases pyroglutamic acid. In animals the 
glutaminyl cyclization is involved in posttranslational modification and activation of peptide-
based hormone and chemokine precursors [30]. Recently it was established that the driving 
force in neurodegenerative processes is the pyroGlu modification at the N-terminus of Aβ 
peptides processed by QC. In humans one isoform is localized in Golgi-vesicles, the other isoform 
is present in the regulated secretory pathway. In the brain, the secretory isoform is 
predominantly expressed. This unveils the inhibition of secretory QC as a strategy in AD 
treatment without side effects. The enzyme-specific inhibition is required in order to avoid 
noxious side effects. The elucidation of the reaction mechanism might make the development of 
mechanism-based QC inhibitors (e.g. transition-state analog compounds) possible.  
Mechanistic and structural investigations were accomplished using the mitochondrial isoform of 
QC from Drosophila melanogaster. Regarding enzyme kinetic and structural properties, this 
enzyme is highly similar to the secretory hQC. Zn(II)-isoDromeQC wild type and variants 
harboring mechanism-relevant amino acids substitutes were heterologously expressed in E. coli. 
The His6-tagged enzyme was purified using Ni-chelating chromatography, whereas the untagged 
protein was purified employing hydrophobic interaction chromatography, anion exchange 
chromatography and size exclusion chromatography. With the purified Zn(II) enzymes kinetic 
investigations were carried out including substrate specificity and pH-dependence studies. The 
substitution of the catalytically active Zn(II) ion into Co(II) yields an UV/Vis and EPR-active 
enzyme with almost the same enzymatic activity compared to the Zn(II) enzyme. The mentioned 
spectroscopic methods were used to obtain information about reaction trajectory, the binding 
modes of substrates and products. In addition the structure-function relationship of the enzyme 
was investigated in terms of the active center residues E190, D228 and D293. In particular the 
functions of these activecenter amino acids could be elucidated by successful crystallization 
trials.  
The analysis of the results reveal that the active-center amino acids D288, D293, E190 (side 
chains) and D293 (main chains) as well the metal ion are required for sufficient substrate 
binding. The function of D293 remains hypothetical due to the absence of a direct substrate-
amino acid interaction. Substrate binding can also be mediated by hydrogen bonds between N-
terminal substrate amino acids in the active center and between C-terminal substrate amino 




aromatic amino acid in the second N-terminal position, a positive charge and at least two or 
more amino acids. A special role for substrate binding could be assigned for residue E190 and 
the catalytically active metal. Preferentially at mild alkaline pH, E190 accepts one proton from 
the α-amino group of the N-terminal substrate glutamine and increases nucleophilicity of the 
appropriate α-nitrogen. In a synchronized manner the metal and the γ-carboxamide oxygen 
form a non-covalent interaction and leave a polarized γ-carbon lacking a negative charge. In 
particular the EPR data indicate a highly distorted Co(II) coordination geometry as a very early 
(within 160 ms) event in the course of catalysis. The reaction mechanism postulated by Schilling 
et al. proposes a tetrahedral reaction intermediate that is typical for an addition-elimination 
mechanism or second order nucleophilic substitution with a tetrahedral reaction intermediate 
(SN2t), respectively [60]. This hypothetical intermediate state could be stabilized by the metal-
oxanion interaction. This might be the reason for the observed strong and short-lived 
delocalization in the electronic sphere of the metal. The relaxation of this excited state, 
observed by EPR spectroscopy, might be caused by the decomposition of the mentioned 
intermediate state accompanied by the release of ammonia. The liberation of the gaseous 
ammonia was indicated by crystal structures. Putatively a proton is transferred by the amino 
acid D228 to the leaving amino group. Former investigations [94] suggested a proton transfer 
pathway using amino acids E190, D293 and D228. The substitution of one of these residues 
leaves an almost enzymatic inactive variant. Controversially discussed was the liberation of the 
product as rate-limiting step. A stable product-enzyme complex, product inhibition and the 
exclusion of preceding catalytic steps as rate-limiting would confirm this idea. Nevertheless, the 
high concentration of product compounds or substrates used in the applied assays might 
disarrange the dissociation equilibrium.  
New information about the binding mode of N-terminal glutamate substrates were obtained by 
crystallization and EPR measurements. In contrast to four-coordinate Co(II) during the 
conversion of glutamine substrates, the binding of N-terminal glutamate provokes a five-
coordination sphere of the metal ion. Both γ-carbonyl oxygens are non-covalently bound to the 
metal ion. Assuming that this conformation is catalytically inactive due to lack of a leaving 
hydroxyl group, it was proposed that the glutamyl cyclization takes up a proton from the solvent. 
Statements concerning the mechanism remain hypothetical for now.  
Information with regard to the mentioned substrate-binding motifs was obtained by co-
crystallization of QC with AFA and confirmed by EPR experiments. Further, a nitrogen-metal 





6 Outlook  
 
The question of the existence and the structure of the tetrahedral intermediate could not clearly 
be answered in this work. First trials to inhibit the QC activity using phenylphosphorodiamidate 
that mimics a tetrahedral transition state did not yield any results. Possibly a randomized 
attempt with further tetrahedral intermediate analogs will provide information about the 
appearance and the structure of such an intermediate. The question of whether further active-
center residues are involved in substrate binding could be answered by further site-directed 
mutagenesis. Especially the function of W317 that may form hydrophobic interactions to the N-
terminal substrate amino acid could be helpful. Substitutions of the mentioned non-polar amino 
acids in the substrate binding pocket (I291, F313, W196) by polar amino acids (cf. Section 4.1.1) 
could shed light on whether the preference for substrates with aromatic amino acids in the 
second position is caused by hydrophobic interactions.  
A further aspect will be the specific inhibition of secretory hQC which is mainly responsible for 
pyroGlu modification in the brain.  
 
Kinetic measurements and EPR studies regarding the reaction trajectory of the glutamyl cyclase 
mechanism need to be performed. The detected substrate binding in Co(II)-isoDromeQC_D228N 
and D293N raise the question whether these variants are catalytically active when incubated 
with N-terminal glutamate substrates. Open questions in terms of the cyclization mechanism, in 
particular of the protonation of the leaving water, can possibly be answered by measuring 
glutamyl cyclization activity in dependence of pH. If the leaving water molecule receives protons 
from the solvent during the reaction, an increase of the pH value in the applied reaction tube 
should be detectable during the reaction. This would provide important insights into the 
mechanism of this reaction and would unveil a significant difference to the glutaminyl cyclization 
mechanism. Additionally it is worth investigating whether bidentate substrates and the resulting 
five-coordinate Co(II) is catalytically active.  
Hypothetically, should the entire elucidation of the glutamyl cyclization mechanism unveil stark 
differences to that of glutaminyl cyclization, it could be possible to diminish the 
pathophysiological pyroGlu modifcation of Aβ peptides without impairment of the physiological 
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8.2 Thermal stability study of the iDQC wild type and the variants 
         Table 4.1 Single measurements of the thermal denaturation 
enzyme melting pointsA mean valueB 
wild typ (His6) 
328 (± 0.05) 
330 (± 0.07) 
332 (± 0.08) 
330 (± 2.00) 
E190Q (native) 
334 (± 0.28) 
334 (± 0.24) 
-- 
334 (± 0.00) 
D293N (His6) 
318 (± 0.06) 
321 (± 0.05) 
321 (± 0.05) 
320 (± 1.73) 
D293A (His6) 
323 (± 0.06) 
322 (± 0.06) 
321 (± 0.07) 
322 (± 1.00) 
D228N (His6) 
334 (± 0.12) 
332 (± 0.09) 
331 (± 0.14) 
332 (± 1.53) 
A
) Single measurements in the absolute temperature (K) with standard error 
B
) Mean values in the absolute temperature (K) (with standard deviation,  















[QC]=0.1 mg/ml, 10mM KPO
4
, 
10°C before denat, 94°C after denat.
1nmstep, 1s per point
wavelength (nm)





























[QC]=0.1 mg/ml, 10mM KPO
4
, 
10°C before denat, 94°C after denat.























[QC]=0.1 mg/ml, 10mM KPO
4
, 
10°C before denat, 94°C after denat.























[QC]=0.1 mg/ml, 10mM KPO
4
, 
10°C before denat, 94°C after denat.






















Col 5 vs Col 6 
Col 5 vs D293N 
Zn(II)-isoDromeQC_E190Q, 
[QC]=0.1 mg/ml, 10mM KPO
4
, 
10°C before denat, 94°C after denat.



























50 mM Tris; pH 8.0; 30°C
[D293N]  = 2.25 mg/ml (58.1 µM)
[QQ] (mM)
























(mM)= 7,119 (± 1,902)




(mM)= 8,661 (± 2,911)
E/min
-1


















50 mM Tris; pH 8.0; 30°C
[QGP] (mM)




















E/min = 0,0238(± 0,0004) min
-1
 
E/min = 0,0199(± 0,0003) min
-1
 
E/min = 0,0178 (±0,0005) min
-1
 
, [QC]=1.77 mg/ml (45,6 µM)
isoDromeQC D293N_QFRH 
50 mM Tris; pH 8.0; 30°C
[QFRH] (mM)


















x column 1 vs y column 
x column 3 vs y column 1 
x column 1 vs y column 




(mM)= 0,451 (± 0,029)




(mM)= 0,402 (± 0,029)




(mM)= 0,480 (± 0,033)
,[QC]= 0.6 mg/ml (15.8 µM)
isoDromeQC D292A_QFRH 
50 mM Tris; pH 8.0; 30°C
[QFRH] (mM)

























(mM)= 0,618 (± 0,039)




(mM)= 0,465 (± 0,027)




(mM)= 0,443 (± 0,017)
, [QC]= 0.6 mg/ml (15,4 µM)= 0.6 mg/ml (15.8 µM)
isoDromeQC D293N_QGP 
50 mM Tris; pH 8.0; 30°C
[D293N]  = 0,732 mg/ml (18.9 µM)
[QGP] (mM)





































   
   





[QC]= 1.05 mg/ml (27,7 µM) [QC]= 1.05 mg/ml (2,77 µM)[ C]= 1.05 g/ l (27,7 µ ) [QC]= 0.5 mg/ml (1.32 µM)[ ]  .6 g/ l (15.8 µM)
[QC]= 1.05 mg/ml (27.7µM) [QC]= 1.05 mg/ml (27.7µM) [QC] = 2.12 mg/ml (54.55 µM)























KM = 0,070 mM+/-0,0118
Vmax = 	0,0058	+/- 0,0002	
K = 	0,0413 +/-0,0111
Zn(II)-isoDromeQC_E190Q_1 
4 mM QQ,  [QC] = 5.59 mg/ml (147.5 µM)
[QQ] mM 




















KM = 0,039 mM+/-0,0198
Vmax = 	0,0057	+/- 0,0002	
K = 	0,0250 +/-0,0063
























KM = 0,031 mM+/-0,0092
Vmax = 	0,0062	+/- 0,0002	





8.5 Catalytic efficiency in dependence of pH 
 
pH dependence: mitochondrial isoform of Drosophila melanogaster QC  
-wild type (his6-tag)- 
Single determination of kcat/KM
 (s-1mM-1): 
[QC] = 0.005 mg/ml (0.132 µM); substrate: 11.85 µM Q-βNA (KM = 0.15 mM ± 0.01) 
100 mM Tris, 50 mM Mes, 50 mM Na+-acetate, T = 303 K 
 


















pka1 6.56 0.06 0.03 
pka2 9.1 0.02 0.01 
y0 0.92 0.32 0.16 
R 0.98 0.01 0.01 
 
pH KM (mM) kcat (s
-1) kcat/KM  
(s-1 mM-1) 



























































































pH-dependence: IsoDromeQC E190Q (his6-tag), determination of kcat/KM  
[QC] = 4.85 mg/ml (125.13 µM); Substrat: 19.57 µM Q-βNA (KM = 0.15 mM ± 0.01) 
100 mM Tris, 50 mM Mes, 50 mM Na
+
-Acetat, T = 30 °C 












1.10e-3 1.61e-4 8.07e-5 
pka1 6.82 0.04 0.02 
pka2 9.45 0.14 0.07 
y0 0.98 0.01 0.01 
R 1.10e-3 1.61e-4 8.07e-5 
 
pH KM (mM) kcat (s
-1) kcat/KM  
(s-1 mM-
1) 
5.24 n.d.  (±)  
7.00 0.43±0.011  (±)  


























































































































pH-dependence: IsoDromeQC D228N- (his6-tag), determination of kcat/KM  
[QC] = 5.51 mg/ml (142.40 µM); Substrat: 43.50 µM Q-β-NA (KM = 0.435 mM, in 3KP,  
pH 7.0, T = 30 °C) 100 mM Tris, 50 mM Mes, 50 mM Na
+
-Acetat, T = 30 °C 




















pka1 6.33 ±0.06 ±0.03 













pH KM (mM) kcat (s
-1







































































































































pH-dependence: IsoDromeQC D293N- (his6-tag), determination of kcat/KM  
[QC] = 6.01 mg/ml (155.3 µM); Substrat: 99.50 µM Q-β-NA (KM = 0.97 mM, in 50 mM Tris,  
pH 8.0, T = 30 °C) 100 mM Tris, 50 mM Mes, 50 mM Na
+
-Acetat, T = 30 °C 




















pka1 6.38 0.06 0.03 
pka2 9.39 0.04 0.03 









pH KM (mM) kcat (s
-1



































































































































pH-dependence: IsoDromeQC D293A- (his6-tag), determination of kcat/KM  
[QC] = 1.1 mg/ml (28.42 µM); Substrat: 320 µM Q-βNA (KM = 4.35 mM, in 3 KP pH 7.0,  
T = 30 °C) 100 mM Tris, 50 mM Mes, 50 mM Na
+
-Acetat, T = 30 °C 













3.37e-3 2.65e-4 1.33e-4 
pka1 6.79 0.10 0.05 
pka2 9.09 0.15 0.08 
y0 -- -- -- 
R 0.99 3.38e-3 1.69e-3 
 
pH KM (mM) kcat (s
-1






























KM-Werte from v/[S]-charakteristikwith hyperbolic fit, kcat/KM 
linear fit (1
st




























































































































8.6 Solvent Isotopic effect  
Measured by Dr. Franziska Seifert) Zn(II)-isoDromeQC wild type with Q-AMC measured using fluorescence 
spectroscopy assay (cf. Section2.6.2) Assay: QC-AMC-assay (fluorescence), QC-GDH-assay 
(absorbance)Buffer:25 mM sodium phosphate, 50 mM NaCl, pH/D 7.5, Temperature: 30 °C
 
 
8.7 Kinetic data Zn(II)-enzyme versus Co(II)-enzyme  
Measured by Dr. Seifert Franziska. Measured using UV/Vis- and fluorescence spectroscopy (cf. Section 
2.6.1 and 2.6.2) Conditions: 50 mM Tris, pH 8.0, 30°C, * from Schilling et al. 2007 
 
8.8 β-Secondary isotopic effect measured by Dr. Franziska Seifert using Q-AMC and D5-Q-AMC  
Determined with fluorescence spectroscopy (cf. 2.6.2) 
Assay: QC-AMC-assay (fluorescence) Buffer: 25 mM sodium phosphate, 50 mM NaCl, pH 7.5 Substrate: Q-















































































































Conditions:50 mM Tris, pH 8.0, 30°C, * from Schilling et al. 2007

















Co2+-iDQC 1.88 0.25 4.17 0.18 6.94 1.25 11.39 0.07
Zn2+-iDQC 1.92 0.26 4.13 0.17 8.57 1.20 12.88 0.06




























-1) KM (mM) kcat/ KM (mM
-1s-1)
Q-AMC* 0.71  0.06 0.45  0.04 0.084  0.003 5.29  0.57
D5-QAMC* 0.70  0.06 0. 44  0.04 0.083  0.004 5.36  0.46
KIE = 1.01 KIE = 1.02 EIE = 1.01 KIE = 0.99




8.9 Determination of inhibition constant of the tripeptide AFA 
Measured by Dr. Franziska Seifert using UV/Vis spectroscopic assay (cf. 6.1.1) 
 Tripeptide AFA – competitive inhibitor, Ki = 0.62  0.05 mM  
 
8.10 Determination of product inhibition constant of pEFRH 
Measured by Dr. Franziska Seifert using UV/Vis spectroscopic assay (cf. 6.1.1) 
 pEFRH – competitive inhibitor, Ki = 1.88  0.02 mM (KM = 0.57 mM)  
 
8.11 Determination of product inhibition constant of pEFA 
Measured by Dr. Franziska Seifert using UV/Vis spectroscopic assay (cf. 6.1.1), conditions cf. 
pEFA – competitive inhibitor, Ki = 3.12  0.2 mM (KM = 0.72 mM)  
 
Ki (mM) KM (mM) 
spez Akt 
(U/mg) kcat (s-1) 
     
 
3.1376 0.862 6.846 4.323 
     
 
3.3604 0.731 7.111 4.491 
 
2.87647 0.579 6.204 3.918 
Mean 3.12482333 0.724 6.72033333 4.244 
St.-







































conditions: [isoDromeQC] = 0.89 µg/ml, 0.3 mM NADH, 15 mM 
Ketoglutarat, 30 U/ml GDH, 0.05 M Tris, pH 8.0, 30°C
 pEFRH – competitive inhibitor, Ki = 1.88  0.02 mM (KM = 0.57 mM)
conditions: [isoDromeQC] = 0.89 µg/ml, 0.3 mM 
NADH, 15 mM Ketoglutarat, 30 U/ml GDH, 0.05 M 
NaPP, 0.1 M NaCl, pH 6.8, 30°C
[Gln-Gln] (mM)









































Data collection PETRA III B14 Bessy II 14.1 Bessy14.1 
Wavelength 0.826610 0.91841 0.91841 
Spacegroup P1 P1 P1 
Cell dimensions    
a (Å) 46.62 46.31 45.74 
b (Å) 48.13 47.98 47.82 
c (Å) 74.57 74.61 74.42 
 85.24 85.16 85.28 
 74.61 74.64 74.16 
 73.66 73.76 73.56 
Resolution range (Å) 36.321-1.119 23.980-1.703 32.878-1.930 
No. of reflections 841365 (177910) 134932 (19372) 60353 (6739) 
No of unique reflections 215282 (45958) 59736 (10230) 27382 (3050) 
Completeness (%) 93.0 (87.8) 91.7 (86.5) 95.7 (85.9) 
I/sigma (I) 15.55 (2.77) 11.75 (2.08) 12.54 (2.08) 
Rmerge (%) 4.7 (58.5) 7.4 (58.6) 8.4 (65.6) 
Redundancy 3.9 (3.87) 2.26 (1.89) 2.20 (2.21) 
B-factor from Wilson  
Plot (Å²) 
16.229 24.257 37.073 






















Refinement PHENIX PHENIX PHENIX 
Resolution range 36.321-1.119 23.980-1.703 32.878-2.225 
Reflections(working/test) 215209 28583 27358 
Rwork/Rfree (%) 15.58/17.94 18.25/22.75 18.26/24.26 
    
Number of Atoms 5878 5752 5081 
Protein 5008 5126 4930 
Ligand    
Water 868 624 149 
B-factor Protein 20.6 26.2 15.82 
B-factor Ligands    
B-factor Water 35.3 39.1 15.58 
    
Deviation from ideals    
(r.m.s.d.)    
Bond distances (Å) 0.014 0.005 0.008 
Bond angles (°) 1.656 1.039 1.199. 
Dihedrals (°) 13.378 13.231 14.557 
    
Ramachandran Plot    
Favoured regions (%) 95.74 94.5 93.20 
Allowed regions 3.44 5.14 6.30 
Outlier regions 0.82 0.80 0.50 





wild type +QFRH 
Co(II)isoDromeQC 
wild type +EFRH 
Co(II)isoDromeQC 
wild type +AFA 
Data collection PETRA III In-house facitlity PETRA III 
Wavelength 0.826610 1.541790 0.826610 
Spacegroup P1 P1 P1 
Cell dimensions - - - 
a (Å) 46.26 46.32 46.42 
b (Å) 47.83 47.81 47.92 
c (Å) 74.68 74.81 74.83 
 85.12 85.30 85.51 
 74.71 74.65 74.25 
γ 73.89 74.20 74.09 
Resolution range (Å) 43.023-1.312 24.044-1.419 42.138-1.308 
No. of reflections 540409 (62287) 217373 (36039) 541743 (73394) 
No of unique reflections 128424 (14932) 98482 (16365) 130007 (17667) 
Completeness (%) 90.4 (91.3) 87.40 (78.7) 90.1 (90.7) 
I/sigma (I) 15.17 (2.36) 14.01 (2.91) 20.12 (2.54) 
Rmerge (%) 5.2 (66.2) 5.4 (39.7) 65.4 (3.6) 
Redundancy 4.21 (4.17) 2.20 (2.20) 2.5 (4.15) 
B-factor from Wilson  
Plot (Å²) 
20.28 20.308 22.361 















wild type +QFRH 
Co(II)isoDromeQC 
wild type +EFRH 
Co(II)isoDromeQC 
wild type +AFA 
Refinement PHENIX PHENIX PHENIX 
Resolution range 43.023-1.312 24.044-1.419 42.138-1.308 
Reflections(working/test)    
Rwork/Rfree (%) 14.31/18.18 15.46/19.40 16.16/19.63 
 - - - 
Number of Atoms 5945 5951 5721 
Protein 5022 5013 5013 
Ligand 61 74 42 
Water 860 862 664 
B-factor Protein 19.39 18.99 20.78 
B-factor Ligands 32.71 29.32 29.53 
B-factor Water 32.97 34.31 35.59 
 - - - 
Deviation from ideals - - - 
(r.m.s.d.) - - - 
Bond distances (Å) 0.013 0.014 0.013 
Bond angles (°) 1.619 1.647 1.714 
Dihedrals (°) 13.869 14.234 14.459 
 - - - 
Ramachandran Plot - - - 
Favored regions (%) 95.77 95.11 94.94 
Allowed regions 3.42 4.08 4.08 
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